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Abstract 
Heat Shock Protein 90 (Hsp90) is a molecular chaperone which plays an active role in 
maintaining protein homeostasis. Hsp90 is known to be highly expressed in tumour 
cells where it regulates stability and function of several key oncogenic client proteins 
including Akt kinase, EGFR, CDK and PDGFR. These client proteins are mutated or 
overexpressed in tumours and are involved in tumour progression and metastasis due to 
their roles in signalling pathways, cell cycle and apoptosis.  
Hsp90 has two isoforms, namely Hsp90α and Hsp90β and share 85% sequence 
homology. Hsp90β is the constitutive isoform, however, Hsp90α is highly induced in 
many cancers and is responsible for tumourigenesis. Previous studies from our 
laboratory established Hsp90α mRNA and protein to be highly expressed in glioma cell 
lines and tissues compared to normal tissue and cells. In a follow up study, Hsp90α was 
silenced using predesigned small interfering RNA (sihsp90α) with high target 
specificity and it showed a clinical impact on the chemosensitivity to Temozolomide 
(TMZ). Thus, Hsp90α could be a therapeutic target for the treatment of glioma.  
This study utilized a Hsp90-inhibitor 17-AAG and hsp90α-specific siRNA (sihsp90α), 
either as single agent or in combination, to inhibit Hsp90 function in glioblastoma. 
Hsp90α mRNA and protein expression levels post treatment were evaluated using qRT-
PCR and confocal microscopy. To determine if Hsp90α inhibition influenced Akt 
kinase activity, a Hsp90 client protein, Akt activity was examined in treated and control 
cells using a Akt Kinase activity kit. Novel results from the study revealed that Hsp90α 
was significantly down-regulated at both the mRNA and protein levels which were 
associated with reduced cell viability. Hsp90α inhibition resulted in loss of Akt kinase 
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activity which validated the role of Hsp90α in chaperoning tumour progression. The use 
of 17-AAG concomitant with sihsp90α did not demonstrate synergistic anti-tumour 
effects in glioblastoma in vitro.  
Furthermore, the application of siRNA as an alternative to small-molecule inhibitors in 
the treatment of human disease has shown therapeutic potential. However, a major 
hurdle to its utility has been the difficulty in delivering these anionic macromolecules in 
vivo. In this study, the ability of Tat peptide to enhance siRNA-mediated knockdown of 
hsp90α and siRNA stability in serum was investigated. In glioblastoma, Tat-mediated 
sihsp90α transfection concomitant with 17-AAG exhibited significant downregulation 
of Hsp90α mRNA and protein levels with increased peptide concentrations. Hsp90α 
suppression was associated with reduced Akt kinase activity and cell viability. The 
sihsp90α/Tat complex significantly improved sihsp90α stability in human serum for up 
to 36 h post serum exposure.  
Finally, the combination therapy induced hsp90α knockdown and reduced Akt kinase 
activity in vivo. Although these results are preliminary and requires further validation, 
the anti-cancer activity is promising. These results suggest that the combination 
treatment with sihsp90α and 17-AAG may have therapeutic potential in GBM. 
 
The novel work of this thesis has been published in: 
Mehta A, Shervington L, Munje C, & Shervington A (2011). A Novel Therapeutic 
Strategy for the Treatment of Glioma, Combining Chemical and Molecular Targeting of 
Hsp90α. Cancers 3, 4228-4244.  
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1.1 Glioma 
 
There are several distinct cancers that are currently recognised of which those affecting 
the central nervous system (CNS) are amongst the most uncommon. In the UK, 
approximately 4500 people are diagnosed with malignant brain tumours every year 
corresponding to around 2 out of a 100 cancers diagnosed (Cancer Research UK). Of all 
the benign and malignant brain and CNS tumours, gliomas are the most common and 
accounts for approximately 45-50% of all those diagnosed, and are most common in 
people aged 60 years or over (Figure 1.1.1). In 2008, a total of 9337 individuals were 
diagnosed with brain tumours in the UK, of which ~52% confer malignant and 
progressive forms of the disease, with 41.5% of men and women likely to survive for at 
least 1 year and a five-year survival rate of ~15% in both men and women (Cancer 
Research UK). The following year, brain tumours caused 3674 deaths in the UK which 
account for more than 2% of all cancer deaths (Cancer Research UK).  
The different glioma grade classification currently available as established by the World 
Health Organisation (WHO) assigns gliomas a grade on a scale of I-IV to reflect the 
degree of malignancy with grade IV being most malignant (Table 1.1.1). The most 
common, metastatic and malignant histological type of brain tumour which accounts for 
65% of all gliomas is glioblastoma multiforme (GBM) (Ohgaki & Kleihues, 2005). 
Although other gliomas with astrocytic, oligodendroglial origin account for 70% of all 
brain tumours. Malignant gliomas belong to the hypervascular neoplasms, mostly 
responsible for rapid growth and poor prognosis of the tumour (Harada et al., 2003). 
GBM is more predominant in elderly patients where diagnosis at late stages of the 
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disease has been reported to be a major prognostic factor of poor survival (Ohgaki et al., 
2004).  
 
 
 
Figure 1.1.1: Latest malignant brain tumours incidence statistics (Cancer Research UK). 
 
 
Table 1.1.1: WHO grading and survival rates of gliomas (Liu et al., 2012).  
WHO 
Grade 
Glioma Survival 
I Pilocytic astrocytoma 10 years + 
II Diffuse astrocytoma/ oligodendroglioma/ oligoastrocytoma 5-10 years 
III Anaplastic astrocytoma / oligodendroglioma/ oligoastrocytoma 2-5 years 
IV Glioblastoma multiforme (GBM) 9-12 months 
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1.2 Treatment for malignant gliomas 
 
Despite recent technological advancement the treatment of malignant gliomas remains 
adamant. At present, the standard treatment for GBM involves surgical resection of the 
tumour followed by radiotherapy, and concomitant and adjuvant chemotherapy, which 
up till now has failed to improve the prognosis and quality of life in patients affected. 
Treatment options for recurrent GBM include chemotherapy, reirradiation, surgery, best 
supportive care with corticosteroids or gene therapy (Thumma et al., 2012). 
 
1.2.1 Surgical resection 
Surgical resection is a vital aspect of the management of patients with GBM and the 
extent of resection is strongly associated with longer survival (Lanzetta & Minniti, 
2010; Mueller & Chang, 2009). Upon initial diagnosis, maximal surgical resection is 
critical and has been correlated with survival (Gerstein et al., 2010). However, this is 
compromised by the fact that gliomas are normally in close proximity to vital 
anatomical structures and often lack a defined tumour edge thus negating the possibility 
of surgical resection in patients with recurrent tumours. Although, studies suggest that 
surgery prolongs survival, the reported maximum survival advantage is less than 6 
months in patients without residual tumour (Lanzetta & Minniti, 2010). 
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1.2.2 Radiotherapy 
Radiation therapy has been the standard procedure of care for many years for patients 
with GBM. Radiotherapy (RT) (standard dose of 60 Gray (Gy); absorbed radiation 
dose) is given as a postoperative clinical course to ensure removal of any residual 
tumour that has remained after surgery with progression-free survival of 14.9 weeks 
(Lanzetta & Minniti, 2010; Siu et al., 2012). However, radiation therapy is not without 
risk with radiation induced injuries occurring in a certain proportion of patients which 
further complicates the treatment course and can compromise care. Although, survival 
rate is significantly longer in patients subjected to radiotherapy than non-irradiated 
patients (10.6 months vs 1.9 months) (Lanzetta & Minniti, 2010), reirradiation produces 
only a modest benefit in patients with recurrent GBM (Thumma et al., 2012). 
 
1.2.3 Chemotherapy 
Chemotherapy (CT) has been a part of the standard treatment against GBM since the 
1970’s. The most common systemically administered chemotherapeutic drugs include 
1,3-bis (2-Chloroethyl)-1-nitrosourea (BCNU or carmustine), procarbazine, vincristine 
and lomustine, or temozolomide (Table 1.2.1). BCNU is one of the oldest drugs used to 
treat GBM. The BCNU wafer (Gliadel
®
), a synthetic biodegradable polymer, 
impregnated with carmustine is a clinically approved chemotherapeutic agent for the 
treatment of newly diagnosed and recurrent GBM (Cohen et al., 2009). Although, 
BCNU is lipophilic in nature, substantial body toxicity has limited its treatment 
efficacy. BCNU wafer implants are associated with complications such as cerebrospinal 
fluid (CSF) leakage, hydrocephalus, seizures, cerebral edema, intracranial infection and 
cyst formation (Bock et al., 2010).   
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Table 1.2.1: Summary of the commonly used chemotherapeutic agents for the treatment of 
brain tumours. 
Class of agent 
Commonly 
employed agents 
Mechanism of action Reference 
Alkylating agents 
/Chloroethylnitros
o-ureas (CENUs) 
Temozolomide, 
Carboplatin,  
Procarbazine, 
Chlorambucil /  
BCNU 
(carmustine) 
CCNU (lomustine) 
Addition of methyl group 
to DNA residues, DNA 
cross linking agents / 
DNA cross linking agents, 
alkylating and 
carbamoylating agents 
(Liu et al., 
2012; Quiros 
et al., 2011) 
Antimicrotubule 
agents 
Vincristine, 
Vinblastin 
Blocks formation of 
microtubules resulting in 
cell cycle arrest in 
metaphase 
(Mabeta & 
Pepper, 2009) 
Topoisomerase I 
inhibitors 
Irinotecan 
Inhibit action of DNA 
repair enzyme 
topoisomerase I 
(Jaeckle et al., 
2010) 
Anti-angiogenic 
agents 
Bevacizumab 
Inhibit formation of new 
tumour blood vessels 
(Lai et al., 
2011) 
Platinum 
compounds 
Cisplatin, 
carboplatin  
DNA cross linkers 
(Tallen et al., 
2008) 
 
 
Temozolomide (TMZ) a second generation imidazotetrazine alkylating agent is the 
commonly used chemotherapeutic agent which mainly targets tumour recurrence 
following surgical removal of the tumour due to its ability to cross the blood brain 
barrier (Lanzetta & Minniti, 2010; Quiros et al., 2011; Siu et al., 2012). TMZ (Figure 
1.2.1) was first synthesized in the early 1980s at Aston University and was effective 
against a broad range of tumours including gliomas (Friedman et al., 2000). 
Characteristics that justified the use of TMZ for clinical evaluation in patients with 
cancer included wide drug distribution into the mouse brain, its lipophilic nature, 
complete (100%) bioavailability of the drug after dosing and no additional requirement 
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of enzymatic conversion into active anti-tumour component (Cohen et al., 2009). In 
2005, a study by Stupp et al. showed that TMZ supplemented with radiotherapy had 
significant survival benefit in patients with primary glioblastoma compared to patients 
treated with radiotherapy alone (Stupp et al., 2005). TMZ (commercially known as 
Temodar
®
/Temodal
®
) coupled with radiation therapy showed modest improvement in 
the median survival from 12-15 months (Minniti et al., 2009). These encouraging 
results led TMZ plus radiotherapy to be globally accepted as a standard therapy for 
glioblastoma multiforme. Clinical studies with TMZ revealed further details about its 
pharmacokinetics. The blood half-life of TMZ ranges between 1.6-1.8 h with peak 
plasma concentration attained within 0.33 and 2 h after drug administration 
(Wesolowski et al., 2010).  
 
 
 
Figure 1.2.1: Molecular structure of TMZ (Fukushima et al., 2009). 
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1.2.3.1 TMZ: Mechanism of action 
The cytotoxic effect of TMZ is exerted by methylation of the O
6
 position of guanine 
which deters the next replication cycle due to the formation of G:T mispair eventually 
leading to cell death (Fukushima et al., 2009). TMZ initiates G2/M cell cycle arrest in 
the glioma cells which leads to cell death by autophagy (Kanzawa et al., 2004). TMZ 
undergoes non-catalytic conversion into methyltriazen-1-yl imidazole-4-carboxamide 
(MTIC) at a pH above 7.44 (physiological pH) (Friedman et al., 2000). After drug 
ingestion the C
4
 position of the tetrazinone ring of the TMZ undergoes hydrolysation 
whereby loss of carbon dioxide results in MTIC. MTIC rapidly degrades into 5-amino-
imidazole-4-carboxamide (AIC), an inactive carboxylic acid derivative, and a highly 
reactive methyldiazonium ion at physiological conditions (Friedman et al., 2000) 
(Figure 1.2.2). This highly reactive ion spontaneously transfers methyl group to the 
DNA nucleotide at the O
6
 and N
7
 positions of guanine, N
1
 and N
3
 or adenine and N
3
 of 
cytosine to form a methylated-DNA adduct (Fukushima et al., 2009).  
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Figure 1.2.2: Mechanism of action of TMZ. The half-life of TMZ is approximately 1.8 h, but 
the half-life of the active component MTIC is slightly longer. Figure modified from (Friedman 
et al., 2000).  
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1.2.3.2 Chemotherapy: its advantages and disadvantages 
Cytotoxic chemotherapeutic drugs targets cancer cells over normal cells due to their 
enhanced proliferation rate. However, effects of chemotherapy are prevalent in normal 
cells due to the lack of site/cell specific treatment approaches. Taking this into account, 
chemotherapy is an effective treatment for lower grade gliomas resulting in high 
survival expectancy (Stupp & Baumert, 2003). There is a growing concern about 
increased chemo-resistance with higher grade gliomas including GBM and overcoming 
this hurdle has been the priority in order to improve treatment therapy against this fatal 
disease (Sarkaria et al., 2008). 
The efficacy of chemotherapy in patients is very low and only a handful of patients 
treated are cured of the disease (Quiros et al., 2011). Moreover, treatment options are 
very limited for recurrent GBM with a median overall survival in patients of only        
25 weeks (Minniti et al., 2009). The expression of DNA repair enzyme O
6
-methyl-
guanine-DNA-methyltransferase (MGMT) in most glioblastomas has been attributed as 
the main reason for treatment resistance to TMZ (Esteller et al., 2000). Side effects 
observed in patients treated with alkylating agents such as TMZ include 
thrombocytopenia, anaemia, fatigue and mild nausea, with rare occurrence of stomach 
ache and headache. Dose reduction is often required in patients illustrating hematologic 
complications due to the short blood half-life of TMZ which constrain the accumulation 
of drug at therapeutically effective concentrations in the tumour area, thus limiting the 
use of TMZ for chemotherapy (Ekeblad et al., 2007; Sarin et al., 2008).  
Although it is hard to predict the cost effectiveness of the treatment of malignant 
gliomas, a few studies have assessed the total cost of the treatment therapy (Lamers et 
al., 2008; Mabasa & Taylor, 2006). The estimated total cost of care for the treatment of 
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a patient with GBM is £36,000 per life-year gained mostly attributed to the high 
acquisition costs of TMZ (Linz, 2008). Despite its modest effects there is an urgent 
need to replace the present TMZ based standard post resection glioblastoma 
chemotherapy with other more stable and cost effective treatments.  
Surprisingly, glioblastomas treated with concomitant chemotherapy and radiotherapy 
tend to accumulate considerable amounts of genetic mutations over a period of time 
which leads to tumour recurrence. For instance, loss of the MSH6 gene (gene encoding 
mismatch repair protein) is the consequence of X-ray therapy and TMZ treatments 
which eventually leads to progressive tumour growth and recurrence (Cahill et al., 
2007). Furthermore, the expression level of O
6
-methlyguanine-DNA-methyltransferase 
(MGMT) determines the effectiveness of TMZ since MGMT removes the methyl 
adducts from the O
6
 position of the guanine and hence acts to reverse the cytotoxic 
effects induced by TMZ (Hegi et al., 2005).  
Although, TMZ combined with radiotherapy has been shown to improve survival times 
in patients with GBM, the 5-year survival for GBM remains dismal (Stupp et al., 2009). 
The low therapeutic index of this combination treatment is attributed to the acquired 
drug resistance in glioblastoma (de Groot & Gilbert, 2007). Thus, identifying and 
understanding the processes responsible for the effectiveness of the TMZ plus 
radiotherapy may help improve treatment therapy for GBM. In recent years information 
has revealed a genetic and molecular basis of resistance, unregulated proliferation and 
anti-apoptotic mechanisms which remains the major obstacle to the successful treatment 
of brain tumours (Sarkaria et al., 2008). This has led to the discovery of novel 
chemotherapeutic drugs that inhibit key molecular targets which have crucial roles in 
assisting signalling pathways responsible for malignancy (Mercer et al., 2009; Ziegler et 
al., 2008). In contrast, the effectiveness of anti-cancer drugs targeting individual protein 
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or signalling pathways have been low and in some cases completely lost, due to 
accumulation of mutations and variations in tumour cells considered as a major concern 
in cancer therapy (Wong et al., 2007; Xiao et al., 2006).  
 
1.2.4 Present and Future perspectives: Gene therapy 
GBM is characterised by several genetic and signalling abnormalities, including several 
growth factors such as epidermal growth factor receptor (EGFR), platelet-derived 
growth factor receptor (PDGFR) and vascular endothelial growth factor receptor 
(VEGFR), that ultimately lead to the irrepressible growth, angiogenesis, survival and 
differentiation (Minniti et al., 2009). The molecular characterisation of GBM could 
contribute towards identification of optimal therapeutic targets, however, the major 
challenge in the use of targeted therapies is to select novel agents which have the 
potential to yield survival benefit in patients with GBM (Cloughesy & Mischel, 2011). 
Several phase I/II clinical trials have evaluated the treatment efficacy of inhibitors of 
growth factor receptor transduction pathway and angiogenesis (Cohen et al., 2009; 
Jaeckle et al., 2010; Lai et al., 2011; Uhm et al., 2011). 
Gefitinib (Iressa, AstraZeneca) and erlotinib (Tarceva, Osi Pharmaceuticals), two main 
EGFR tyrosine kinases inhibitors, have been previously utilized as single agents in 
patients with recurrent GBM but the survival response observed was dismal (Prados et 
al., 2008). EGFR is a 170-kDa receptor tyrosine kinase which activates several 
signalling pathways such as the phosphatidyl-inositol 3’-kinase (PI3K)/Akt and 
Ras/mitogen-activated protein kinase (MAPK), subsequent to phosphorylation which 
contributes towards several biological processes including cell proliferation, 
angiogenesis, survival and differentiation (Holsken et al., 2011). No survival benefits of 
33 
 
combining erlotinib with RT and TMZ were observed compared to RT and TMZ alone 
and has been discontinued from clinical practice (Minniti et al., 2009).  
Imatinib (Gleevec, Novartis) is a PDGFR inhibitor which when used as a single agent 
has demonstrated limited activity in patients with recurrent GBM (Holdhoff et al., 
2010). PDGF signal through the alpha and beta receptor tyrosine kinase, whereby 
binding of ligand induces phosphorylation and subsequent activation of PI3K, MAPK 
and Akt signalling pathways. Modest survival benefits of imatinib have been 
accompanied with toxicity including neutropenia, thrombocytopenia and edema 
(Timotheadou, 2011). To enhance survival benefits in patients with GBM, regimens 
incorporating imatinib and TMZ have showed encouraging results with low side-effects.  
Bevacizumab (Avastin, Genentech), a recombinant monoclonal antibody that selectively 
binds and blocks the VEGF, has previously shown significant survival benefits in 
patients with recurrent malignant glioma (Pope et al., 2011). VEGF is a key factor 
responsible for angiogenetic processes which stimulate endothelial cell proliferation, 
extracellular matrix degradation and cell migration. Bevacizumab prevents VEGF from 
binding to its receptors on the surface of endothelial cells thereby reducing tumour 
vascularisation and subsequent reduction in tumour growth. A phase II trial of 
bevacizumab and irinotecan has shown encouraging response in patients with recurrent 
GBM (Kang et al., 2008; Reardon et al., 2012). A combination of bevacizumab with 
conventional RT and CT has shown promising anti-tumour effects with improved 
progression-free and overall survival, and moderate toxicity in patients with newly 
diagnosed GBM (Lai et al., 2011; Narayana et al., 2012; Vredenburgh et al., 2011).  
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1.3 Heat Shock Protein 90 (Hsp90) 
 
The molecular chaperone Hsp90 is highly abundant molecular chaperone (Workman et 
al., 2007), and constitutes 1-2% of total cellular proteins under non-stressed conditions 
(Taipale et al., 2010). While the amino acid sequence of a protein dictates its native 
conformation, most proteins fail to fold efficiently in the highly concentrated and 
complex environment of the cell without the help of heat shock molecular chaperone 
proteins (Bagatell & Whitesell, 2004) (Figure 1.3.1). Since its discovery in the 1960s, 
study of chaperone structure and function has been the active area of research due to its 
essential house-keeping functions including protein folding and translocation across 
membranes, and most importantly the post-translational regulation of cell signalling 
molecules (Whitesell & Lindquist, 2005). Hsp90 is unique since it is not required for 
the de novo synthesis of most polypeptides but it is required for folding of particular 
subset of proteins that have difficulty in reaching the active conformation. Alternatively, 
most but not all of its client proteins are conformationally labile signal transducers and 
have vital role in growth and survival processes (Whitesell & Lindquist, 2005). 
Over the past decade, Hsp90 has emerged as an important biomolecule responsible for 
cancer cell survival under obnoxious conditions (Kang et al., 2011). Although, Hsp90 is 
present in all cells, Hsp90 protein level is induced by heat shock, oxidative stress and 
nutritional deficiencies in many cancers including glioma but not in normal human 
brain tissue (Shervington et al., 2006). This over-expression has been attributed to the 
hostile conditions and stressful environment prevalent in tumours (Price et al., 2005; 
Shervington et al., 2008).  
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Figure 1.3.1: Hsp90 regulates the stability and activity of client proteins shown here to 
function as a vital component of a multi-protein complex. Hsp90 mediated conformational 
stabilisation functions as a multi-protein complex consisting of Hsp90, its co-chaperone proteins 
and accessory proteins that assist in client protein activation. The co-chaperone components of 
the Hsp90 complex are dependent on specific client proteins, most commonly include p23, 
Hsp70 and p60/Hop (Shervington et al., 2006). In this case, p23 and immunophilin Cyp40 
associate with the Hsp90 complex and maintains client proteins in a stable and non-aggregated 
form, which in the presence of specific signals such as ligand binding, phosphorylation permits 
activation of the client protein. Client proteins are degraded via the ubiquitin-proteasome 
pathway in the absence of appropriate stimulus. Figure modified from (Bagatell & Whitesell, 
2004). 
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1.3.1 Glioma: Role of Hsp90 
An increased expression of heat shock protein seen in cancer cells, in addition to the 
levels seen in normal cells, is common among solid tumours including gliomas 
(Whitesell & Lindquist, 2005). Molecular chaperones act as biochemical buffers for the 
molecular and genetic instability commonly observed in solid tumours. In addition, 
chaperones also permit tolerance to genetic alterations including mutations of 
fundamental signalling molecules which would otherwise be fatal (Bagatell & 
Whitesell, 2004). This exemplifies the vital role of Hsp90 in maintaining cellular 
homeostasis in the hostile environment imminent in gliomas. Moreover, gliomas have 
induced levels of Hsp90α (inducible isoform of Hsp90) protein as compared to its 
normal counterpart which has minimal or no presence of the chaperone protein 
(Shervington et al., 2008). Furthermore, oncogenic client proteins of Hsp90 such as Akt 
kinase, C-RAF, MET oncogene, CDK4, hypoxia inducible factor 1α (HIF-1α), human 
telomerase reverse transcriptase (hTERT), PDGFR, EGFR and mutant p53 hugely 
contribute to the pathogenesis of glioblastomas (Powers & Workman, 2006) (Figure 
1.3.2). The pharmacologic inhibition of Hsp90 in tumour cells has also been reported to 
cause client protein degradation via the ubiquitin-proteasome pathway (Holmes et al., 
2008). The ability to achieve multiple effects via a single drug target may potentially 
prove to be remarkably promising in the treatment of cancer. CDK4 is a serine/ 
threonine kinase that plays a pivotal role in cell cycle progression from G1 to S phase 
whose function is reliant on active Hsp90 and inhibition of Hsp90 causes destabilisation 
and degradation of CDK4 which further leads to cell cycle halt at G1 phase 
(Shervington et al., 2006).  
Recently, an overwhelming array of Hsp90 client proteins have been identified (Table 
1.3.1). Hsp90 mainly involved in protein chaperoning of client proteins that actively 
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participate in glioma progression include CDK4, EGFR, FAK, Akt, hTERT, p53, 
PDGFR, MAPK, MMP2, PI3K, EF-2 kinase, and HIF-1α and appear to play vital roles 
in cell cycle regulation and signal transduction (Sauvageot et al., 2009; Graner & 
Bigner, 2005).  
 
 
 
Figure 1.3.2: Hsp90 is essential for the stability and function of several oncogenic client 
proteins in glioblastoma. The roles of various client proteins in glioblastoma have been listed. 
Inhibition of Hsp90 could consequently interfere with the 10 hallmarks of cancer. Figure 
modified from (Hanahan & Weinberg, 2011).  
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Table 1.3.1 A list of Hsp90 client proteins (Zuehlke & Johnson, 2010).  
Transcription factors Eml4-Alk Raf-1, B-Raf, Ste11 
12(S)-HETE receptor EphA2 RET 
AF9/MLLT3 ErbB2 RET/PTC1 
BCL-6 ERK5 Ron 
CAR FGFR3, -4 Ryk 
Cytoplasmic v-erbA FOP2-FGFR1 SGK-1 
EcR GRK2 and GRK6 Slt2 
Nanog GSK3β SRPK1 
PPARα (PPARβ) HER3 SSCMK1 
PXR IκB kinases α, β, γ, ε SSTK  
Hap1 Insulin receptor TAK1 
HSF-1 IGFR1 TBK1 
IRF3 Integrin-linked kinase TGFβ receptors I and II 
Mal63 IP6K2 TrkB 
Oct4 IRAK-1 TrkAI and III 
p53 Ire1α Tyk2 
AhR JAK1 Ulk1 
HIF-1α JNK VEGFR1, VEGFR2 
HIF-2α c-Kit Wee1, Swe1 
HIF-3α KSR ZAP-70 
Sp1 LATS1, LATS2 Others 
Stat3 Lkb1 α2C adrenergic receptor 
Stat5 LRRK2 AID 
TDP-43 MAPK6 Annexin II 
TonEBP/OREBP MEK ANP receptor 
Ure2 MEKK1 and MEKK3 Apaf-1 
VDR Mik1 ApoB 
WT1 MLK3 Argonaute-1 (Ago1) 
Kinases MOK, MAK, MRK Argonaute 2 , 4 
Akt/PKB c-Mos ATG8 (GABARAP) proteins 
ALK1, ALK5 mTOR Axin 1 
AMPKα, AMPKγ NIK Bcl-2 
ASK1 p38 Bcl-xL 
Aurora B p90RSK Beclin 1 
Bcr-Abl PDGFRα Bid 
BTK PDK1 BLM helicase 
c-Abl PI4KIIβ Bms1 
Cdc2 Pim-1 BRCA1 
Cdk2, -4, -6, -9, -11 Pink1 BRCA2 
Chk1 PKCλ, PKCε and other PKCs BRMS1 
Tpl-2 Plk1 Cna2 
DDR1 Pnck Calmodulin 
DAPK1, -2, -3 pp60v-src, c-src Calponin 
eEF-2 kinase PRKD2 CARM1 
EGF receptor PRKDC β-catenin 
ElF2-α kinases HRI, Perk PTK6 CB2 cannabinoid receptor 
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Continued from previous page 
CD91 KSHV K1 R2TP complex through Pih1 
Cdc13 Kir6.2 Rab-αGDI 
Cdc25a and Cdc25c LAMP-2A Rab11a 
Cdk5 activator p35 LAP Rac/Rop GTPase Rac1 (rice) 
Clostridium toxin CDT LIS1 Rac1 
CFTR tRNA Ral-binding protein 1  
Chronophin Synthetase complex Rapsyn 
ClC-2 chloride channel Macrophage receptor Raptor 
Cineole synthase 1 Mdm2 Reovirus protein σ1 
COG complex MMP2, MMP9 REV1 
CTA1 MRE11/Rad50/NBS1 (MRN)  Reverse transcriptase HBV  
Ctf13/Skp1  Msps/XMAP215/ch-TOG Ribosomal proteins S3 &S6 
Cup MTG8 Ribosomal protein L2  
Cyclin B MUC1 Ricin catalytic A chain 
Cyclophilin D  NadA RIG-I 
Cyr1 Na+-K+-Cl- cotransporter 1 RNA-dep.  
Actin, tubulin RPM1 and RPS2 Rpb1 
DEDD Nod1, Nod2, NALP2, NALP3 R-protein I-2 
Diphtheria toxin NALP4, NALP12, IPAF SENP3 
Dengue virus protein E NELF-E SIR2 
DNA polymerase α Neuropeptide Y SKP2 complexes 
DNA polymerase η NRDG1 SMYD1, SMYD2, SMYD3 
DNMT1 Nox1, Nox2, Nox3, Nox5 snoRNP complexes 
Dsn1 Nsl1 SREC-I 
eNOS, nNOS  NS1 DNA helicase Ssl2 
F1F0-ATP synthase NSP3 SUR1  
FLIPS and FLIPL Nup62 Survivin 
Gα0, Gα12 N-WASP SV40 large T-antigen 
Free βγ subunit of G protein OGT α-synuclein 
Glutathione S-transferase  OsCERK1 Tab2/3 
Guanylate cyclase, soluble P1  Tau protein 
HDAC6 P300 Telomerase 
Hepatitis B core protein P450 CYP2E1 Thiopurine S-methyltrans. 
Hepatitis C protein NS3 P2X7 purinergic receptor Thrombin receptor (PAR-1) 
Hepatitis E capsid protein PARK7 (DJ-1) Thromboxane synthase 
HERG PB1/2 influenza RNA pol. Tissue plasminogen activator  
Histones 1,2A, 2B, 3 & 4 PCNA Titin 
Huntingtin Perilipin TLR4/MD-2 complex 
c-IAP1 PIDD TOM40 
Importin β1 Piwi TRIM8 
IPO4 PIWIL2 Triosephosphate isomerase 
Importin-α6 (KPNA5) Mg-dependent phosphatidate Trithorax  
PIP3 Phosphohydrolase Tyrosine hydroxylase 
INrf2 (=Keap1) Polysomal ribonuclease 1  UCH-L1 
Clostridium toxin iota PRMT5 URI complex 
IRS-2 Prolactin receptor Vaccinia core protein 4a 
Encephalitis virus E protein Prostacyclin synthase Vimentin 
JlpA Proteasome WASF3 
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Akt is a serine/threonine protein kinase (also known as protein kinase B, PKB) activated 
by growth factor stimuli such as insulin and PDGF (Miyata, 2005). Akt is present in the 
cell as an enzymatically active complex in association with Hsp90 (Figure 1.3.3). Hsp90 
prevents Akt inactivation by evading its dephosphorylation by phosphatases. 
Association with functional Hsp90 is essential for Akt stability and binding of inhibitors 
to Hsp90 results in its destabilisation and is subsequently targeted for proteasomal 
degradation (Won et al., 2009). Additionally, the ability of Hsp90 to bind to hTERT is 
crucial for assembly of telomerase complexes responsible for cancer cell 
immortalisation (Patel et al., 2008). The anti-apoptotic signalling is regulated by the 
association of hTERT and Akt with Hsp90, and subsequent phosphorylation of both the 
client proteins (Shervington et al., 2006).  
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Figure 1.3.3: The role of Hsp90 in regulating cellular apoptosis by modulating the function 
and stability of Akt. The low-affinity interaction between the Hsp90, co-chaperones and the 
client protein, in this case Akt, maintains it in a latent but readily activated state. However, 
oncogenic mutations of client protein Akt result in higher requirements of Hsp90 function. 
Figure modified from (Terasawa et al., 2005).  
 
 
1.3.2 Structure and functions of Hsp90 protein 
Hsp90 belongs to a family of molecular chaperones known to be highly conserved from 
prokaryotes to eukaryotes (Brown et al., 2007). Hsp90 mainly resides in the cytoplasm 
and exists predominantly as a homodimer (Whitesell & Lindquist, 2005). It has three 
domains: N-terminal domain with ability to bind ATP, middle domain and C-terminal 
domain which facilitates the homo-dimerization of Hsp90 monomers (Xiao et al., 2006) 
(Figure 1.3.4). The N-terminal ATP binding domain requires the binding and hydrolysis 
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of the ATP to execute and maintain the proper chaperoning of its client proteins. The 
conformational change in Hsp90 as a result of the phosphorylation at the N-terminal 
domain of Hsp90 further assists the conformational activation of its client proteins 
(Goetz et al., 2003). In eukaryotes, a versatile, highly charged linker sequence connects 
the N-terminal domain to the middle domain (Brown et al., 2007). The length and 
composition of this linker region is variable among the different organisms. Structural 
analysis of the N-terminal domain of Hsp90 shows the existence of an ATP-binding 
site. Moreover, biochemical studies of this domain also suggest that the intermolecular 
interaction between the two N-terminal domains of the Hsp90 homodimer occur in an 
ATP-dependent manner which gives Hsp90 characteristic ATP-driven chaperoning 
activity (Brown et al., 2007). Inhibition of ATPase dependent Hsp90 activity using 
inhibitors such as radicicol and geldanamycin that binds to the N-terminal domain of 
Hsp90 was one of the important findings of the 20
th
 century in anticancer research (Roe 
et al., 1999). For the past decade, Hsp90 has been considered as primary therapeutic 
target for the treatment of cancer.  
The middle domain is proteolytically resistant and contains a catalytic loop that accepts 
the terminal phosphate of ATP bound to the N-terminal ATP binding pocket of Hsp90 
(also called the γ-phosphate) (Brown et al., 2007). Structural studies of Hsp90 indicate 
that the middle domain is involved in the interface of many client proteins including 
p53 and Akt (Fontana et al., 2002; Muller et al., 2004). Also, a recently discovered co-
chaperone AHA1 (activator of Hsp90 ATPase homologue 1) interacts with Hsp90 and 
accelerates ATP hydrolysis by promoting association between the N-terminal and the 
middle domains (Meyer et al., 2004). The middle domain and the C-terminal domain of 
the Hsp90 are associated via another versatile linker region that drastically facilitates the 
ATPase activity of Hsp90 (Whitesell & Lindquist, 2005). C-terminal truncations of 
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Hsp90 eliminate its ability to hydrolyze ATP, therefore signifying the importance of the 
dimeric nature of C-terminal domain for Hsp90 activity (Prodromou et al., 2000). More 
importantly, the C-terminal domain contains the MEEVD motif (highly conserved 
pentapeptide) which is responsible for recruiting several co-chaperones containing the 
tetratricopeptide repeats, such as immunophilins and Hsp90 organizing protein (Hop), 
which corroborates the C-terminal domain as an essential subunit for Hsp90/co-
chaperone complex formation (Scheufler et al., 2000).  
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Figure 1.3.4: Structure of Hsp90 showing the different domains in the homodimer. A: The 
crystal structure of Hsp90 illustrates the N-terminus (red) that holds the ATP binding site 
essential for the binding and hydrolysis of ATP. Middle domain (yellow) has a critical role of 
interacting with many client proteins. The C-terminal domain (green) contains the MEEVD 
motif which recruits several co-chaperones essential for Hsp90 chaperone activity. B. Schematic 
structure of Hsp90. The numbers signify the position of amino acids. Figure modified from (Ali 
et al., 2006; Fukuyo et al., 2010).  
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The structural mechanism adapted by Hsp90 for its chaperone activity resembles a 
‘molecular clamp’. In the absence of ATP, the N-terminal domain of the Hsp90 
homodimer binds its client proteins by maintaining an open-state (Figure 1.3.5) (Brown 
et al., 2007). Once bound to ATP, Hsp90 homodimer undergoes conformational 
changes that permit transitory interaction between the N-terminal domains of the 
homodimer which ultimately leads to the formation of the closed-form of Hsp90 
homodimer and clamping of the substrate protein. Ultimately, the client proteins are 
activated through this ATPase-driven cycle involving Hsp90/co-chaperone complex 
(Voellmy & Boellmann, 2007).  
 
 
Figure 1.3.5: ATPase driven Hsp90 dependent activation of client protein. The Hsp90 
homodimer maintains an open state which facilitates capture of client proteins. Once associated 
with ATP, Hsp90 homodimer undergoes conformational changes including transitory 
interaction between the two N-terminal domains with concomitant activation of the captured 
client protein. Figure modified from (Brown et al., 2007). 
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Two cytoplasmic isoforms of Hsp90 exists in humans, namely Hsp90α (inducible 
expression) and Hsp90β (constitutively expressed), who share sequence homology of 
85% (Shervington et al., 2008). Hsp90 is mainly a homodimer, but monomers (α or β) 
and heterodimers can also exist (Sreedhar et al., 2004). The α isoform readily forms 
dimers, whereas β isoform dimerizes with less efficiency. The C terminal of Hsp90 is 
mainly responsible for dimerization (Figure 1.3.4). Another distinctive isoform, 
Hsp90N is associated with cellular transformation. Hsp90N shares sequence homology 
with Hsp90α, but it lacks the N-terminal domain which is a mandatory requirement for 
the ATP-driven Hsp90 chaperoning (Grammatikakis et al., 2002). Gene sequencing 
experiments identified hsp90α cDNA sequence in chromosome 14 and hsp90β cDNA 
sequence in chromosome 6 at the genomic locations at 14q32-33 and 6p21 for hsp90α 
and hsp90β, respectively, have been documented as functional (Sreedhar et al., 2004).  
 
1.3.3 Transcriptional regulation of hsp90α 
The transcription of human hsp90α gene is regulated by the 5’ upstream promoter 
sequences bearing the heat shock elements (HSEs) known to regulate gene expression 
of hsp90α (Sreedhar et al., 2004). The heat shock factor 1 (HSF1) binds to the HSEs 
and marks the initiation of hsp90α gene transcription. Under normal conditions, HSF1 is 
bound to cytosolic Hsp90 and Hsp70 and hence avoids transcription of heat shock 
genes. However, under stress, or upon inhibition of Hsp90, the Hsp90 chaperone refolds 
partially denatured client proteins which liberates HSF1 consequently resulting in its 
translocation to the nucleus where it initiates transcription of hsp90 gene (Kamal et al., 
2004). Hence, through a feedback mechanism, Hsp90 regulates its own gene expression 
whereby under normal conditions, HSF1 binds to Hsp90 and prompts gene transcription 
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to a halt (Westerheide & Morimoto, 2005). The exact mechanism responsible for the 
dissociation of Hsp90 from HSF1 under stress or in response to its inhibition of Hsp90 
inhibitors is still unclear. However, under stressful conditions it may alter protein 
stability by increasing the concentration of partially folded proteins which compete for 
Hsp90, consequently increasing the concentration of the active HSF1 (Powers & 
Workman, 2007). Figure 1.3.6 illustrates the negative feedback mechanism between 
Hsp90/Hsp70 and HSF1 which regulates transcription of the hsp90 genes.  
 
 
Figure 1.3.6: Transcriptional regulation of Hsp90. a) Under normal condition, HSF1 exists 
as a complex with Hsp90 and Hsp70. b) Under stress, Hsp90/Hsp70 dissociates from HSF1 to 
stabilise denatured proteins (c). d) Monomeric HSF1 now translocates to the nucleus where it 
can trimerize. e) HSF1 undergoes a series of post-translational phosphorylation events before it 
activates hsp90 gene transcription (f). g) HSF1 is inactivated when cellular concentrations of 
Hsp90 and Hsp70 increases. Figure adapted from (Powers & Workman, 2007).  
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1.3.4 Rationale for targeting the Hsp90α protein 
Hsp90 is involved in cell survival and signalling pathways that regulate cell 
proliferation. High levels of Hsp90 protein has been reported in several cancers 
including gliomas and has been correlated with tumour progression in glioma (Ohba et 
al., 2010; Porter et al., 2010). In addition, Hsp90 client proteins including PDGFR, 
EGFR and Akt play central role in survival and growth signalling pathways in glioma 
which validates targeting Hsp90 as an anti-cancer approach (Sauvageot et al., 2009). 
The inducible isoform Hsp90α is highly expressed in brain tumours and is known to be 
involved in cell cycle progression, apoptosis, malignant invasiveness and metastasis 
(Gaspar et al., 2009; Shervington et al., 2008). Furthermore, not only does Hsp90 
facilitate tumour cell survival in noxious tumour environments, but in its presence 
tumour cells tolerate genetic alterations to vital signalling molecules that would 
otherwise be fatal (Westerheide & Morimoto, 2005). Therefore, down regulation of 
Hsp90α mRNA and protein levels in glioblastoma may induce tumour cell death.  
A recent study on glioma cell lines showed that hsp90α was elevated (27-fold increase) 
in 3/3 glioma cell lines and 8/8 glioma tissue specimens as compared to extremely low 
or absent in normal brain cell lines and tissue specimens analysed (Shervington et al., 
2008). The inducible isoform, Hsp90α has also been reported to be released into the 
extracellular matrix surrounding tumour cells where it assists in activation of MMP2, in 
addition to contributing to tumour metastasis (Eustace et al., 2004). Due to the 
important role played by Hsp90α in tumour survival and progression as discussed 
above, and its induced protein levels in glioblastoma validates Hsp90α as an important 
therapeutic molecular target in glioblastoma, whose etiology is so multifaceted.  
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Various methods exist to silence/downregulate Hsp90 levels in vitro. Established 
approaches involve the use of Hsp90 inhibitors such as geldanamycin (GA), radicicol 
(RA) and 17-allylamino-17-demethoxygeldanamycin (17-AAG) that target the Hsp90 
protein. These inhibitors bind to the N-terminal domain of Hsp90 and interfere with its 
heat shock chaperoning by eradicating its ability to hydrolyse ATP (Fukuyo et al., 2010; 
Porter et al., 2010). Another approach using small interfering RNA (siRNA) has 
emerged as an effective silencing tool for post-transcriptional down regulation of target 
gene since the discovery of RNA interference (RNAi) pathway in invertebrates (Fire et 
al., 1998). RNAi mediated down regulation of hsp90α gene in glioblastoma in vitro 
using siRNA has been shown to induce chemosensitivity in glioblastoma (Cruickshanks 
et al., 2010).  
  
50 
 
1.4 Silencing Hsp90 protein 
 
Benzoquinone ansamycins, represented by 17-AAG and GA (Figure 1.4.1), were the 
first class of Hsp90 inhibitors known to have potent anti-cancer effects in vitro and in 
vivo (Li et al., 2009). These benzoquinone antibiotics bind to the N-terminal nucleotide 
binding pocket of Hsp90 thereby blocking the activation/maturation of client proteins 
(Figure 1.4.2), by inhibiting the crucial Hsp90 ATPase activity, primarily required 
during tumour growth (Graner & Bigner, 2005). In doing so, they induce ubiquitination 
and proteasomal degradation of aforementioned client proteins by the 26S proteasome 
(Taldone et al., 2008). Radicicol is another macrocyclic antibiotic isolated from fungus 
Monocillium nordinii and Monosporium bonorden (Figure 1.4.1), and targets the ATP 
binding site on the N-terminal domain of Hsp90 illustrated in Figure 1.4.2 (Duerfeldt & 
Blagg, 2010). Hsp90 inhibitors like GA and RA have been used in pre-clinical settings 
and have shown potent tumour inhibitory ability; however, its anti-cancer potential has 
been condemned mainly due to hepatotoxicity in animal models and has thus led to the 
development of GA derivatives with similar anti-cancer function but with considerably 
low toxicity profile (Li et al., 2009). This led to the discovery of 17-AAG which entered 
phase I clinical trials in 1999 and its intravenous formulations have shown encouraging 
results in more than 30 clinical trials with signs of therapeutic activity observed in 
melanoma, breast cancer, prostate cancer, and multiple myeloma (Gaspar et al., 2010; 
Li et al., 2009; Porter et al., 2010). Presently, 17-AAG is in phase II/phase III clinical 
trials in adults with advanced solid tumour malignancies (Gaspar et al., 2009; Siegel et 
al., 2012). Several clinical trials evaluating the combination of 17-AAG with other 
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targeted agents have demonstrated anti-tumour activity in patients with solid tumours 
(Holzbeierlein et al., 2010; Hubbard et al., 2011; Iyer et al., 2012).  
 
 
 
Figure 1.4.1: Chemical structures of Hsp90 inhibitors. Figure modified from (Fukuyo et al., 
2010). 
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Figure 1.4.2: Crystal structure of Hsp90 with insert showing the bound GA on the N-
terminal domain. Figure adapted from (Duerfeldt & Blagg, 2010). 
 
 
A study in 2003 demonstrated that Hsp90 in cancer cells binds to 17-AAG with >100-
fold higher binding affinity in comparison to Hsp90 in normal cells (Kamal et al., 
2003), which could suggest that the enhanced binding affinity may be due to the 
presence of Hsp90 in a multiprotein complex (active) state in tumour cells (Bagatell & 
Whitesell, 2004; Whitesell & Lindquist, 2005). Not only does 17-AAG have enhanced 
binding affinity for Hsp90 but only a small dose of it is required to inhibit tumour 
growth in glioma cell lines as compared to the dose required to inhibit growth in non-
tumourigenic cells (Sauvageot et al., 2009). Although, a high level of Hsp90 is present 
in most cells, 17-AAG selectively binds and kills tumour cells compared to normal cells 
(Kamal et al., 2003). Under clinical settings, the ability of 17-AAG to target tumour 
cells over normal cells can be used to establish a therapeutic window of dosing where 
only the glioma cells are specifically targeted.  
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17-AAG is lipophilic in nature, which facilitates its passage through the blood brain 
barrier (BBB) (Sauvageot et al., 2009). In addition, 17-AAG has an improved toxicity 
profile making it an ideal therapeutic candidate in GBM (Schulte & Neckers, 1998). 
The ability of 17-AAG to inhibit tumour growth when used in combination with another 
drug was recently realised when 17-AAG was administered with trastuzumab in patients 
with metastatic breast cancer and demonstrated promising anti-cancer activity with 
tolerable levels of toxicity (Modi et al., 2007). Also, 17-AAG was experimentally 
shown to induce radiosensitization in glioma cell lines, however, 17-AAG failed to 
synergize with TMZ treatment (Ohba et al., 2010; Sauvageot et al., 2009).  
Although 17-AAG has demonstrated promising anti-tumour activity in vitro and in vivo, 
several drawbacks including low water-solubility, instability in solution and low oral 
bioavailability limits its use in further clinical development (Porter et al., 2010). In 
order to address this issue, Kosan Biosciences developed 17-dimethylaminoethyl-
amino-17-demethoxygeldanamycin (17-DMAG) which retained Hsp90 inhibitory 
properties with improved water solubility and oral bioavailability profile compared with 
17-AAG (Li et al., 2009).  
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1.5 Silencing hsp90α using siRNA 
 
RNA interference (RNAi) is an evolutionarily conserved genetic silencing mechanism 
used to achieve sequence-specific post-transcriptional downregulation of target genes 
(Lee & Kumar, 2009;Siomi, 2009). The process of RNAi was first reported by Fire and 
Mello in the invertebrate nematode Caenorhabditis elegans but soon after RNAi was 
encountered in plants and vertebrates (Fire et al., 1998;Kim et al., 2009). RNAi can be 
induced by endogenously encoded microRNAs (miRNAs) or exogenously administered 
small interfering RNAs (siRNAs) but in either case the 21-23 base pair long 
oligonucleotides associate with a protein complex called the RNA induced silencing 
complex (RISC) in the cytoplasm to drive the sequence-specific degradation of the 
target mRNA (Shan, 2010). Long precursor dsRNA is spliced into short siRNAs, a 
duplex with anti-sense strand (guide strand) and a sense strand (passenger strand), by an 
enzyme called Dicer (an RNA III-family endonuclease). Following the Dicer cleavage, 
mature siRNAs associate with Argonaute family of proteins, namely Argonaute 2 
(Ago2), which functions as a core component of the RISC, to form the active RISC 
(Sashital & Doudna, 2010). In doing so, Ago2 retains the guide stand of the mature 
siRNA, crucial for the sequence-specific siRNA-mediated silencing of the 
complementary mRNA, while the passenger strand is removed (Figure 1.5.1). Finally, 
the guide strand binds to the target mature mRNA triggering mRNA degradation and 
subsequent inhibition of protein production (Sashital & Doudna, 2010).  
Post-transcriptional gene silencing using siRNA results in rapid reduction in mature 
mRNA levels; however, stable proteins require a longer period of time for depletion. 
Further, the effects of siRNA are temporary and only lasts for up to 3-5 doubling times 
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which can be attributed to the gradual dilution of siRNA through cell duplication (Kim, 
2003). siRNAs designed to specifically target hsp90α in glioma cannot only reduce 
mRNA levels but may have tumour inhibitory effects through down-regulation of 
Hsp90 protein level and consequently sensitise glioma cells to apoptosis (Chen et al., 
2009). 
 
 
 
Figure 1.5.1: The schematic of RNA interference mechanism. The precursor dsRNA is 
cleaved into siRNA duplex by the Dicer enzyme which then forms the RISC in association with 
Ago2 protein. Being the effector of RISC, Ago2 retains the guide strand (anti-sense) and 
negates the passenger strand from the RISC complex. The active single-stranded siRNA formed 
as a result of this then targets the mRNA subsequently inhibiting protein synthesis. Figure 
modified from (Kim et al., 2009).  
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A functional siRNAs which mediates gene silencing are 21 base pairs in length and are 
generated from longer dsRNA by the Dicer enzyme (Tran et al., 2003). Previously, it 
was established that both Hsp90 mRNA and protein levels are induced in glioma cell 
line and tissue (Shervington et al., 2008). Recent publication from our laboratory 
employed three sets of siRNAs, each sequence being target-specific at different regions 
on hsp90α gene (Cruickshanks et al., 2010). Exon 5 of hsp90α is targeted by both 
siRNA 1 and 2 while siRNA 3 targets hsp90α exon 9. The results demonstrated that 
siRNA treatment of glioma cells significantly reduced hsp90α expression after 24 h and 
completely silenced its expression 48 h after sihsp90α transfection (Cruickshanks et al., 
2010). In contrast, normal cells showed no signs of sihsp90α mediated gene silencing.  
An in vitro experiment on glioblastoma cell line (U87-MG) assessed the ability of 
sihsp90α targeting hsp90α to induce TMZ chemosensitivity when treated 
concomitantly. The study reported that the use of sihsp90α with TMZ considerably 
reduced the TMZ dose (by 13-fold) required to attain a comparable inhibitory effect on 
glioma cells as compared to when TMZ was used independently (Cruickshanks et al., 
2010). However, novel treatment regimens are now emerging fundamentally based on 
molecular targets and utilizing various advanced gene delivery systems. 
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1.6 Cell-penetrating peptides as delivery vehicles 
 
The brain is the most delicate organ in the body and is protected by the blood brain 
barrier from potentially toxic molecules circulating in the blood which includes 
molecules of therapeutic activity (Patel et al., 2009) (Figure 1.6.1). Despite recent 
advances in the treatment of neurological disorders, disorders related to the central 
nervous system including brain cancers by far outnumber the fatalities from all other 
types of systemic cancer or cardiovascular diseases. The poor prognosis in terminally ill 
patients with malignant glioma has been attributed largely to a lack of effective drug 
delivery systems (Patel et al., 2009).  
 
 
 
Figure 1.6.1: Blood brain barrier restrains entry of toxic substances (Patel et al., 2009).  
 
58 
 
 
Malignant gliomas remain to be one of the most critical and life threatening cancers 
without a cure (Sathornsumetee et al., 2007). Despite recent technological advances in 
surgical tumour resection, chemotherapy and radiation therapy, the disease progression 
is rapid after recurrence and prognosis is poor with a median survival of patients not 
more than 2 years (Sauvageot et al., 2009). Therefore, it is important to develop more 
effective therapies for the treatment of malignant gliomas.  
While the cellular origins of GBMs still remain firmly unidentified, there is increasing 
evidence that the malignant phenotype is driven by a subset of cells with stem-like 
qualities (Sauvageot et al., 2009). The origin of these glioma stem cells is widely 
debated whereby it could arise from endogenous stem cells or from more differentiated 
glioma cells which have accrued multiple mutations that confer stem cell-like 
characteristics (Sauvageot et al., 2007). At a molecular level, GBMs exhibit several 
mutational aberrations and signalling abnormalities which eventually results in 
uncontrolled proliferation, invasion and angiogenesis. Phosphatase and tensin 
homologue (PTEN) is a lipid phosphatase which restricts growth and survival signals 
mediated by the phophoinositide-3 kinase /Akt/mammalian target of rapamycin 
(mTOR) pathway. Loss of functional PTEN has been noted in approximately 30-40% of 
GBMs caused by mutational deletion within the PTEN on the chromosome 10 tumour 
suppressor gene (Wang et al., 1997; Sansal & Sellers, 2004), which leads to 
uncontrolled growth due to constitutive Akt activation.  
About 40% of GBMs exhibit amplified EGFR which results in induced proliferation, 
increased angiogenesis and inhibition of apoptosis. Additionally, 40% of GBMs express 
constitutively autophosphorylated variant of the EGFR known as EGFR variant III 
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known to increase proliferation and inhibit apoptosis in brain tumours by activating the 
Ras/Raf/MAPK and the PI3K-Akt signalling pathways (Sauvageot et al., 2009). GBMs 
also show aberrations in the platelet-derived growth factor (PDGF) signal transduction 
pathway due to the coexpression of PDGF-A and -B ligands and PDGF-α and -β in 
most glioma cells and endothelial cells creating an autocrine loop which can initiate cell 
transformation processes. Also, PDGF receptor (PDGFR) expression is upregulated in 
endothelial cells of tumour vasculature, which is undetected in blood vessels in normal 
brain, may suggest that PDGF produced by glioma cells may induce angiogenesis by 
binding to neighbouring endothelial cells (Sauvageot et al., 2009).  
Hsp90 plays a vital role in regulating cellular processes such as protein folding and 
degradation, and signal transduction; through its association with a list of well-
characterised client proteins, Hsp90 regulates their stability, phosphorylation states and 
function (Premkumar et al., 2006; Karkoulis et al., 2010). The client proteins that are 
overexpressed or mutated in GBM include EGFR, Raf, MEK, PDGFR, Cdk-4, -6 and    
-9, Akt and p53 (Pratt & Toft, 2003). With a diverse list of oncogenic clients, inhibiting 
Hsp90 could promote simultaneous shutdown of multiple signal transduction pathways 
involved in cell survival and proliferation, thus offering a better prognosis than single 
targeted agents.  
The discovery of RNAi for knockdown of protein expression through gene silencing 
using siRNA has revolutionised the area of functional genomics (Moschos et al., 2007a; 
Arthanari et al., 2010). The elucidation of the function of several genes using RNAi has 
led to a widespread interest amongst academic groups and biotechnology companies to 
investigate the therapeutic potential of RNAi using siRNA in the treatment of cancer 
(Mahanthappa, 2005; Karagiannis & El-Osta, 2005; Pu et al., 2006). Gene silencing 
using siRNA has been shown to significantly reduce Hsp90α mRNA levels in 
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glioblastoma (Cruickshanks et al., 2010). Although, transfection is relatively straight 
forward in vitro, achieving high transfection in vivo is challenging since electroporation 
is not practical for use in vivo (Meng et al., 2009).  
 
1.6.1 Challenges faced in siRNA-mediated gene shutdown  
Targeting Hsp90 in vitro is successful and straight forward (Sauvageot et al., 2009), 
whereas gene silencing utilizing target-specific siRNA is rather difficult to achieve in 
vivo without using delivery vehicles (Arthanari et al., 2010). Cancer siRNA therapy 
using neat siRNA in xenograft models is challenging due to low serum stability 
attributed to the rapid degradation of the dsRNA by the nucleases, non-specific immune 
stimulation and poor cellular uptake (Boado, 2005; Lundberg et al., 2007; Schiffelers et 
al., 2004). Thus, the major hurdle for glioma therapy is to improve drug/oligonucleotide 
delivery to the target site to achieve a more efficient and prolonged therapeutic effect. 
Under the circumstances, therapeutic approaches need to consider siRNA delivery in a 
manner that will not only ensure complete integrity of the cargo but will also permit 
sustained siRNA release for prolonged effects. The delivery of mature siRNAs benefits 
RNAi significantly since its action is mediated in the cytosol which thus eliminates the 
physiological barrier of the nuclear membrane (Grunweller et al., 2003). 
There have been numerous attempts to overcome the limited access of therapeutic 
molecules to the brain. siRNA is an anionic macromolecule whose cellular 
internalisation is rather difficult since it does not enter the cell by a passive diffusion 
mechanism (Shim & Kwon, 2010). An ideal siRNA delivery system would therefore 
enhance its cellular uptake, reduce enzymatic degradation and improve 
pharmacokinetics (i.e. longer half-life). Delivery of siRNA to various cell types has 
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been performed using cell-penetrating peptides (CPPs) which can stretch up to 30 
amino acids long (Jarver & Langel, 2004).  
 
1.6.2 Approaches to enhance oligonucleotide/drug delivery into the 
brain 
 
1.6.2.1 Intracellular siRNA delivery using carrier peptides 
Exploring peptides as cell delivery agents for oligonucleotides has received much of the 
impetus from the discovery of protein transduction domains, also known as CPPs, such 
as Drosophila melanogaster homeobox protein helix 3 peptide (Penetratin) (Coursindel 
et al., 2012).Carrier peptides are short cationic peptides, with lengths of no more than 
30 amino acids, that have been widely used for its enhanced intracellular cargo 
delivering ability (Meade & Dowdy, 2007) (Figure 1.6.2). The positive charge of the 
CPPs facilitates electrostatic bond formation with the negative charged phosphate 
backbone of the nucleic acids to form stable complexes which protect siRNA from 
degradation (Morris et al., 2008). These peptides, together with the carrier siRNA, bind 
to the anionic cell membrane and prompt cellular internalisation through a endocytosis-
mediated process (Meade & Dowdy, 2008). Carrier peptide mediated transport of 
siRNA into the cells can be via covalent or a non-covalent binding (Figure 1.6.3).  
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Figure 1.6.2: Cell penetrating peptides have been used for the delivery of various cargos. 
CPPs facilitate delivery of hydrophilic macromolecules across the plasma membrane but their 
internalisation mechanism is widely debated and is suggested to be influenced by the cell type 
and cargo. Figure modified from (Mae & Langel, 2006). 
 
 
 
Figure 1.6.3: CPP-mediated siRNA delivery (Endoh & Ohtsuki, 2009). A) Covalent 
attachment of the CPP to siRNA. B) Non-covalent complex formed between CPP and siRNA by 
electrostatic interactions. 
 
 
63 
 
1.6.2.2 Cellular Internalisation of CPPs 
The exact mechanism of cellular uptake of the CPPs remains elusive and is still 
extensively debated. Although it has been suggested that the uptake mechanism for 
different CPPs may vary influenced by the kind of CPP, cell type and size of the cargos 
(El-Andaloussi et al., 2005). Previous studies suggested that the Tat48-60 CPP (derived 
from HIV-1 trans-activator protein) internalisation did not involve endocytosis as 
indicated by receptor-, energy- and temperature-independent uptake (Patel et al., 2007). 
The studies designed a model of Tat peptide uptake, according to which the highly 
positively charged basic residues of the peptides have the ability to strongly adsorb to 
the negatively charged phospholipids of the cell membrane through electrostatic 
interactions which leads to local invagination of the cell membrane with subsequent 
formation of inverted micelles and, ultimately, release of the peptide inside the cell. 
Similar studies on live cells demonstrated that the uptake of Tat48-60 was inhibited at low 
temperatures which implicate endocytosis as a major mechanism for peptide uptake by 
the cells (Console et al., 2003). Intriguingly, clathrin-dependent endocytosis, lipid 
raft/caveolin-dependent endocytosis and macropinocytosis have all been associated as 
key mechanisms of CPP/cargo uptake by the cells (Fittipaldi et al., 2003; Wadia et al., 
2004; Wender et al., 2000).  
The intracellular fate of the transduced CPP and its cargo depend on the internalisation 
pathway followed. If the CPP is transduced into the cytoplasm, it could possibly interact 
with its cytoplasmic target or undergo proteasomal degradation, interact with nuclear 
target following importation to the nucleus (Patel et al., 2007). Alternatively, if the 
CPPs are internalised by endocytosis and taking into account the type of endocytosis, it 
may enter the cytoplasm or the nucleus after escaping lysosomal entrapment, which 
results in degradation, or be carried to the Golgi apparatus or the endoplasmic 
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reticulum. Once again, the type of CPP and cargo, the cell type under investigation and 
the nature of linkage between the CPP and cargo governs which transduction pathway 
will be followed. 
 
1.6.2.3 Membrane Interaction 
The interaction between the CPP and the surface of the cell has been firmly established 
as the first step in cellular internalisation initiation, whether it is through endocytosis or 
transduction (Patel et al., 2007). It is believed that the cellular uptake of cationic 
peptides does not involve cognate receptors. Furthermore, the role of negatively charged 
cell surface proteoglycans in the electrostatic membrane interaction of peptides has been 
emphasised by several studies (Tyagi et al., 2001; Rusnati et al., 1999; Rusnati et al., 
1998). Proteoglycans are glycoproteins which consist of one or more 
glycosaminoglycan chains (GAGs) linked to the core protein covalently. The GAGs are 
long linear polysaccharides that bear a negative charge at physiological pH mainly 
attributed to the presence of polysulphates such as chondroitin sulphate, dermatan 
sulphate and heparan sulphate (Richard et al., 2005). The ubiquitously expressed 
heparan sulphate proteoglycans have been associated with translocation of full length 
Tat protein with high binding affinity as compared to the truncated Tat peptide which 
interacts with lower affinity (Goncalves et al., 2005; Sandgren et al., 2002; Ziegler & 
Seelig, 2004).  
It is clear that cationic macromolecules such as peptides possess huge potential as 
delivery vehicles by virtue of electrostatic interaction which facilitates internalisation 
through adsorptive endocytosis. Moreover, the proteoglycans internalised by 
endocytosis are subjected to subsequent lysosomal degradation as a resource of their 
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turnover (Patel et al., 2007). Thus, the cargo molecules electrostatically bound to the 
proteoglycans are likely to be endocytosed and degraded if they do not dissociate before 
vesicle fusion.  
 
1.6.2.4 Endocytotic pathways: Macropinocytosis  
Endocytosis can be defined as the energy-dependent uptake of macromolecules and is 
characterised by vesicle formation (Patel et al., 2007). They can be categorised into two 
types namely, phagocytosis for internalisation of large molecules, and pinocytosis for 
uptake of fluids and solutes. Although, phagocytosis can only occur in specialised cells 
of the immune system, pinocytosis can occur in all the cells through at least four 
different endocytosis pathways; caveolin mediated, clathrin mediated, caveolin and 
clathrin independent and macropinocytosis, with all four pathways associated with 
cellular internalisation of CPPs and cargos (Drin et al., 2003; Ferrari et al., 2003; 
Kaplan et al., 2005; Richard et al., 2005). The specific pathway of CPP-cargo uptake 
will depend on the size of the endocytic vesicles formed and intracellular trafficking of 
the vesicles. For example, caveolin pits are ~50-80 nm in diameter, clathrin vesicles are 
~120 nm in diameter, caveolin and clathrin independent endocytic vesicles are ~90 nm 
in diameter. The macropinosomes arising from macropinocytosis are 1-5 µm in 
diameter (Conner & Schmid, 2003).  
Being an actin-dependent form of endocytosis, macropinocytosis has been suggested as 
the major route of cellular internalisation of cationic CPPs (Khalil et al., 2006; Nakase 
et al., 2004; Wadia et al., 2004). This could be attributed to the fact that uptake by 
macropinocytosis involves internalisation of significant volumes of extracellular fluids 
including CPPs which are mainly concentrated on the surface of the cell. However, 
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whether macropinocytosis is the only pathway of CPP uptake into the cell is debatable. 
For instance, Tat coated liposomes (200 nm) were shown to penetrate into cells without 
loss of integrity, taking into consideration the size of the liposomes, entry into cells is 
precluded by uptake mechanisms other than macropinocytosis since the vesicle sizes are 
considerably smaller than liposomes (Torchilin et al., 2001). In addition, liposomes 
modified with a high density of octaarginine were preferentially internalised by 
macropinocytosis in contrast to liposomes modified with low density of oligoarginine 
which resulted in uptake by clathrin-mediated endocytosis (Khalil et al., 2006). 
Although they suggested that the high density of oligoarginine is required to stimulate 
macropinocytosis, a similar concentration of free peptide did not stimulate 
macropinocytosis. On the contrary, Dowdy et al. showed that Tat peptide was not only 
internalised by macropinocytosis but was essential in inducing macropinocytosis and 
that uptake of Tat-Cre fusion protein was inhibited by amiloride which is a 
macropinocytosis inhibitor (Kaplan et al., 2005; Wadia et al., 2004). Interestingly, in 
HeLa, HepG2 and Chinese hamster ovary (CHO) cells fluorescently labelled Tat 
peptide was shown to be internalised via the clathrin-dependent endocytosis, whereby 
inhibiting clathrin-dependent endocytosis was shown to reduce Tat uptake by ~50% and 
inhibited transferrin which is a classical marker of clathrin-dependent endocytosis by 
85% (Potocky et al., 2003; Richard et al., 2005).  
 
1.6.2.5 Non-endocytotic uptake 
The uptake of CPPs occurs not only through energy-dependent endocytotic pathways 
but via a non-endocytotic/transduction pathway (Patel et al., 2007). This energy- and 
receptor-independent uptake mechanism has been shown to be the primary uptake 
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mechanism for the Tat peptide in CHO and HeLa cells (Zaro & Shen, 2005). 
Furthermore, the physiological relevance of the transduction pathway is illustrated by 
uptake of functionally intact transcription factors from which CPPs such as Tat are 
derived. With most studies focusing on endocytotic internalisation of CPPs, few efforts 
have concentrated on understanding the transduction mechanism which have led to 
suggest two hypothetical models with minimal experimental evidence, namely direct 
membrane penetration and inverted micelle (Patel et al., 2007). Both uptake 
mechanisms follow a 3-step process of internalisation: (a) membrane interaction, (b) 
membrane permeation and (c) release of CPP into the cytosol. Steps 2 and 3 are where 
the main differences between endocytosis and transduction exists, wherein endocytosed 
CPPs are confined in vesicles and may be released into the cytosol, however, transduced 
CPPs directly localise in the cytoplasm following membrane permeation. 
 
1.6.2.6 Endosomal escape of macromolecules internalised by endocytosis 
During endocytosis, the macromolecules are compartmentalised after vesicle fusion and 
budding events. The vesicle content is then targeted to different parts of the cell 
depending on the different endocytotic pathways. For instance, caveolin-mediated 
endocytosed vesicles are targeted to the golgi apparatus or to the endoplasmic reticulum 
by retrograde transport mechanism (Fischer et al., 2004). In clathrin-mediated 
endocytosis, some vesicles are recycled to the plasma membrane while others are 
directed to the lysosomes (Conner & Schmid, 2003; Richard et al., 2005). 
Macropinosomes resulting from macropinocytosis have different intracellular fates 
which vary with cell type. In macrophages they have been shown to shrink and merge 
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with lysosomes but in the human epithelial carcinoma cell line (A431) and HeLa cells 
they are mainly recycled back to the extracellular space (Conner & Schmid, 2003).  
Few reports have suggested the inefficient escape of fluorescently labelled CPPs from 
endosomal compartments due to being confined in vesicles, verified by punctate 
staining patterns with confocal laser scanning microscopy (Fuchs & Raines, 2004). A 
report by Potocky et al. demonstrated punctate as well as diffuse staining of Tat-derived 
CPPs in the cytoplasm and the nucleus, that could be attributed to pH change in the 
endosomes which alters CPP conformation, subsequently facilitating endosomal escape 
(Potocky et al., 2003). Biologically active cargos, when entrapped in endosomes are 
ineffective and therefore endosomal escape and retention of functional activity of the 
cargo is vital. In order to instigate endosomolysis, lysosomotropic agents such as 
chloroquine and HA2 fusion peptides have been utilized to enhance peptide delivery of 
oligonucleotides and proteins (Lundberg et al., 2007). The N-terminal domain of 
influenza virus hemagglutinin-2 (HA2) induces pH-dependent lysis of the membrane at 
low pH and has been shown to stimulate the escape of Tat-Cre fusion protein and p53 
conjugated to oligoarginine (Michiue et al., 2005). In addition to lysosomotropic agents, 
photochemical internalisation (PCI) which involves disruption of the endosomes by 
reactive oxygen species generated by photosensitizers upon irradiation, enhance release 
of peptide nucleic acid (PNA)-CPP and fluorescently labelled CPP entrapped in 
endosomes (Maiolo, III et al., 2004; Shiraishi & Nielsen, 2006).  
 
1.6.3 CPP-mediated siRNA delivery 
The therapeutic applications of non-covalently linked carrier peptide/siRNA complexes 
have been recently reported in vitro and in vivo by several studies (Crombez et al., 
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2009a; Eguchi et al., 2009; Han et al., 2010; Kim et al., 2010b; Kumar et al., 2007). 
The Tat48-60 peptide is a short cationic peptide derived from the human 
immunodeficiency virus type 1 (HIV-1) Tat transcriptional activator protein which has 
been widely employed for intracellular delivery of oligonucleotides (Shim & Kwon, 
2010). Although the actual Tat protein is 101-amino acids in length, the laboratory 
version of the Tat protein is the 86-amino acids derived during tissue culture passaging 
(Jeang et al., 1999). The Tat protein consists of five domains of which domain four is 
the most significant because it contains the basic RKKRRQRRR motif responsible for 
direct RNA binding and nuclear localisation of the protein (Ruben et al., 1989; Weeks 
et al., 1990).  
The utility of Tat peptide for intracellular delivery of various cargos including β-
galactosidase, horseradish peroxidase, RNase A in vitro was first performed in 1994 
(Fawell et al., 1994). They showed that the 36 amino acid long Tat37-72 fragment 
promoted uptake of the 177 kDa β-galactosidase protein in mammalian cells. With 
respect to delivery, two interesting domains included in this segment of the peptides 
were the basic domain and the adjacent α-helix (Loret et al., 1991). To identify the 
domains responsible for peptide internalisation, synthetic Tat peptides with deletions in 
the α-helical and the basic cluster domain were prepared (Vives et al., 1997). The        
α-helical domain which was previously thought to mediate transduction was found to be 
discrete to the cellular uptake of the cargos. The whole basic cluster domain (48-60 
residues), however, was found to be responsible for the ability of Tat to internalise 
cargos since deletions in this domain resulted in reduced Tat uptake by the cells.  
Polyamidoamine dendrimer-Tat conjugated with bacterial magnetic nanoparticles has 
been shown to deliver EGFR siRNA to human glioblastoma cells in vitro and xenograft 
models (Han et al., 2010). A study by Chiu et al. demonstrated a clear correlation 
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between the siRNA localisation, cellular uptake and RNAi efficiency using siRNA-
Tat47-57 conjugates in HeLa cells which represent a collective criteria required for 
siRNA delivery and effective gene silencing (Chiu et al., 2004). Consequently, higher 
concentrations of the conjugates resulted in further increase in cellular uptake and RNAi 
activity. In addition, modification to the peptide backbone structure of the siRNA-  
Tat47-57 conjugate did not inhibit siRNA uptake neither did it influence the RNAi 
efficacy (Chiu et al., 2004). The siRNA localisation pattern observed using unmodified 
and modified peptide conjugates were identical suggesting that the siRNA localisation 
was dictated by interaction with RISC and not the Tat47-57 peptide. Furthermore, the 
siRNA-Tat47-57 conjugate localisation to the cytoplasm was a decisive factor for 
efficient RNAi activity, mainly attributed to the localisation of the dicer enzyme to the 
cytoplasm and restriction of RNAi in human cells to the cytoplasm (Billy et al., 2001; 
Zeng & Cullen, 2002).  
The use of RNAi has been suggested as a therapeutic alternative to small-molecule 
inhibitors for the treatment of human diseases. A report by Moschos et al., showed that 
lung delivery of target-specific siRNA using Tat48-60 peptide induced gene knockdown 
of p38 MAP kinase mRNA by 20-36% in vitro and 20-30% in vivo (Moschos et al., 
2007a). Interestingly, Tat48-60 peptide alone was shown to significantly downregulate 
p38 MAP kinase mRNA expression in vivo which may suggest a regulatory role of 
Tat48-60 on the p38 MAP kinase expression. This could be attributed to the uptake of 
TNFα and EGF receptors through clathrin-dependent endocytosis without their 
activation (Fotin-Mleczek et al., 2005). In addition, since DNA-binding domain of the 
transcription factors form major component of cationic CPPs, it can be anticipated to 
interfere with host gene transcription (Moschos et al., 2007b). A study by Baker et al. 
utilized Tat48-60 to deliver a cytotoxic peptide mimic of the cyclin-dependent kinase 
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inhibitor, p21
WAF1/CIP1
 in glioma cell lines and showed significant reduction in cell 
viability after 24 h (Baker et al., 2007). In the event of DNA damage, the cell responds 
by upregulation of p53 and p21
WAF1/CIP1
 expression which inhibits cyclin-dependent 
kinases and cell replication. The proliferating cell nuclear antigen (PCNA) is a 36 kDa 
polypeptide which has a critical role in DNA replication, repair and protein-protein 
interaction (Cazzalini et al., 2003). The authors showed that Tat(48-60)-p21
WAF1/CIP1
 
peptide which contains the PCNA interacting protein (PIP) sequence blocks PCNA-
dependent DNA replication and subsequently induced apoptosis in glioblastoma cells 
(Baker et al., 2007).  
In some cases, CPP-mediated siRNA delivery requires additional molecules to facilitate 
siRNA/CCP dissociation in the cell cytoplasm. A study by Endoh et al. reported that 
Tat conjugated siRNA showed no gene silencing due to entrapment of the conjugates in 
the endosomes following efficient internalisation (Endoh et al., 2008). However, 
photostimulating fluorescently labelled Tat resulted in its release from the endosome 
subsequently increasing the gene silencing efficiency. Other agents which have been 
frequently used to destabilize endosomal membranes and improve cytosolic release of 
CPP-siRNA include chloroquine and influenza virus-derived hemagglutinin peptide 
(Shim & Kwon, 2010). 
The CPPs have tremendous potential in biotechnology attributed mainly to their ability 
to increase uptake of biologically active proteins or macromolecules into the cells. To 
achieve this potential it is of utmost importance to understand the pathway of CPP entry 
into the cell and subsequent localisation to intracellular compartments (Wadia & 
Dowdy, 2002). A study by Rhee and Davis used a small peptide called C105Y, 
covalently attached to poly-L-lysine (polyK) condensed DNA complexes to increase 
cellular uptake both in vitro and in vivo (Rhee & Davis, 2006). C105Y was found to 
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translocate through the membrane and to the nucleus in an energy-independent manner, 
however, nucleolar localisation was energy-dependent. The internalisation of C105Y 
was suggested to be via a caveolin- and clathrin-independent pathway. The synthetic 
peptide C105Y which averages 25 nm in diameter, provides gene transfer of cystic 
fibrosis transmembrane regulator (CFTR) gene, to the airway epithelial cells in CFTR-
deficient mice which was sufficient to partially correct the chloride transport defect with 
concomitant reversion of down-regulated NOS-2, a characteristic of cystic fibrosis 
mouse nasal epithelium (Ziady et al., 2002). C105Y has also been demonstrated to 
enhance gene transfer in the liver, lung and spleen in vivo and increase the intensity and 
duration of reporter gene expression in vitro (Ziady et al., 2004).  
Interestingly, there are peptides which have the ability to recognise molecular targets 
that can influence several aspects of cellular physiology and pathology. Mimetic 
peptides including the sequence derived from functional protein domains can potentially 
make multiple contacts with target proteins once delivered to appropriate intracellular 
compartments. A recent report used bioactive CPPs from the human cytochrome c as 
prediction template to identify CPPs that imitate the apoptogenic activity of the native 
protein (Jones et al., 2010). Two sequences namely, Cyt c
77-101
 and Cyt c
86-101
 (Figure 
1.6.4) were observed to induce tumour cell apoptosis in vitro. Quantitative analysis 
confirmed Cyt c
77-101
 as an extremely efficient CPP with enhanced propensity for 
cellular penetration and was selected for modification and development of chimeric 
apoptogenic agent targeting the nuclear pore complex (NPC), specifically the FG 
nucleoporins (FG Nups) which facilitates redistribution of NPC proteins, significantly 
enhancing its apoptogenic potency (Jones et al., 2010). Utilisation of mimetic peptides 
such as Cyt c
77-101
 with high translocation efficacy for siRNA delivery may enhance 
73 
 
cytotoxicity that combines the apoptogenic properties of the CPP and a bioactive target-
specific siRNA. 
 
 
 
Figure 1.6.4: Cryptic CPP sequence of Cyt c. The quaternary structure of Cyt c and the 
distribution of highly probable CPP sequences are mainly located in the C-terminal helix. The 
primary sequence, peptide sequences and abbreviations of cryptic CPPs have been illustrated. 
Figure modified from (Jones et al., 2010).  
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Although, CPPs have been proved to translocate across the plasma membrane of 
eukaryotic cells, they have been found to be toxic when used at high concentrations 
which could be due to lytic properties or membrane perturbation (Hallbrink et al., 2001; 
Saar et al., 2005). Studies on CPP-mediated uptake of cargo have focused on achieving 
high delivery yields with few studies aimed towards the classification of toxicity status 
of the peptides. The toxicity results of single CPPs and different cargos are divergent 
which makes comparison between studies rather challenging. Likewise, various studies 
use different cell lines, cell passages, incubation times and concentrations etc. making 
comparisons even more complicated (El-Andaloussi et al., 2007). The effects of CPPs 
on membrane integrity can be measured as a function of cytoplasmic lactate 
dehydrogenase (LDH) released into the medium utilizing LDH leakage assays.  
Previous reports have shown that Tat48-60 has no influence on membrane integrity even 
at higher concentrations (20 µM) in Bowes human melanoma cells (Hallbrink et al., 
2001). In addition, Tat48-60 at 50 µM concentration was shown to be non-cytotoxic in 
glioblastoma, astrocytoma, colorectal adenocarcinoma and breast carcinoma cells in 
vitro (Baker et al., 2007). Tat47-57 together with dsDNA has been shown to be non-toxic 
in HeLa cells at concentrations up to 50 µM (El-Andaloussi et al., 2007). In contrast, 
Tat47-57 showed higher membrane disturbance at the same concentration as a free 
peptide and drastically reduced the cell viability as a fluoresceinylated Tat47-57 at         
20 µM, but not as free peptide. This highlights the importance of measuring both 
membrane disturbance and long-term cytotoxicity when studying CPPs since they do 
not necessarily correlate (El-Andaloussi et al., 2007). Thus, it is clear that the toxicity of 
CPPs is heavily dependent on the cargo molecule, coupling strategy, peptide 
concentration and the cell line investigated.   
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1.7 Gene silencing and protein inhibition of cancer 
molecular targets and its implications in vivo 
 
The structurally rigid and anionic nature of the siRNA molecule confer the cell 
membrane as an impermeable barrier and remains a major hurdle for using RNAi in 
vivo without delivery vectors (Gondi & Rao, 2009). Several techniques have been 
implicated to address this issue, including electroporation, encapsulation in liposomes 
and viral delivery systems. However, these approaches lack real potential for clinical 
use due to severe drawbacks such as limited efficiencies in in vitro and in vivo systems, 
cytotoxicity, cell damage and undesired immunogenic effects (Suhorutsenko et al., 
2011). In contrast, synthetic CPPs have shown an ability to deliver various cargos, for 
example, DNA, RNA and proteins in vitro (Lindberg et al., 2011). 
CPPs have been extensively employed for intracellular delivery of siRNA (Chiu et al., 
2004; Han et al., 2010; Moschos et al., 2007a). The concept of target-specific killing of 
glioblastomas by inducing synthetic RNAi response using CPPs has shown particular 
promise in vivo. A study by Michiue and co-workers, used Tat peptide to deliver 
sequence-specific siRNAs to knockdown EGFR and Akt, both oncogenic clientele of 
Hsp90, as a combinatorial approach to induce tumour cell specific apoptosis and 
significantly increased survival in intracerebral glioblastoma mouse models (Michiue et 
al., 2009). For siRNA delivery, a dsRNA-binding domain (not gene specific) was fused 
on to the Tat peptide which masks the anionic charge of the siRNA and allows efficient 
siRNA delivery into the entire cell population by improving the stoichiometric ratio 
between the peptide and siRNA cargo which enhances cellular uptake and biological 
activity of the cargo as well as providing greater protection from serum during systemic 
passage (Coursindel et al., 2012). 
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Another study utilized an improved variant of the amphipathic peptide MPG consisting 
of hydrophobic and hydrophilic domains derived from HIV gp41 and SV40 T-antigen 
respectively, a 21 amino acid peptide known as MPG-8 was shown to form 
nanoparticles with siRNA target specific to cyclin B1, promote its efficient delivery into 
primary cell lines and prevents tumour growth in tumour mouse models following i.v. 
injection (Crombez et al., 2009b). Subsequently, a third 20-mer peptide, known as 
CADY, has also shown anti-cancer activity in prostate carcinoma when complexed with 
siRNA following entry into the cells by direct translocation (Divita et al., 2009).  
An added benefit of CPPs is that these vectors enter the entire cell populations in a non-
toxic fashion and as most CPPs are synthesised, the addition of predesigned structures 
and modification with different chemical entities is relatively straightforward widening 
their possible applications (Andaloussi et al., 2011). Theoretically, the RNAi response 
utilizing siRNAs that can be readily redesigned could selectively target oncogenic 
pathways to induce a lethal RNAi response which could evolve as rapidly as the tumour 
genetics evolves and could thereby allow treatment of recurrent tumours.  
The RNAi knockdown efficiency using sihsp90α/Tat complexes in combination with 
17-AAG will be examined in intracranial glioblastoma mouse models. Following 
tumour implantation, the tumour growth will be monitored by measuring the weight of 
the mice, histological staining as well as by luciferase quantitation in tissue specimens. 
The Akt kinase activity will be quantitated to determine whether loss of Akt activity 
was subsequent to Hsp90α inhibition in vivo. These efforts will highlight whether the 
novel approach to dual targeting of Hsp90α possesses therapeutic potential in GBM.  
Due to the limited resources and expertise to conduct intracranial surgery at UCLan, the 
experimental procedures presented in this chapter were performed at the Institute of 
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Technology, University of Tartu, Estonia, in collaboration with the research group of 
Professor Ulo Langel and under the supervision of Dr Kaido Kurrikoff. The procedures 
involving gene expression and Akt kinase activity were performed at the UCLan, UK. 
The research group at Tartu specializes in the development and utility of peptide 
cellular transporters in vitro and in vivo (Andaloussi et al., 2011; Suhorutsenko et al., 
2011).  
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1.8 Summary  
 
1. GBM is one of the most devastating cancers with poor prognosis and lack 
effective treatment therapies (Balducci et al., 2012). The present standard 
treatment for GBM involves surgical resection of the tumour followed up with 
radiotherapy and concomitant chemotherapy associated with modest survival 
benefits (Thumma et al., 2012). 
2. The Hsp90 is highly abundant molecular chaperone and constitutes 1-2% of total 
cellular proteins under normal conditions (Workman et al., 2007). Hsp90 has 
emerged as an important biomolecule that chaperones cancer survival under 
obnoxious conditions by regulating stability and activity of its oncogenic client 
proteins including key proteins involved in signal transduction, cell cycle control 
and transcriptional regulators, and contributes to tumour growth and progression 
(Zhu et al., 2010). 
3. The highly inducible isoform Hsp90α is highly expressed in brain tumours and 
is known to be involved in cell cycle progression, apoptosis and metastasis 
(Shervington et al., 2008; Gaspar et al., 2009). Hsp90α gene and protein 
expression levels in glioma cell lines and tissue specimens was highly induced 
as compared to normal brain cell lines and brain tissue (Shervington et al., 
2008), which serve as a rationale for targeting Hsp90α.  
4. Benzoquinone ansamycin 17-AAG has demonstrated potent anti-cancer effects 
in vitro and in vivo (Li et al., 2009). 17-AAG binds to the N-terminal nucleotide 
binding pocket of Hsp90 and subsequently prevents its stabilizing interactions 
with client proteins thereby preventing tumour growth.  
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5. RNA interference is the mechanism of inducing sequence-specific post-
transcriptional gene silencing initially observed in invertebrate nematode but 
later encountered in plants and vertebrates (Fire et al., 1998; Kim et al., 2009). 
Exogenously administered siRNAs associate with protein complex known as 
RISC to drive the sequence-specific degradation of target mRNA. Hsp90α-
specific siRNA exogenously introduced into glioblastoma cells was shown to 
significantly reduced Hsp90α gene and protein expression in vitro consequently 
inducing chemosensitivity to TMZ (Cruickshanks et al., 2010).  
6. The blood brain barrier confers an impermeable barrier to toxic molecules 
circulating in the blood including molecules of therapeutic activity which largely 
attributes to poor prognosis in patients with malignant gliomas (Patel et al., 
2009). The cell-penetrating peptides (CPPs) are short cationic peptides that have 
been widely used for the intracellular delivery of various cargos (Meade & 
Dowdy, 2007). The therapeutic applications of CPP/siRNA complexes have 
been widely reported in vitro and in vivo (Eguchi et al., 2009; Kim et al., 
2010b;Han et al., 2010).  
7. The structurally rigid nature and the anionic charge of the siRNA molecule 
confer the cell membrane as an impervious barrier for RNAi therapy in vivo. 
Several studies have demonstrated the induced synthetic RNAi response 
utilizing CPPs in vivo (Crombez et al., 2009b; Divita et al., 2009; Michiue et al., 
2009).  
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1.9 Aims and objectives of this study 
 
Hsp90α has been identified as a potential anti-glioma target according to recent findings 
from our laboratory. This novel investigation aims to target Hsp90α using a chemical 
approach (17-AAG) as well as molecular approach (siRNA) in GBM. Furthermore, this 
study will utilise cell-penetrating peptides for siRNA transfection/delivery and 
investigates its treatment efficacy and toxicity profile in vitro with a view to examine 
treatment effects in xenograft models.  
The overall objective is to provide proof of concept for a new therapeutic strategy for 
treating glioblastomas. 
This study aims; 
1. To assess Hsp90α gene and protein expression profile in glioblastoma and non-
tumourigenic cells after treatment with 17-AAG and siRNA. 
2. To evaluate potential benefits of 17-AAG and sihsp90α as a therapeutic strategy. 
3. To optimise a validated siRNA/CPP strategy. 
4. To assess pharmacological stability of neat siRNA and siRNA/CPP complexes. 
5. To evaluate the treatment efficacy of peptide-delivered siRNA combined with     
17-AAG in GBM in vitro and in vivo. 
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CHAPTER 2 
 
MATERIALS AND METHODS 
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2.1 Cell Culture  
 
2.1.1 Cell line description 
The cell lines used in this study were purchased from the European Collection of Cell 
Cultures (ECACC) and the American Type Culture Collection (ATCC) with no 
evidence of the presence of infectious viruses or toxic products. The normal human glial 
cell line was purchased from ATCC. The cells were handled according to the 
recommendations by the Advisory Committee on Dangerous Pathogens (ACDP) for 
Category 2 containment. Mycoplasma testing was performed on all the cell lines used in 
this study. A detailed cell line description and their source have been listed in Table 
2.1.1. 
The cells were received as frozen ampoules in 1 ml plastic cryotubes containing the 
cells with the appropriate freezing medium supplemented with 10% Foetal bovine 
serum (FBS), 2 mM L-glutamine and 10% (v/v) Dimethyl sulfoxide (DMSO).   
 
2.1.2 Media and reagents  
Media preparations for cell growth were carried out under aseptic conditions by the 
addition of required supplements as recommended by the ECACC/ATCC specific to the 
cell line (Table 2.1.1). Both DMEM and EMEM were supplied in 500 ml bottles, to 
which 50 ml of FBS and 5 ml of L-glutamine (200 mM) were aseptically added to 
achieve a final concentration of 10% FBS and 2 mM L-glutamine, respectively. The 
prepared medium was correctly labelled with the date of preparation and stored at 4
º
C 
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for up to 4 weeks. The media formulations, reagents and chemicals used in tissue have 
been listed in the appendix (Table 7.1.1). 
The volume of the supplements added to the medium was calculated using the formula: 
 
x = a x b 
    c 
 
Where, a = final concentration, b = final volume, c = stock concentration and x = 
required volume. 
This formula has been utilized in most calculations to determine the volume and 
concentration of the reagents and chemicals used throughout the study. 
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Table 2.1.1: Cell lines used in cell culture and their media supplements. 
Cell lines 1321N1 GOS-3 U87-MG SVGp12 
Description Human astrocytoma 
Human brain mixed astro-
oligodendroglioma 
Human glioblastoma-
astrocytoma Epithelial-like 
cell line 
Human non-tumourigenic 
cell line 
Grade I II/III IV N/A 
Supplier ECACC, UK DSMZ, Germany ECACC, UK ATCC, UK 
Culture media and 
supplements 
DMEM, 10% FBS and 
2mM L-glutamine 
DMEM, 10% FBS and 
4 mM L-glutamine 
EMEM, 10% FBS,  
2mM L-glutamine, 1% (v/v) 
non-essential amino acids, 
and 1mM sodium pyruvate 
EMEM, 10% FBS,  
2mM L-glutamine, 1% (v/v) 
non-essential amino acids, 
and 1mM sodium pyruvate 
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2.1.3 Resuscitation of frozen cells 
The cell lines supplied in cryotubes were immediately stored in liquid nitrogen on 
arrival. The cell medium was pre-warmed to 37
º
C before the frozen ampoules with the 
cells were thawed. Resuscitation of cells was carried out as recommended by 
ECACC/ATCC. The frozen cryotubes stored in liquid nitrogen were removed and 
thawed at 37
º
C in a water bath for 1-2 min. The cells were resuspended in 1 ml of 
medium in a 15 ml centrifuge tube and centrifuged at 1000 rpm for 5 min at room 
temperature. The supernatant medium was discarded and the cells were resuspended in 
1 ml of fresh pre-warmed medium and aliquoted into 25 cm
2
 flasks already containing 5 
ml of pre-warmed medium. The flasks were labelled with the name of the cell line, 
passage number and date and gently rocked to ensure even distribution of cells in the 
medium. The cells were incubated at 37
º
C with 5% CO2 in filtered air. For slow 
growing cells, the medium was changed after every 48 h of incubation to maintain 
sufficient nutrient levels for the cells. All the cell lines used were restricted to 5-7 
passages to perform all the experiments. 
 
2.1.4 Subculture and cell library maintenance  
The cells were observed under a light microscope after overnight incubation. The cell 
growth was monitored daily until a mono-layer of cells up to 75-80% confluence was 
obtained. The cell culture medium was removed and the cells were washed with pre-
warmed PBS (1X) pH 7.4 to remove any remaining culture medium. Trypsin EDTA 
was added (1 ml/25 cm
2
) into each flask and incubated at room temperature for 2 - 4 
min. The flasks were rocked to ensure maximum cell detachment and examined using a 
light microscope. The cells were then resuspended in 2 ml of fresh medium to inactivate 
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the trypsin EDTA. A small aliquot (20 µl) of resuspended cells was transferred to an 
eppendorf tube for cell counting and the remaining cells were subjected to 
centrifugation at 1000 rpm for 5 min. To maintain growth, cells (~2 x 10
4
 cells/cm
2
) 
were subcultured into a 75 cm
2
 flask. The flask was labelled with cell line, passage 
number and date and incubated under standard cell culture conditions. To maintain cell 
library, approximately 1 x 10
6
 cells were re-suspended in a cell freezing medium 
(culture medium with 10% DMSO) in 1 ml aliquots and transferred into cryoprotective 
ampoules labelled with cell line name, passage number and date. The ampoules were 
placed in Mr Frosty passive freezer (Nalgene, UK) filled with isopropanol and placed in 
-80
º
C overnight. Following the overnight storage, the ampoules were then transferred 
into liquid nitrogen. The cell information was entered in the data entry log book, stating 
the position of storage in liquid nitrogen. This simplifies tracing cells at a later date for 
further use. While 1 x 10
6
 cells were frozen for stock maintenance, 2 x 10
6
 cells were 
frozen at -80
º
C without freezing medium for mRNA isolation.  
 
2.1.5 Quantification of cells 
The 20 µl aliquot in the eppendorf tube was diluted by adding Trypan Blue to determine 
the total number of cells, viable (glowing cells) and dead (stained cells). To count cells 
a haemocytometer was prepared by attaching a cover slip using applied pressure to 
create Newton’s refraction rings. Both sides of the chamber were filled with the stained 
cell suspension and the cells were counted under a light microscope using ×20 
magnification. The cell count from only the middle square was used for cell 
quantification.  
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2.2 Cell treatment with Temozolomide and 17-
allylamino-17-demethoxygeldanamycin (17-AAG) 
 
Temozolomide was kindly provided by Katherine Ashton (Royal Preston Hospital, 
Preston, UK). It was then dissolved in DMSO to achieve a stock concentration of      
100 mM. Cell culture media was used to make up a final concentration of 1.05 mM, in 
which cells were incubated for 48 h. 17-AAG was obtained from InvivoGen (UK) and 
was reconstituted in DMSO to give a stock concentration of 2 mM. The stock was then 
diluted in culture medium to achieve a final working concentration of 0.225 µM which 
was added to the cells followed by incubation for 48 or 72 h. The final concentration of 
DMSO in the control cells did not exceed 1%. 
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2.3 Oligonucleotide sequence and electroporation 
conditions 
2.3.1 siRNA sequence/target gene alignment 
 
The siRNA used in this study to target hsp90α gene has previously been shown to 
promote RNAi in glioblastoma cells (Cruickshanks et al., 2010). Three sets of pre-
designed hsp90α siRNA duplexes were purchased from Ambion (Life Technologies, 
UK). The siRNA were designed for maximum potency and specificity using a highly 
effective and extensively tested algorithm which guarantees a minimum of 70% 
reduction of the targeted mRNA. The hsp90α specific siRNAs have been listed and the 
target exon depicted in Figure 2.3.1.  
The sihsp90α oligo 2 was used for gene silencing in this study mainly ascribed to its 
ability to induce chemosensitivity in glioblastoma as previously established in our 
laboratory (Cruickshanks et al., 2010). A standard nucleotide BLAST (Altschul et al., 
1990) was performed using this siRNA sequence and the Human genomic + transcript 
nucleotide database available from BLAST, that showed only 2 hits for transcripts. 
These were Hsp90α [transcript variant 1 (NM_001017963.2) and 2 (NM_005348.3)] 
showing a 100% identity demonstrating high specificity for Hsp90α. 
Additionally, a BLAST2SEQ was performed with the same siRNA sequence against all 
the variants of the isoform Hsp90β (NM_001271971.1, NM_001271970.1, 
NM_001271972.1, NM_007355.3, NM_001271969.1), showing less than 50% match 
for all the variants indicating no specificity for Hsp90β. 
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Figure 2.3.1: The sihsp90α sequences and depiction of target exon location. The different 
sihsp90α oligos previously used have been shown with the highlighted sihsp90α oligo utilized 
in this study (modified from Ambion, UK).  
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2.3.2 Cell electroporation and transfection with siRNA 
 
The Silencer
®
 Pre-designed siRNA used for transfections were obtained from Ambion 
(Life Technologies, UK). The siRNA sequences consisted of 21-nt and targets 
Hsp90AA1 gene with sense strand: 5’CGUGAUAAAGAAGUAAGCGtt3’ and 
antisense: 5’CGCUUACUUCUUUAUCACGtt3’. The annealed siRNA was 
resuspended in nuclease-free water (400 µl) to achieve a stock concentration of 100µM 
which was further diluted to 50 µM working concentration prior to use. 
 
2.3.2.1 siRNA electroporation  
Electroporation is a method used to introduce siRNA into mammalian cells. The 
procedure involves the use of electric pulse which temporarily disturbs the phospholipid 
bilayer, thus allowing molecules like DNA/RNA to pass into the cell (Chen et al., 
2007). Recent work from our laboratory optimised and validated electroporation 
conditions for siRNA transfection targeting hsp90α mRNA (Cruickshanks et al., 2010). 
The current study focuses on the use of sihsp90α oligo 2 to target hsp90α mRNA and 
further aims to determine its anti-tumour efficacy when used alone or as a combination 
with Hsp90-inhibitor.  
The electroporation conditions vary according to the cell types. Factors that influence 
the electroporation efficiency are pulse length, number of pulses and concentration of 
siRNA. The siRNA transfections were carried out using the siPORT™ siRNA 
Electroporation Kit according to the manufacturer’s instructions (Ambion, UK).       
Bio-Rad gene pulser Xcell was used for electroporation. Electroporation parameters 
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used in this study were: 3 pulses (square wave type pulse) at 400 V for 100 µsec with 
0.1 sec intervals between the pulses.  
 
2.3.2.2 si-FAM control siRNA transfection procedure 
To evaluate whether the electroporation parameters described above translate into 
efficient siRNA transfection in vitro, U87-MG and SVGp12 cells were transfected with 
Silencer
®
 FAM labelled Negative Control siRNA (si-FAM; Ambion, UK). For 
transfection, U87-MG cells and SVGp12 cells (7.5 x 10
5
 cells/electroporation sample) 
were centrifuged at 1000 rpm for 5 min at room temperature. The cells were 
resuspended in 75 µl of siPORT
™ 
siRNA electroporation buffer (designed to help the 
cells recover after electroporation) and then transferred to 1 mm electroporation cuvette 
and 1.5 µg of si-FAM was added to the cuvette. The cells in the cuvette were 
electroporated using parameters: 3 pulses (square wave type pulse) at 400 V for         
100 µsec with 0.1 sec intervals between the pulses. The cuvette was then incubated for 
10 min at 37
º
C and the cells were transferred to chamber slides containing pre-warmed 
culture medium. The cells were incubated overnight under normal cell culture 
conditions. The transfection of siRNA into the cells was visualised using the Axiovert 
200 LSM 510 laser scanning confocal microscope (Carl Zeiss, UK) which showed that 
the siRNA was efficiently delivered to the cells (Figure 2.3.2).  
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Figure 2.3.2: Uptake of si-FAM in U87-MG and SVGp12 cells. The U87-MG (A) and 
SVGp12 (B) cells show uptake of si-FAM (green fluorescence) as confirmed by colocalisation 
with phase contrast.  
 
 
2.3.2.3 sihsp90α and 17-AAG treatment 
The sihsp90α treatment procedure is the same as above only the si-FAM control siRNA 
was replaced with sihsp90α and the cells were transferred to a 25 cm2 tissue culture 
flasks containing pre-warmed medium. The cells were incubated for either 48 or 72 h 
after which the cells were harvested for qRT-PCR analysis to assess hsp90α expression 
and Hsp90α protein levels. For concurrent combinatorial assays involving sihsp90α and 
17-AAG, 17-AAG (0.225 µM) was added to the pre-warmed medium prior to 
transferring cells into the flask.  
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2.4 Cell viability assay 
 
The cell viability was assessed using CellTiter-Glo
®
 Luminescent cell viability assay 
(Promega, UK) according to the manufacturer’s protocol. This assay determines the 
number of viable cells based on the quantitation of ATP present signalling the presence 
of metabolically active cells. The addition of the reagent results in cell lysis and 
generation of luminescent signal proportional to the amount of the ATP present and the 
amount of ATP is directly proportional to the number of cells present in each well 
(Crouch et al., 1993).  
 
2.4.1 Protocol for cell viability assay 
Briefly, cultured cells were seeded (1 x 10
3 
 cells/well) in a white flat-bottom 96-well 
plate. A control well containing only the culture medium without cells was used to 
obtain a value for background luminescence. After 24 h, the test compound (TMZ and 
17-AAG) was added to the wells and incubated at standard cell culture conditions. 
Following incubation with the drug, the 96-well plate was equilibrated to room 
temperature for 30 min. The CellTiter-Glo reagent was prepared by mixing the 
CellTiter-Glo buffer and CellTiter-Glo substrate (1:1). A working stock was prepared 
by mixing appropriate volume (depending on the number of wells used) of CellTiter-
Glo reagent with culture media (1:1). The contents of the 96-well plate were emptied by 
gently tapping on a clean paper towel and washed twice with PBS. From the working 
stock prepared, 200 µl was added to the appropriate wells of the 96-well plate. The 
contents of the 96-well plate were mixed for 2 min on a shaker to induce cell lysis and 
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the plate was subsequently incubated at room temperature for 10 min to stabilize 
luminescent signal. The luminescent signal was recorded using Tecan GENios Pro
®
 
(Tecan, Austria). 
 
2.4.2 Cell line growth curves  
The growth curve of the three glioma cell lines and non-tumourigenic cells was 
generated to evaluate the growth characteristics of each cell line. Three glioma cell lines 
and non-tumourigenic cell line were seeded in a 96-well plate and the cell growth was 
monitored for 6 days using the CellTiter-Glo reagent as described in section 2.4.1. The 
growth curves have been shown in Figure 2.4.1. 
 
 
 
Figure 2.4.1: Growth curves of all the cell lines used in this study. The values shown are 
mean ±SD, n = 3.  
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2.5 Isolation of mRNA 
 
The mRNA isolation procedure was performed using a commercially available mRNA 
isolation kit (Roche Applied Science, UK). The kit is safe to use as no aggressive 
organic reagents were used and the mRNA isolated using this kit was of the highest 
purity.  
The principle of this kit is that the poly (A)
+
 tail of the mRNA hybridizes to a Biotin-
labelled Oligo(dT)20 probe provided with the kit. These biotin labelled probes are in 
turn captured by streptavidin-coated magnetic particles which are then separated from 
the cell lysate using a magnetic separator (Figure 2.5.1). The excess fluid is removed 
using PBS buffer and the mRNA is eluted from the particles by incubating with 
redistilled water. 
All the components of the kit and composition of all reagents used and the volume of 
reagents and buffers used to conduct this investigation are listed in the appendix (Table 
7.1.2 & 7.1.3). 
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Figure 2.5.1: Experimental overview of the method of mRNA isolation technique (Roche 
Applied Science, UK). Figure modified from the mRNA isolation kit instruction manual.  
 
 
2.5.1 Procedure 
The cells were washed twice with cold PBS, lysed using lysis buffer and were 
mechanically sheared six times using 21-gauge needle. The Biotin-labelled Oligo(dT)20 
probe was added to the sample and mixed to form the hybridization mix. 
Simultaneously, the Streptavidin-coated Magnetic Particles aliquoted in an eppendorf 
were immobilized using a Magnetic Particle Separator and rinsed in lysis buffer to 
remove any excess storage buffer. The Biotinylated dT-A hybrids were immobilized 
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with the SMPs by resuspending the SMPs in the hybridization mix followed by 
incubation at 37
º
C for 5 min. After incubation, the hybrid-linked SMPs were separated 
from the fluid with a Magnetic Particle Separator and the fluid was discarded. The 
SMPs were washed with Wash Buffer (thrice) and the mRNA was eluted from the 
SMPs with redistilled water following incubation at 65
º
C for 2 min. The eluted mRNA 
was transferred to a fresh eppendorf and stored at -20
º
C for various downstream 
applications.  
 
2.5.2 Analysis of nucleic acid by alkaline gel electrophoresis 
The isolated mRNA was analysed on an alkaline gel to determine whether the RNA 
remained intact or had been degraded. A 2% gel was prepared by dissolving 0.6 g of 
agarose (Geneflow, UK) in 30 ml of distilled water utilizing a microwave. The gel was 
heated until a transparent molten solution had formed. The molten gel was then allowed 
to cool down to 50
º
C prior to the addition of NaOH (stock 10 M) and EDTA (stock    
0.5 M) to achieve a final concentration of 50 mM and 1 mM, respectively. The solution 
was poured into a gel cast and left undisturbed for 30-45 min to solidify. Once 
solidified, running buffer with a final concentration of 50 mM NaOH and 1 mM EDTA 
prepared in distilled water was poured into the gel tank. The mRNA samples with the 
loading dye at 1:4 (dye:sample) were run at 50 V for 1-2 h. The gel was stained with 
freshly made ethidium bromide (0.5 µg/ml) for ~10 min and destained in distilled water 
before gel analysis by GENE GENIUS bioimaging system (Syngene, UK).  
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2.5.3 Quantifying the isolated mRNA using NanoDrop
™
 
Spectrophotometer 
The isolated mRNA was quantified using a NanoDrop
™
 1000 Spectrophotometer 
(Thermo Scientific, UK) which measures the optical density of 1 µl of the sample with 
high accuracy and reproducibility. The full spectrum (220-750 nm) spectrophotometer 
uses a patented sample retention technology that employs surface tension alone to hold 
the sample in place. mRNA sample (1 µl) is pipetted onto the end of a fiber optic cable 
and a second fiber optic cable is then brought into contact with the liquid sample 
causing the liquid to bridge the gap between the two fiber optic cables. A pulsed xenon 
flash lamp provides the light source and a spectrophotometer utilizing a linear CCD 
array is used to analyse the light after passing through the mRNA sample. The 
instrument is connected to computer based software and controlled through the 
computer. The software calculates and displays A260, A280, A260/A280 and concentration 
in ng/µl.  
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2.6. cDNA synthesis 
 
The mRNA isolated previously was reverse transcribed into cDNA using First Strand 
cDNA Synthesis Kit (Roche Applied Science, UK). The Master Mix was prepared by 
adding the components listed in Table 2.6.1. Avian Myeloblastosis Virus (AMV) 
reverse transcriptase is the enzyme which synthesizes the cDNA strand at the 3’end of 
the poly (A) mRNA where oligo dT is used as a primer. All the reagents were thawed 
on ice. A sterile microfuge tube was used to pipette specified volumes of Reaction 
Buffer (10X), MgCl2 (25 mM), Deoxynucleotide Mix, Oligo-p(dT)15 Primer, RNase 
Inhibitor, AMV Reverse Transcriptase, sterile water and finally the RNA sample 
isolated previously. The mixture was vortexed, centrifuged and incubated at 25
º
C for 10 
min to allow annealing of the primer to the mRNA template. The mixture was then 
incubated at 42
º
C for 1 h which allows cDNA formation via reverse transcription. 
Subsequently, the AMV reverse transcriptase in the mixture was denatured by 
incubating at 99
°
C for 5 min and cooling to 4
°
C for 5 min. The isolated cDNA was then 
used as template for qRT-PCR. 
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Table 2.6.1: The following components were used in the order of listing for cDNA 
synthesis.  
Reagents Volumes Final concentration 
Reaction buffer (10X) 2.0 µl 1X 
25mM MgCl2  4.0 µl 5 mM 
Deoxynucleotide Mix 2.0 µl 1 mM 
Oligo-p(dT)15 Primer  2.0 µl 1.6 μg 
RNase Inhibitor 1.0 µl 50 units 
AMV Reverse Transcriptase 0.8 µl 20 units 
Sterile Water variable - 
RNA sample variable 100 ng 
Total volume 20 µl - 
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2.7 Bioinformatics: Gene sequence and Primer design 
 
Bioinformatics is the application of statistics and computer science to the field of 
molecular biology that enables us to congregate, analyse and represent biological 
information in order to comprehend various processes involved in healthy and diseased 
states. The field of bioinformatics has rapidly expanded with progress in full genome 
sequencing, functional genomics, pharmacogenomics, proteomics and biopathway 
modelling (Curioso et al., 2008).  
Ensembl and NCBI allow users to assess the nucleotide sequence of the genes of 
interest. NCBI provides genomic databases, sequence identification tools and genome 
specific resources. NCBI provides verification for genes that have been found through 
computational techniques. The sequence obtained from NCBI can then be exported to a 
software application called Primer 3, which designs a left and right primer for that 
particular gene. The gene sequence for GAPDH and hsp90α were obtained from NCBI 
(See appendix Figure 7.2.1 and 7.2.2). The primers for hsp90α and the control GAPDH 
were designed using Primer 3 (Figure 2.7.1 & 2.7.2). 
There are two major isoforms of Hsp90, namely Hsp90α and Hsp90β (Sreedhar et al., 
2004). This study focuses on downregulation of hsp90α gene expression due to its 
induced levels in glioma cell lines and tissues (Shervington et al., 2008). The hsp90α 
and GAPDH gene locations were found using public databases, namely 
1. Genecards at (http://genome-www.stanford.edu/genecards/index.shtml) 
2. NCBI at 
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=nucleotide&cmd=search&term) 
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Figure 2.7.1: Primers for hsp90α. The output page of Primer 3 provides the right and the left 
primers.  
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Figure 2.7.2: Primers for GAPDH. The output page of Primer 3 provides the right and the left 
primers.  
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2.8 Quantitative Real Time Polymerase Chain 
Reaction (qRT-PCR) 
 
Polymerase chain reaction (PCR) is a method that allows logarithmic amplification of 
short DNA sequences usually 100 to 600 bases long allowing quantification of very low 
copies of mRNA that would otherwise not show up if other analytical techniques such 
as northern blotting was used. qRT-PCR was performed to amplify the hsp90α and 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH, as a control) using LightCycler
®
 
FastStart DNA Master
PLUS
 SYBR Green I (Roche Applied Science, UK). The samples 
along with a negative sample (no cDNA) were run on the LightCycler real-time PCR 
detecting system (Roche Diagnostics, Grenzach-Wyhlen, Germany). The composition 
of the reagents provided within the LightCycler FastStart DNA Master
PLUS
 SYBR 
Green I kit has been listed in the appendix (Table 7.1.4). The quantities of the reagents 
required for each RT-PCR reaction are listed in Table 2.8.1.  
 
 
Table 2.8.1: The quantities of reagents required of each RT-PCR reaction.  
Reagents Quantity 
Molecular biology-grade H2O 12 µl 
Enzyme Master Mix 4 µl 
PCR primer mix (1µl left + 1µl right) 2 µl 
Single-stranded cDNA template 2 µl 
Total  20 µl 
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Each qRT-PCR capillary contained the volumes of reagents as listed above and the 
negative sample contained 2 µl of PCR-grade water instead of cDNA. The PCR 
protocol considered consist of pre incubation, amplification, melting and cooling steps 
which took approximately 50 min to complete and the various steps included are listed 
in Table 2.8.2. To confirm the amplification specificity of the RT-PCR run, the PCR 
products were subjected to a melting curve analysis and agarose gel electrophoresis. 
The primers for the genes were prepared by TIB MOLBIOL (Berlin, Germany). 
Different annealing temperatures derived, calculated or optimised are listed in        
Table 2.8.3.  
 
 
Table 2.8.2: LightCycler program for qRT-PCR utilizing FastStart DNA Master
PLUS
 
SYBR Green I kit.  
Analysis mode Cycles Segment 
Target Temperature 
(
°
C) 
Hold Time 
(sec) 
Pre incubation 1  95 600 
Amplification 35 
Denaturation 95 15 
Annealing Variable (Table 2.8) 15 
Extension  72 9 
Melting 1 
Denaturation 95 0 
Annealing 
10 higher than 
amplification 
40 
Extension 95 0 
Cooling 1  40 30 
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Table 2.8.3: Primer sequences used to amplify target genes, specifying expected amplicon size and annealing temperature.  
Gene Primer sequence 
Expected amplicon 
(bp) 
Primer Annealing Temperatures (
°
C) 
Primer 3 GC/AT rule * TIB MOLBIOL Experimental 
Temperature 
hsp90α 
Sense: 5’–TCTGGAAGATCCCCAGACAC–3’ 
Antisense: 5’–AGTCATCCCTCAGCCAGAGA–3’ 
189 
60 
59.9 
62 
62 
55.4 
55.6 
63 
GAPDH 
Sense: 5’–GAGTCAACGGATTTGGTCGT–3’ 
Antisense: 5’–TTGATTTTGGAGGGATCTCG–3’ 
238 
59.97 
60.01 
60 
58 
56.2 
54.8 
56 
 
* GC / AT rule: A method of calculating the primer annealing temperature using the formula: T = 2
° 
(A + T) + 4
° 
(G + C), where A, C, G and T 
represent the number of adenine, cytosine, guanine and thymine bases respectively in the primer sequence concerned.  
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2.8.1 Agarose Gel Electrophoresis 
The amplified PCR products were run on 2% agarose prepared by dissolving 0.8 g of 
agarose in 40 ml of TAE buffer (1X). Once the solution had been micro-waved, which 
ensures that the agarose particles have completely dissolved, the solution was poured 
into a casting tray that had previously been prepared by the insertion of the sample 
comb. Once the gel had solidified, 300 ml of TAE buffer was added to the 
electrophoresis apparatus and then the comb was removed. 8 µl of sample and 2 μl of 
loading buffer were loaded into each of the wells. The loading buffer consisted of 25 mg 
bromophenol blue, 25 mg xylene and 4 g sucrose in 10 ml of distilled water. AGE was 
run at 50 V and the gels were stained in ethidium bromide (0.5 µg/ml). The materials 
and reagents used for gel electrophoresis are listed in Table 7.1.5. 
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2.8.2 Copy number calculation  
The quantification of the target amplicon was expressed as a copy number. In real time 
PCR, a positive reaction is detected by the accumulation of a fluorescent signal defined 
as the cycle threshold (Ct) which reflects the number of cycles required for the 
fluorescent signal to cross the threshold. The Ct levels are inversely proportional to the 
amount of target nucleic acid in the sample. Genomic DNA was used as an external 
standard to demonstrate that 1 µg corresponds to 3.4 x 10
5
 copies of a single gene 
(Wittwer et al., 2004). Previously in our laboratory (Mohammed & Shervington, 2008; 
Shervington et al., 2007), genomic DNA of known concentrations were used as a 
standard to amplify GAPDH gene using the LighCycler instrument. The Ct which 
serves as a tool for calculating the starting template amount was used to plot a standard 
curve to determine the copy number in unknown samples. A standard curve was 
generated with different concentrations of genomic DNA in duplicate: 0.005, 0.05, 0.5, 
5 and 50 ng (known copy numbers) and their corresponding average Ct’s (Table 2.8.4 
and Figure 2.8.1). The equation generated (y=-1.3124Ln(x) + 32.058) was rearranged to 
(=EXP((Ct value-32.058)/-1.3124)) and used to determine copy numbers of the mRNA 
expression of all the genes used throughout this study.  
 
 
Table 2.8.4: Different concentrations and dilutions of DNA with known copy numbers 
used for quantitative PCR amplification and the corresponding crossing points. 
Concentration of Genomic DNA (ng) Average Ct Copy number 
0.005 30.15 1.7 
0.05 29.10 17 
0.5 26.42 170 
5 22.60 1700 
50 18.30 17000 
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Figure 2.8.1: Standards used to generate the copy numbers for each gene. LightCycler 
quantification curve generated by known concentrations of genomic DNA was amplified, which 
shows that the higher the concentration of DNA the lower the Ct value (A). The negative 
control (primer alone) shows no fluorescence acquisition until after 30 Ct. (B) The standard 
generated from the crossing points shows the relationship between the Ct values and the copy 
numbers of the amplified genomic DNA using GAPDH reference gene (Figure adapted from 
Mohammed, 2007).   
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2.9 Laser Scanning Confocal Imaging Microscopy 
 
Cells were seeded (1 x 10
5 
cells/well) on culture slides in 6 well plates 24 h prior to 
treatment. Following treatment with sihsp90α and 17-AAG, the cells were fixed with 
4% paraformaldehyde, washed three times with warm PBS and subsequently 
permeabilized with 0.3% Triton X-100 at room temperature for 7 min. The cells were 
then washed three times with warm PBS and incubated in blocking solution followed by 
1 h of incubating in the primary monoclonal antibody against Hsp90α antigen 
(Cambridge Bioscience, UK). After the incubation, the cells were washed thrice with 
PBS and exposed to a light sensitive fluorescein isothiocyanate secondary antibody 
(goat anti-rat IgG FITC) for 1 h with gentle agitation. Finally, cells were washed three 
times with PBS in the dark and counter stained with PI (Vectashield, UK), mounted and 
fixed on slides for analysis. For each sample, a total of 150 cells were counted using 
Axiovert 200M LSM 510 laser scanning confocal microscope (Carl Zeiss Ltd, UK). A 
typical example of fluorescent staining is shown in Figure 2.9.1.  
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Figure 2.9.1: A typical example of Hsp90α staining in U87-MG cells. Column 1 represents 
Hsp90α staining with FITC-conjugated secondary antibody, 2 shows the nuclei staining with PI 
and 3 shows the colocalisation of Hsp90α and nuclei staining.  
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2.10 Protein extraction and quantitation 
 
After the treatment, cells were spun down at 1200 rpm for 5 min to give a cell pellet. 
The cells were washed with ice-cold PBS and lysed using CelLytic M Cell Lysis 
Reagent (Sigma, UK). For every 1 x 10
6
 cells, 50 µl of CelLytic M lysis buffer was 
added ensuring complete suspension. The cells were centrifuged at 13000 rpm and 4
 º
C 
for 15 min. The supernatant was transferred to a fresh pre-chilled microcentrifuge tube. 
Protease inhibitor (1µl) was added to inhibit protease activity. Protein concentration was 
calculated using the Bradford protein assay, a spectroscopic analytical method to 
determine the protein concentration in the sample solution utilizing Coomassie Blue 
dye. The presence of protein molecules in a solution causes the Coomassie Blue dye to 
undergo an absorbance shift as a result of the colour transformation where red form of 
the dye is converted into a blue form when bound to protein. The increase of absorbance 
reading is proportional to the amount of bound dye and to the concentration of protein 
present in a sample. 
The unknown protein concentrations were calculated using the standard curve (Figure 
2.10.1). Increasing concentration of bovine serum albumin (BSA) ranging between           
1-8 µg/µl prepared in PBS (1X) was used to derive a standard curve. A small aliquot of 
BSA/sample (1 µl) was added to 1 ml of Coomassie Blue Reagent (1:10 dilution in 
distilled water) and the absorbance was measured in a cuvette at 595 nm. The 
spectrophotometer was blanked using 1 ml of Coomassie Blue Reagent without the 
sample.  
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Figure 2.10.1: Protein quantitation standard curve derived using BSA. The equation was 
used to calculate the concentration of protein in test samples. The values shown are mean ± SD,        
n = 3. 
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2.11 Akt/PKB kinase activity quantitation  
 
Akt/PKB activity was measured using the non-radioactive Akt/PKB Kinase Activity 
Assay (Enzo Life Sciences, UK). The assay is based on a solid phase enzyme-linked 
immuno-absorbent assay (ELISA) which utilizes synthetic peptide (Tetramethyl-
benzidine, TMB) as a substrate readily phosphorylated by PKB, pre-coated on the wells 
of the microtiter plate and a polyclonal antibody which binds specifically to the 
phosphorylated form of the substrate to produce colour intensity in proportion to the 
phosphorylated TMB. Once the samples are added, the addition of ATP to the wells 
initiates the reaction. The colour intensity is measured at 450 nm using a microplate 
reader. The assay procedure is summarised in Figure 2.11.1 and the components of the 
kit are listed in the appendix (Table 7.1.6). The assay was performed as per 
manufacturer’s instructions. 
 
 
 
Figure 2.11.1: A summary of the steps involved in the Akt/PKB Kinase Assay. Figure 
modified from the manufacturer’s instruction manual.  
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2.11.1 Standard curve using purified recombinant active PKB/Akt  
1. Initially PKB Substrate Microtiter Plate, Antibody Dilution Buffer, Kinase 
Assay Dilution Buffer, 20X Wash Buffer, TMB Substrate and Stop Solution 2 
were brought to room temperature prior to use. The Microtiter plates were 
soaked with Kinase Assay Dilution Buffer (50 µl) at room temperature for       
10 min. The liquid was carefully aspirated from each well and varying quantities 
of purified Active PKB (30 µl) were added to the wells at this point. Kinase 
Assay Dilution Buffer with no kinase was used as a blank. The reaction was 
initiated by addition of diluted ATP (10 µl) to each well, except the blank. The 
wells were covered with plate sealer and incubated at 30
º
C for 60 min on a 
shaker with rotate angle at 60 rpm. The reaction was stopped by emptying the 
contents of the wells followed by the addition of Phosphospecific Substrate 
Antibody (40 µl to each well except the blank) and incubated at room 
temperature for 1 h. At this point the liquid was aspirated and the wells were 
washed four times with 1X Wash Buffer (100 µl). Anti-Rabbit IgG: HRP 
Conjugate was diluted to 1 µg/ml and 40 µl was added to each well except the 
blank and further incubated at room temperature for 30 min. The washing step 
was repeated as described above. Once the liquid was carefully aspirated, TMB 
Substrate (60 µl) was added to each well and incubated at room temperature 
until colour development. Stop Solution 2 (20 µl) was added to each well and 
the intensity of the colour was measured at a wavelength of 450 nm and the 
standard curve has been shown below (Figure 2.11.2). To determine the Akt 
kinase activity in treated and untreated samples, protein samples (10 µg) were 
added to the Microtiter plate. The equation generated was rearranged to (x = y + 
0.182/0.475) and used to determine the Akt levels in the samples. 
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Figure 2.11.2: Standard curve for Akt kinase activity assay obtained using purified 
recombinant active Akt. The provided recombinant active Akt was diluted in Kinase Assay 
Dilution Buffer to give final concentration from 5-40 ng/assay. The equation derived from the 
curve was then used to calculate the Akt activity in treated and untreated samples based on the 
absorbance readings. This graph is typical of three independent experiments. Data values are 
mean ± SD, n = 3.  
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2.12 Peptide synthesis  
 
The peptides Tat, Cyt c
77-101
 and C105Y were prepared by solid phase using a standard 
Nα–Fmoc(N-(9-fluorenyl)methoxycarbonyl) protection strategy on Rink amide 
methylbenzhydrylamine (MBHA) resin (NocaBiochem, UK) with O-(6-Chloro-1-
hydrocibenzotriazol-1-yl)- 1,1,3,3-tetramethyluronium hexafluorophosphate (HCTU; 
AGTC Bioproduts Ltd.)/HoBt (Advanced ChemTech) activation on a 0.2 mmol scale 
with Kaiser tests performed at each step to confirm coupling and/or deprotection (Baker 
et al., 2007). The peptides were purified to apparent homogeneity by high-performance 
liquid chromatography (Genesis C18 column) and predicted masses of all the peptides 
(average M + H
+
) were validated by matrix-assisted laser desorption ionisation-time of 
flight spectrometry (MALD-TOF) operated in positive ion mode using Kratos Analytic 
Kompact probe. All the peptides were supplied by Professor John Howl (University of 
Wolverhampton) (Table 2.12.1).  
 
 
Table 2.12.1: The amino acid sequence of the cell penetrating peptides used in this study.  
Name Peptide sequence Molecular weight 
Tat48-60 H-GRKKRRQRRRPPQ-NH2 1718.06 
C105Y H-CSIPPEVKFNKPFVYLI-NH2 1993.46 
Cyt c
77-101 
H-GTKMIFVGIKKKEERADLIAYLKKA-NH2 2850.52 
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2.13 Gel mobility assay 
 
To examine whether the peptides successfully bind to and form complexes with the 
siRNA, gel mobility assay was performed. sihsp90α (200 nM) was mixed with 
increasing concentration of Tat, Cyt c
77-101
 and C105Y CPPs at different molar 
concentrations ranging from 1:1 to 1:50 (sihsp90α:peptide) in serum-free medium for 30 
min at 37
º
C. The siRNA/peptide complexes were then subjected to electrophoresis on 
15% TBE polyacrylamide gel (Bio-Rad Laboratories, UK) in TBE buffer at 100 V 
under non-denaturing conditions and stained with ethidium bromide (0.5 µg/ml) and 
analysed by UV-transilluminator GENE GENIUS bioimaging system (Syngene, UK).  
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2.14 Serum stability of sihsp90α 
 
Neat sihsp90α (200 nM) or Tat peptide complexed sihsp90α were incubated in EMEM 
with human serum (50%) at 37
º
C. Aliquots (20 µl) were taken from neat sihsp90α 
samples at 1, 3, 6 and 24 h, and immediately stored at -80
º
C. All samples were analysed 
on 15% TBE polyacrylamide gel in TBE buffer at 100 V under non-denaturing 
conditions and stained with ethidium bromide (0.5 µg/ml) and detected by UV-
transilluminator GENE GENIUS Bioimaging system. Aliquots (20 μl) were taken from 
sihsp90α/Tat samples at 1, 3, 6, 24 and 36 h, to which Proteinase K (200 µg/ml; Sigma, 
UK) and SDS (0.5% w/v) was added and incubated for 1 h at 37
º
C which allows 
segregation and digestion of Tat peptide. The sihsp90α was subsequently extracted from 
the samples using phenol:chloroform extraction and analysed on 15% TBE 
polyacrylamide gel and stained with ethidium bromide.  
 
2.14.1 Phenol:chloroform extraction 
To each sample equal volume of water-saturated phenol:cholorform:isolamyl alcohol 
(25:24:1; Sigma-Aldrich, UK) was added. The tubes were inverted to mix the samples 
and then centrifuged at 4
°
C and 13,000 rpm for 10 min. The aqueous phase was 
transferred to fresh eppendorfs tubes and particular care was taken not to disturb the 
interphase. At this point, to each sample 3 M NaOAc (one-tenth of the total volume),    
1 mM EDTA (one-tenth of the total volume) and cold 100% ethanol (2.5X total 
volume) was added. The samples were mixed and incubated at -80
°
C for 20 min before 
centrifugation at 4
°
C and 13,000 rpm for 10 min. The ethanol was decanted from the 
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pellets and discarded, 80% ethanol (300 µl) was used to wash the pellets. The pellets 
(siRNA) were dried for 20-30 min and resuspended in 15 µl of nuclease-free water 
ready for electrophoresis analysis.  
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2.15 Membrane Disturbance analysis 
 
An In Vitro Toxicology Assay Kit was used to measure the membrane integrity as a 
function of the amount of cytoplasmic LDH released into the medium (Sigma, UK). 
This assay is based on the reduction of NAD to NADH by LDH resulting in the 
stoichiometric conversion of a tetrazolium dye. The resulting coloured compound is 
measured spectrophotometrically to evaluate the degree of membrane disturbance.  
Both U87-MG and SVGp12 cells were seeded (1 x 10
4
 cells/well) in 96-well plate 24 h 
prior to treatment with Tat alone or sihsp90α/Tat complexes (50 µl) at concentrations 
ranging from 1:15-1:100 (siRNA:peptide molar ratio) in serum-free medium for 30 min 
at 37
°
C. Following incubation, the cells were centrifuged at 250 x g for 4 min and 25 µl 
was transferred to a clean 96-well flat bottom plate. Lactate Dehydrogenase Assay 
mixture was prepared by mixing equal volume of LDH assay substrate, LDH assay dye 
solution, and 1X LDH assay cofactor preparation. Lactate dehydrogenase assay mixture 
(50 µl) was added to the samples and incubated at room temperature for 25 min. The 
reaction was quenched by the addition of 1 N HCl (1/10 total volume) to each well. The 
absorbance was measured spectrophotometrically at 490 nm. Serum-free medium 
without cells was used as a blank, untreated cells lysed with LDH assay lysis solution 
(1/10 total volume) was used as a control.  
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2.16 Cellular uptake of si-FAM complexed with Tat 
peptide 
 
To examine whether the Tat peptide interacts efficiently with siRNA and is able to 
transfect cells, Silencer
®
 FAM
™
-labelled Negative Control siRNA (si-FAM; Ambion, 
UK) was incubated with various concentrations of Tat, from 15-fold molar excess of the 
peptide compared with siRNA to a 50-fold molar excess for 30 min at 37
°
C in serum-
free medium. Glioblastoma and non-tumourigenic cells were seeded (3 x 10
4
 cells /well) 
in a chamber slide (Lab-Tek
®
, Thermo Scientific, UK) 24 h prior to treatment with the 
complexes. On the day of treatment, the cells were washed with serum-free medium 
prior to incubation with the si-FAM/Tat complexes for 1 h followed by the addition of 
fresh serum-supplemented medium for 1 h. The cells were washed three times with PBS 
followed by fixation using 4% (w/v) paraformaldehyde. The cells were washed 3 times 
with PBS and the si-FAM uptake by the cells was observed using Axiovert 200M LSM 
510 laser scanning confocal microscope (Carl Zeiss Ltd, UK). For observation of si-
FAM a fluorescein isothiocyanate (FITC) filter was used. To determine whether the Tat 
peptide interacts efficiently with the si-FAM, a gel shift assay was performed at molar 
ratios ranging from 15 to 50 and the si-FAM/Tat complexes were assessed on 15% 
polyacrylamide gel. 
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2.17 Long-term toxicity of the Tat peptide in 
glioblastoma and non-tumourigenic cells  
 
The long-term toxicity of the sihsp90α/Tat complexes was quantified by CellTiter-Glo® 
Luminescent cell viability assay as described in section 2.4.1. Briefly, U87-MG and 
SVGp12 cells were seeded (1 x 10
3
 cells/well) 24 h prior to treatment with the 
complexes. Following treatment with sihsp90α/Tat complexes for 24, 48 and 72 h, 
CellTiter-Glo reagent prepared with culture media (1:1) was added to each well. The 
contents of each well were mixed for 2 min on a shaker to induce cell lysis and the plate 
was incubated at room temperature for 10 min. The luminescent signal was recorded 
using Tecan GENios Pro
®
.  
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2.18 Tat-mediated hsp90α knockdown in combination 
with 17-AAG 
 
Glioblastoma or non-tumourigenic cells were seeded in either 96-well plate or   25 cm
2
 
tissue culture flasks 24 h prior to treatment. The sihsp90α/Tat peptide complexes 
formed by mixing increasing concentrations of Tat at molar ratios ranging from 1:15 to 
1:50 in serum-free medium for 30 min, were added to the cells and incubated at 37
°
C 
for 4 h. At this point, fresh serum-supplemented medium was added to the cells and 
further incubated for 24, 48 and 72 h. After incubation, the cells were washed and cell 
viability, gene and protein expression profiles, and Akt activity was assessed as 
described previously. For combinational treatment, 17-AAG was added after the 
transfection, with fresh medium to achieve a final concentration of 0.225 µM and 
incubated for upto 72 h.  
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2.19 RNAi experiments in vivo 
 
2.19.1 Cell culture 
Glioblastoma U87-MG-luc2 (source of parental cell line, ATCC) is a luciferase 
expressing cell line that was stably transfected with firefly luciferase gene (luc2) 
established by lentiviral transduction, a commonly used method to express reporter 
transgenes (Kim et al., 2010a), to achieve high levels of homogenous luciferase 
expression and an in vitro phenotype similar to the parental cell line (Caliper Life 
Sciences). U87-MG-luc2 cells were grown in EMEM supplemented with 2 mM           
L-glutamine, 10% FBS, 1% (v/v) non-essential amino acids and 1 mM sodium pyruvate 
and were cultured at 37˚C in a humidified 5% CO2 incubator. For the tumour 
implantation and luciferase experiments, cells were trypsinized and counted using 
Countess® automated cell counter (Invitrogen) and resuspended in media according to 
experimental requirements.  
 
2.19.2 Intracranial tumour implantation and treatment with 
sihsp90α/Tat complexes and 17-AAG 
All the procedures for animal care and tumour cell implantation followed approved 
animal protocols and guidelines of the Estonian Laboratory Animal Ethics Committee 
(approval number 19 dated 25
th
 September 2009, number 69 and 70 dated 9
th
 Febuary 
2011). The intracranial implantation of U87-MG-luc2 cells into one of the striatums of 
22 homozygous female nude mice (C.Cg/AaNTac-Foxn1nu, Taconic) was performed 
while the animals were under anaesthesia (a mixture of ketamine 75 mg/kg (Bioketan, 
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Vetoquinol) and dexmedetomidine 1 mg/kg (Dorbene, Laboratorios SYBA) i.p. in 
saline) utilizing a stereotaxic frame (Figure 2.19.1). U87-MG-luc2 cells (1 x 10
6
 cells/5 
µl of fresh media without serum) were injected into the right striatum using a syringe at 
stereotaxic coordinates Anterior = +1, Lateral = +2, Vertical = +3.5 from the reference 
point Bregma (+ indicates forward movement of the syringe from the point of reference 
as shown in Figure 2.19.1). Following surgery, the anaesthesia was blocked using the 
α2-adrenergic antagonist atipamezole hydrochloride (Antisedan) at 1mg/kg 
subcutaneously.  
The tumour growth was monitored by measuring the weight, post tumour implantation. 
At the time of tumour implantation the weight of the animals ranged between 11.9-  
18.8 g. The first sign of tumour growth in intracranial tumour models is usually after 
reaching weight losses (~5-10%) at which point the mice (n = 3) were injected with 
sihsp90α/Tat complexes (i.v., 5 mg/kg) and 17-AAG (i.p., 80 mg/kg), and tumour 
tissues were harvested after 24 h and stored immediately at -80˚C. The sihsp90α/Tat 
complexes were formed in nuclease-free water in half the injection volume (100 μl) 
using 0.5 mM sihsp90α and 10 mM Tat peptide stock solutions, at 50-fold peptide 
molar excess to sihsp90α. Following 30 min incubation at 37˚C, 100 μl of 10.8% 
mannitol solution was added to the complexes and the complexes were injected into the 
tail-vein of mice. Subsequently, the mice were injected with 17-AAG (stock 
concentration 25 mg/300 µl in DMSO) intraperitoneally. As the tumours were 
implanted in the right striatum of the mice, the left striatum was used as normal brain 
tissue. Mice (n = 2) treated with siluc/Tat nanoparticles (siRNA targeting luciferase) 
and 17-AAG were used as a negative control for gene expression and Akt kinase 
activity experiments. 
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Figure 2.19.1: Intracranial surgery in mouse. A typical stereotaxic frame utilized for 
intracranial surgery (A). After sedation, the mouse skull was firmly fixed on the frame using ear 
bars and nose clamp (B, for representation only). The stereotaxic coordinates for the injection 
site were measured from the reference point Bregma (C). Figure modified from (Serwer et al., 
2010). 
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2.19.3 Determination of luciferase activity 
For in vitro luciferase experiments, U87-MG-luc2 cells (5 x 10
4
) were seeded in a 24-
well plate 24 h prior to treatment with siluc/Tat complexes. The siluc/Tat complexes 
were prepared using siluc (0.1 mM stock solution) and Tat peptide in serum-free 
EMEM as previously described. Briefly, siluc (200 nM) was added to 1 ml of EMEM 
with increasing concentrations of Tat peptide ranging from 15 to 50-fold peptide molar 
excess to siluc. Tat peptide alone (3, 6 and 10 µM) served as a negative control. After 
30 min incubation, the complexes were added to the cells and incubated for 4 h at 37˚C, 
at which point 1 ml of fresh growth media was added and cells were incubated for 24 h. 
The luciferase gene was downregulated with siluc. The sequence of siluc was: sense 
5’ACGCCAAAAACAUAAAGAAAG3’ and antisense 5’UUCUUUAUGUUUUUGG-
CGUCU3’. The cells were lysed using 0.1% Triton X-100 in Hepes Krebbs Ringer 
buffer (100 μl) on ice for 30 min and the luciferase expression was measured using 
Luciferase Assay System (Promega, Sweden) according to manufacturer’s instructions 
on Glomax luminometer (Promega, Sweden). For luciferase quantitation, protein was 
extracted from the tissue specimens using the Reporter Lysis Buffer (Promega, 
Sweden). The procedure involved taking 1 ml of Reporter Lysis Buffer (1X in PBS) and 
adding it to the ground tissue and subsequently vortexing for 10 min to ensure complete 
suspension of tissue in lysis buffer. The samples were then subjected to repeated freeze-
thaw cycles (to increase protein yield) and centrifuged at 13,000 rpm and 4˚C for         
30 min. The supernatant was transferred to fresh eppendorfs and luciferase activity was 
quantitated using the Luciferase Assay System. After protein extraction, the protein 
levels were quantitated using DC Protein Assay (Bio-Rad) according to manufacturer’s 
instructions to accurately determine luciferase activity. 
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2.19.4 H&E staining 
For H&E staining, mice brain tumour and normal tissue specimens collected were 
frozen immediately in isobutanol bath on dry ice, a freezing method which maintains 
the structural integrity of soft tissues such as the brain tissue. Tissue sectioning was 
performed using a cryotome with a tissue thickness of 15 µm and were mounted on a 
glass slides. The tissue sections were stained with Haematoxylin (0.1%) for 10 min, 
rinsed in deionised water for 5 min and counterstained with Eosin (0.5%) for 30 sec. 
The sections were rinsed in deionised water, dehydrated in 50, 70, 95 and 100% ethanol 
for 1 min each and immersed in xylene for 10 min before mounting the slides for 
analysis. The stained tissue sections were processed using light microscopy.  
 
2.19.5 qRT-PCR and Akt kinase activity analysis 
The frozen tumour and normal brain tissue specimens were ground using a pestle and 
mortar in a cold room and transferred to fresh eppendorfs. For the gene expression 
experiments, mRNA isolation, cDNA synthesis and qRT-PCR were performed as 
described previously (Sections 2.5, 2.6 and 2.8). For the Akt kinase activity assessment, 
protein extraction was performed using Reporter Lysis Buffer as described above. The 
quantitation of protein was performed using Bradford protein assay as described 
previously in section 2.10. Subsequently, the Akt kinase activity in normal and tumour 
tissue specimens were quantitated using Akt/PKB Kinase Activity Assay as described in 
section 2.11.  
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2.20 Statistical analysis 
 
In this study, data have been analysed using the PASW Statistics 18 package using the 
One-Sample Students T-test and Paired-Sample T-test. A p value of * ≤ 0.05 and         
** ≤ 0.001 was considered as statistically significant. 
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CHAPTER 3 
 
RESULTS 
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3.1 mRNA isolation, qRT-PCR and IC50 analysis of 
glioma cell lines and non-tumourigenic cells 
 
3.1.1 mRNA isolation, qRT-PCR: Gene expression evaluation 
After extraction of mRNA from the cell lines, the purity of mRNA was checked using a 
spectrophotometer. The absorbance values measured at 260 nm and 280 nm and the 
concentration of mRNA isolated are listed in the Table 3.1.1. The isolated mRNA was 
further analysed using an agarose gel electrophoresis as shown in Figure 3.1.1. 
 
 
Table 3.1.1: An example of the obtained spectrophotometry reading for glioma and 
normal cell lines and the mRNA concentrations. Data values are mean ± SD, n = 3. 
Cell Lines Ratio (A260/A280)  mRNA concentrations (µg/ml) 
1321N1 1.91 ± 0.03 78 ± 5 
GOS-3 2.05 ± 0.04 151.7 ± 9.7 
U87-MG 2.04 ± 0.04 61.2 ± 7.4 
SVGp12 1.88 ± 02 44 ± 3.2 
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Figure 3.1.1: Agarose gel electrophoresis of mRNA isolated from glioma cell lines. Lanes 1-
4 represent mRNA isolated from 1321N1, GOS-3, U87-MG and SVGp12 (Control). Isolated 
mRNA is distinctly visible.  
 
 
The isolated mRNA (100 ng) was reverse transcribed into cDNA and real time PCR 
was performed to measure the hsp90α and GAPDH gene expression. hsp90α expression 
was found to be highly expressed in all the glioma cell lines (*p < 0.05). The median 
increase in mRNA transcription in glioma cells was 1.85 x 10
2
-fold compared to the 
normal cell line. Although hsp90α was detected in non-tumourigenic cells which was 
used as a control, the expression levels were negligible compared to the glioma cell 
lines (Figure 3.1.2). GAPDH is a housekeeping gene and its expression was used as a 
control throughout all qRT-PCR experiments (Barber et al., 2005).  
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Figure 3.1.2: Gene expressions of hsp90α in glioma cell lines. A) Agarose gel 
electrophoresis: lane 1-4 represents 1321N1, GOS-3, U87-MG and SVGp12 respectively. B) 
The expression levels of hsp90α mRNA relative to GAPDH expression in glioma cell lines and 
non-tumourigenic cells have been shown. Data values are mean ± SD, n = 3. *p ≤ 0.05 and **p 
≤ 0.001 were considered statistically significant.  
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3.1.2 IC50 derivation in glioma cell lines and non-tumourigenic cells 
The three glioma cell lines and one non-tumourigenic cell line were treated with 
increasing concentrations of TMZ and 17-AAG for 48 h and the cell viability was 
analysed using CellTiter-Glo
®
 Luminescent cell viability assay. The IC50 results show 
reduced glioma cell viability with increase in the drug dose (Figure 3.1.3A & B). The 
50% inhibition concentrations (IC50) for glioma cell lines are listed in Table 3.1.2. 
 
 
Table 3.1.2: The IC50 of the chemotherapeutic drug TMZ and Hsp90 inhibitor 17-AAG. 
The values are mean ± SD, n = 3. 
IC50 values 
(µM) 
1321N1 
(Grade I) 
GOS-3  
(Grade II/III) 
U87-MG 
(Grade IV) 
SVGp12 
(Control) 
TMZ 750 ± 25 600 ± 33 1050 ± 38 850 ± 8 
17-AAG 0.38 ± 0.03 0.43 ± 0.05 0.225 ± 0.03 N/A 
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Figure 3.1.3: IC50 evaluation of TMZ and 17-AAG. TMZ (0-1200 µM) inhibits the growth of glioma as well as non-tumourigenic cells (A). Hsp90 
inhibitor 17-AAG (0-0.5 µM) inhibits the growth of glioma cell lines but not normal human astrocyte cells (B). The data values are mean ± SD, n = 3. 
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3.2 Hsp90α inhibition combining chemical and 
molecular approach 
 
3.2.1 Silencing hsp90α in vitro with sihsp90α 
In order to assess the efficiency of silencing hsp90α, U87-MG cells were treated with 
17-AAG, sihsp90α or a combination of sihsp90α/17-AAG to quantitate hsp90α and 
GAPDH mRNA expression by qRT-PCR. Cells transfected with sihsp90α alone 
reduced the mRNA copy number by 96% after 48 h, however, the mRNA copy number 
recovered to 55% after 72 h (Figure 3.2.1). 17-AAG demonstrated a successful 
downregulation of hsp90α expression and reduced mRNA copy numbers by 94 and 
86% after 48 and 72 h, respectively. A combinatorial treatment with sihsp90α and      
17-AAG together silenced hsp90α by 99% after 48 and 72 h. The qRT-PCR results 
were also validated by agarose gel electrophoresis. The level of hsp90α and GAPDH 
was also quantitated in the non-tumourigenic cells SVGp12 to validate targeting 
hsp90α, a therapeutic candidate in this study (Figure 3.2.2). The hsp90α levels in 
SVGp12 demonstrated negligible though detectable levels of mRNA. The different 
treatments did not have significant effect on transcriptional regulation of hsp90α. The 
hsp90α expression levels showed are relative to GAPDH levels. 
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Figure 3.2.1: The effects of 17-AAG and sihsp90α on hsp90α expression in glioblastoma. mRNA expression levels of hsp90α was relative to GAPDH in 
U87-MG cells treated with Hsp90 inhibitor 17-AAG and/or sihsp90α which targets exon 5 on the hsp90α gene were assessed by agarose gel electrophoresis 
(A) and qRT-PCR (B) 72 h. Lane (1) control, (2) sihsp90α, (3) 17-AAG, (4) sihsp90α+17-AAG. sihsp90α represents cells treated with hsp90α specific 
siRNA. sihsp90α+17-AAG represent concurrent assays where the cells were treated with 17-AAG and sihsp90α for either 48 or 72 h. *p ≤ 0.05 and **p ≤ 
0.001 were considered statistically significant (Data values are mean ± SD, n = 3). 
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Figure 3.2.2: hsp90α mRNA level in SVGp12 cells. mRNA expression levels of hsp90α was relative to GAPDH in SVGp12 cells treated with Hsp90 
inhibitor 17-AAG and/or sihsp90α were assessed for 48 h and 72 h by agarose gel electrophoresis (A) and qRT-PCR (B). Lane (1) control, (2) sihsp90α, (3) 
17-AAG, (4) sihsp90α+17-AAG. Data values are mean ± SD, n = 3. 
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3.2.2 17-AAG and sihsp90α exposure promotes Hsp90α protein 
degradation in U87-MG cell line  
Hsp90α protein levels were monitored by immunocytochemistry to correlate the 
transcription to the protein levels following sihsp90α and 17-AAG treatment. Figure 
3.2.3 represents a sample of the stained cells showing a positive staining for Hsp90α. 
Hsp90α protein levels were significantly reduced following independent treatment with 
17-AAG and sihsp90α. Most degradation of Hsp90α protein was observed after 
combinatorial treatment using 17-AAG and sihsp90α simultaneously, whereby 
approximately 4% of the cells strongly expressed Hsp90α after 48 and 72 h (Table 
3.2.1). When used as individual agents, sihsp90α and 17-AAG reduced Hsp90α protein 
levels by 66 and 82%, respectively. Based on the qRT-PCR and Hsp90α protein 
expression data, there was a clear correlation between the Hsp90α mRNA and protein 
expression levels. 
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Figure 3.2.3: Hsp90α protein level in U87-MG assessed using immunohistochemistry. Hsp90α protein expression in glioblastoma after 48 h (A) and 72 h 
(B). The cells were stained with FITC conjugate secondary antibody bound to Hsp90α antigen (green) and propidium iodide (PI) to detect nucleus (red) at 
×40 objective magnifications. Hsp90α was mainly located in the cell cytoplasm. This data is representative of three independent experiments. 
142 
 
Table 3.2.1: Hsp90α expression in U87-MG post 17-AAG and sihsp90α treatment. The 
Hsp90α levels were deduced as the fraction of the observed Hsp90α levels in treated samples 
relative to the total Hsp90α levels in the untreated sample using immunofluorescence after 48 
and 72 h. Hsp90α expression analysis using immunofluorescence was performed by counting 
150 cells in triplicates. sihsp90α represent cells treated with hsp90α specific siRNA. 
sihsp90α+17-AAG represent concurrent assays where the cells were treated with 17-AAG and 
sihsp90α for either 48 or 72 h. This data is typical of three independent experiments. *p ≤ 0.05 
and **p ≤ 0.001 were considered statistically significant. 
Incubation 
Time (h) 
Hsp90α 
protein 
expression (%) 
Control sihsp90α 17-AAG 
sihsp90α +     
17-AAG 
48 
Strong (++) 71.7 ± 1.8 33.9 ± 2.3 ** 18.7 ± 1.2 ** 3.5 ± 1.0 ** 
Weak (+) 23.0 ± 2.0 43.4 ± 1.3 ** 35.2 ± 2.7 ** 37.6 ± 2.6 ** 
Absent (‒) 5.4 ± 0.2 22.7 ± 0.9 ** 46.2 ± 1.5 ** 59.2 ± 2.2 ** 
72 
Strong (++) 72.1 ± 3.6 40.3 ± 0.6 * 16.7 ± 1.7 ** 4.3 ± 1.5 ** 
Weak (+) 26.5 ± 2.3 42.6 ± 1.5 ** 53.4 ± 3.1 ** 25.8 ± 0.9 
Absent (‒) 1.5 ± 1.4 17.2 ± 2.1 ** 28.3 ± 3.1 ** 69.9 ± 0.5 ** 
 
 
3.2.3 Hsp90α inhibition promotes degradation of Hsp90 client 
Akt/PKB kinase in U87-MG cells 
Hsp90 protein regulates conformation, stability and function of many client proteins 
including Akt. Akt is a signalling protein kinase and is a vital component of the 
PI3K/Akt signalling pathway known to be abnormally activated in glioblastoma (Zhu et 
al., 2010). Exposure to Hsp90 inhibitors results in Akt destabilisation and subsequently 
undergoes proteasomal degradation.  
A standard curve was plotted to determine the Akt activity in unknown treated and 
untreated samples. The equation in the graph was utilized to calculate the active Akt 
levels in the samples (refer Figure 2.9). To examine whether sihsp90α and 17-AAG 
affects inhibition of Hsp90α, activity levels of Akt protein, client protein of Hsp90, was 
investigated in control and treated U87-MG cells using 10 µg of total protein. A 
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combination of sihsp90α and 17-AAG reduced Akt activity to 47.3 and 43% after 48 
and 72 h, respectively (Figure 3.2.4). When only 17-AAG was used, it was found to 
reduce Akt levels to 63 and 61% after 48 and 72 h treatments. Silencing hsp90α with 
siRNA inactivated Akt activity by 41% after 48 h. However, after 72 h the Akt activity 
was upregulated to over 100%. The expression profile of Akt emulates that of Hsp90α 
mRNA and the protein level following sihsp90α and 17-AAG treatments (Figure 3.2.1 
& Table 3.2.1).  
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Figure 3.2.4: Hsp90α inhibition results in loss of Akt activity in U87-MG cells. The Akt activity was deduced as the fraction of the observed Akt activity 
in treated samples relative to the total Akt activity in the untreated sample after 48 h (A) and 72 h (B). sihsp90α represent cells treated with hsp90α specific 
siRNA. sihsp90α+17-AAG represent concurrent assays where the cells were treated with sihsp90α and 17-AAG for either 48 or 72 h. *p ≤ 0.05 and             
**p ≤ 0.001 were considered statistically significant (Data values are mean ± SD, n = 3). 
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3.2.4 Combinatorial assays with 17-AAG and sihsp90α inhibits tumour 
growth in U87-MG but does not affect SVGp12 cell viability 
To determine the cell viability, U87-MG and SVGp12 cells were treated with 17-AAG 
and sihsp90α simultaneously for concurrent combinatorial assay. Both gene silencing 
and protein inhibitor approaches showed dramatic reduction in cell viability in U87-MG 
(Figure 3.2.5A). Data showed that sihsp90α, 17-AAG and a combination of sihsp90α/ 
17-AAG reduced cell viability by 27, 75 and 88% after 72 h, respectively. Cytotoxic 
effects of 17-AAG, as a single agent, far exceeded the cytotoxic effects shown by 
sihsp90α at either 48 or 72 h. 17-AAG restricted tumour growth to 51 and 25% and 
sihsp90α treatment impaired tumour growth to 89 and 73% after 48 and 72 h, 
respectively. To determine the therapeutic potential of this combination treatment, non-
tumourigenic cell line SVGp12 was treated with sihsp90α and 17-AAG for 48 and 72 h 
(Figure 3.2.5B). Neither of the treatments significantly reduced SVGp12 cell viability 
after 48 or 72 h, thus demonstrating the tumour-specific targeting of this combination 
treatment. 
To assess whether there was significant difference between sequential and concurrent 
assays using sihsp90α and 17-AAG on growth inhibition, the cytotoxic effects of U87-
MG cells treated sequentially with sihsp90α and 17-AAG were compared to cells that 
received concurrent administration. No significant difference was observed on the cell 
viability as well as the gene knockdown (Figure 3.2.6A & B). 
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Figure 3.2.5: 17-AAG and sihsp90α effect on cell viability in vitro. Cell viability was monitored after cells treated with 17-AAG and sihsp90α after 48 h 
and 72 h in (A) U87-MG and (B) SVGp12. Control represent untreated cells, sihsp90α represent cells treated with hsp90α specific siRNA. sihsp90α+17-AAG 
represent concurrent assays where the cells were treated with 17-AAG and sihsp90α for either 48 or 72 h. *p ≤ 0.05 and **p ≤ 0.001 were considered 
statistically significant (Data values are mean ± SD, n = 3). 
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Figure 3.2.6: There is no significant difference between concurrent and sequential assays. 
sihsp90α-17-AAG represent sequential assays where the cells were treated with sihsp90α for 24 
h followed by 17-AAG for 48 h and vice versa in case of 17-AAG-sihsp90α. 17+si represent 
concurrent assays where the cells were treated with 17-AAG and sihsp90α for 72 h. Lane (1) 
represents Control, (2-3) 17-AAG-sihsp90α and sihsp90α-17-AAG and (4) sihsp90α+17-AAG. 
*p ≤ 0.05 and **p ≤ 0.001 were considered statistically significant (Data values are mean ± SD, 
n = 3).  
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3.2.5 sihsp90α does not synergize with 17-AAG treatment in U87-MG 
cell line  
The ability of sihsp90α to synergize with 17-AAG in U87-MG was examined. The 
efficacy of the concurrent assay with 17-AAG and sihsp90α was assessed using 
interaction ratios generated by a ratio of the observed growth inhibition following 
treatment with both compounds versus growth inhibition using either compound 
independently. A ratio of 1 indicates additive growth inhibition, a ratio greater than 1 
demonstrates synergistic growth inhibition, while a ratio less than 1 suggests sub-
additive effects on growth inhibition (Sauvageot et al., 2009). The interaction ratio 
calculated for concurrent treatments in this study are listed in Table 3.2.2. The results 
indicate that the addition of sihsp90α to 17-AAG does not provide additional efficacy 
on growth inhibition in glioblastoma. However, the data indicates a strong correlation 
between Hsp90α mRNA and protein expression, Akt expression levels and cell viability 
in GBM (Table 3.2.3). 
 
 
Table 3.2.2: sihsp90α does not synergize with 17-AAG treatment in U87-MG. The efficacy 
of the concurrent assay with 17-AAG and sihsp90α was assessed using interaction ratios 
generated by a ratio of the observed growth inhibition following treatment with both compounds 
versus growth inhibition using either compound independently. The data values are mean, ± SD, 
n = 3. *p ≤ 0.05 was considered statistically significant. 
Interaction ratio after sihsp90α alone 17-AAG alone 
48 h 4.62 ± 1.35 * 1.05 ± 0.11 
72 h 3.28 ± 0.19 * 1.18 ± 0.29 
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Table 3.2.3: There was a strong correlation between Hsp90α mRNA expression levels, Akt 
activity and cell viability in GBM. 
 hsp90α mRNA 
expression 
normalised to 
GAPDH (%) 
% Akt/PKB kinase 
activity 
% Cell viability 
Control 
48 h 100 ± 4.78 100 ± 3.5 100 ± 5 
72 h 100 ± 3.78 100 ± 2.5 100 ± 4.5 
sihsp90α 
48 h 4.4 ± 1.29 59.3 ± 3.8 89 ± 3 
72 h 44.6 ± 3.79 105.1 ± 0.79 73 ± 1.5 
17-AAG 
48 h 5.3 ± 1.47 62.7 ± 0.48 51 ± 3.5 
72 h 13.6 ± 2.25 61.1 ± 3.4 24.8 ± 1.9 
sihsp90α+17AAG 
48 h 0.9 ± 0.07 47.3 ± 0.91 48 ± 9 
72 h 0.8 ± 0.05 43 ± 1.28 11.3 ± 1.5 
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3.3 The Effects of Tat-delivered sihsp90α in 
combination with 17-AAG in GBM  
 
3.3.1 Tat peptide effectively binds to sihsp90α but Cyt c77-101 and 
C105Y peptides do not  
To determine whether the CPPs interact efficiently with sihsp90α, a gel shift assay was 
performed. Increasing concentrations of the CPPs ranging from 0.2 µM to 4 µM for Tat 
and 0.2 µM to 10 µM for Cyt c
77-101 and C105Y were incubated with sihsp90α (200 nM) 
for 30 min. Tat peptide was able to bind to the sihsp90α in a dose-dependent manner 
and was observed to be completely retarded at 15-fold Tat molar excess compared to 
sihsp90α, characterised by movement of the band up on the gel (Figure 3.3.1A). Both 
Cyt c
77-101
 and C105Y peptide did not completely retard sihsp90α at concentrations up 
to 50-fold peptide molar excess with 30 min incubations (Figure 3.3.1B). To determine 
whether increasing concentration and incubation time facilitated effective 
siRNA/peptide complex formation, sihsp90α was incubated with Cyt c77-101 and C105Y 
at concentrations up to 100-fold peptide molar excess for 1 and 2 h at 37
°
C. Figure 
3.3.1B showed that higher peptide concentrations of Cyt c
77-101
 and C105Y had no 
significant effect on siRNA/peptide complex formation since no gel shift was observed. 
Subsequently, Cyt c
77-101
 and C105Y peptide were considered redundant for this 
particular study and were discontinued from further analysis. 
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Figure 3.3.1: PAGE gel shift assay to assess the ability of Tat, Cyt c
77-101
 and C105Y 
peptides to form complexes with sihsp90α. Increasing concentrations of the Tat peptides were 
added ranging from equimolar peptide compared with the siRNA to a 20-fold molar excess (A). 
As the peptide concentration increases the siRNA retardation increases and at 15-fold Tat molar 
excess almost all siRNA was completely retarded. Cyt c
77-101
 and C105Y were incubated with 
increasing concentrations of peptide ranging from 5- to 100-fold peptide molar excess to siRNA 
at three different incubations 30 min, 1 h and 2 h (B). Lane M represents siRNA marker and 0 
represents siRNA alone. This is representative of three independent experiments. 
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3.3.2 Serum stability of siRNA in vitro  
Stability studies were performed to characterise the susceptibility of the aqueous and 
complexed siRNA used in this study to human serum as examined by polyacrylamide 
gel electrophoresis. When incubated with human serum (50%) aqueous siRNA was 
unstable in serum after 1 h and exhibits complete degradation after 6 h (Figure 3.3.2A). 
A control without any serum shows presence of siRNA after 24 h which also confirms 
that the oligonucleotide is 21 bp long. In an attempt to improve sihsp90α stability in 
serum, sihsp90α/Tat complexes were formed for 30 min as described previously and 
incubated in 50% human serum for up to 36 h. The sihsp90α integrity was analysed on 
15% TBE polyacrylamide gel. At 15-fold Tat molar excess sihsp90α was stable for 6 h 
which is similar to stability of aqueous sihsp90α. However, 30-fold Tat excess 
improved the sihsp90α stability as stable sihsp90α was observed after 24 h (Figure 
3.3.2B). Further increasing the concentration of Tat peptide to 50-fold excess of 
sihsp90α was associated with sihsp90α remaining intact after 36 h (Figure 3.3.2B).  
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Figure 3.3.2: Stability of aqueous sihsp90α and sihsp90α/Tat complexes in 50% human 
serum. Serum stability of aqueous sihsp90α was assessed in 50% human serum (A). sihsp90α 
incubated without serum was used as control. sihsp90α/Tat complexes were incubated in 50% 
human serum for up to 36 h and stability of sihsp90α assessed on 15% polyacrylamide gel (B). 
At 15-fold peptide molar excess, sihsp90α was stable for 6 h, at 30-fold peptide molar excess 
stable sihsp90α was noted after 24 h. At 50-fold peptide molar excess, sihsp90α was stable after 
36 h.   
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3.3.3 sihsp90α/Tat complexes did not induce membrane leakage in 
U87-MG or SVGp12 cells  
To determine whether Tat peptide alone or complexed to sihsp90α exhibited potential 
toxic side effects, membrane disturbance was studied in U87-MG and SVGp12 cells. 
An LDH leakage assay was used to measure the acute membrane disturbance 30 min 
after treatment with Tat alone or sihsp90α/Tat complexes. Tat did not significantly affect 
membrane integrity up to 10 µM after which approximately 15% membrane leakage 
was induced at 20 µM rendering Tat redundant at concentrations higher than 10 µM 
(Figure 3.3.3A & B). Moreover, Tat demonstrates slightly higher LDH leakage as a 
multi-peptide complexed with sihsp90α compared to when used independently. In non-
tumourigenic cells (SVGp12), Tat showed no significant effect on membrane integrity 
at concentrations up to 20 µM when used alone or at 100-fold Tat excess to sihsp90α.  
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Figure 3.3.3: Membrane integrity analysis using Tat peptide with or without sihsp90α. 
Both  U87-MG and SVGp12 cells were incubated with Tat at 15-, 30-, 50- and 100-fold peptide 
molar excess to sihsp90α (A), which corresponds to final peptide concentration of 3, 6, 10 and 
20 µM when used without siRNA (B). Tat induced LDH leakage (~15%) only at 100-fold 
peptide excess to siRNA or 20 µM when used alone in U87-MG; LDH leakage in SVGp12 was 
negligible. Untreated cells were defined as control and LDH was released using Lysis solution 
to yield 100% LDH leakage. This is representative of three such independent experiments, data 
values are mean ± SD. 
 
 
3.3.4 Tat mediated si-FAM delivery in vitro increases with peptide 
concentration 
To examine whether the siRNA/Tat complexes increased cellular siRNA uptake in vitro, 
fluorescently labelled siRNA (si-FAM) was utilized for uptake and localisation studies. 
Firstly, the ability of Tat to form complexes with si-FAM was assessed by gel shift 
assay. The lowest molar ratio (siRNA:peptide) used for this assay, predetermined by 
complete complex formation using gel shift, was 15-fold peptide molar excess 
compared to sihsp90α (Figure 3.3.1A). All si-FAM (200 nM) formed complexes with 
Tat peptide at 15-fold peptide molar excess demonstrating corresponding retardation 
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efficiency for both sihsp90α and si-FAM (Figure 3.3.4). si-FAM/Tat complexes were 
then used for uptake study at increasing concentrations of up to 50-fold peptide molar 
excess compared to si-FAM. Cells transfected with si-FAM/Tat complexes exhibited 
efficient si-FAM cellular uptake in a concentration-dependent manner. Cellular uptake 
of si-FAM/Tat complexes by U87-MG and SVGp12 cells using 15-, 30- and 50-fold 
peptide molar excess are listed in Table 3.3.1. High si-FAM uptake was noted in U87-
MG as compared to SVGp12 cells. Free si-FAM was not internalised by U87-MG or 
SVGp12 cells as seen by confocal microscopy (Figure 3.3.5 & 3.3.6).  
 
3.3.5 Localisation of si-FAM/Tat complexes in glioblastoma and non-
tumourigenic cells  
The ability of Tat peptide to efficiently transfect U87-MG and SVGp12 cells with       
si-FAM was examined utilizing confocal microscopy. Increasing concentrations of Tat 
peptide were used with si-FAM and its effects on intracellular localisation and 
distribution of siRNA was assessed. In U87-MG cells, at 15-fold peptide molar excess 
to si-FAM, siRNA was mainly located in the cytoplasm though nuclear localisation of 
si-FAM was also detected (Figure 3.3.5). Both cytoplasmic as well as nuclear 
localisation of si-FAM was observed at 30-fold peptide molar excess to si-FAM. At 50-
fold Tat peptide molar excess, although si-FAM was observed to localize to the 
cytoplasm, substantial accumulation of siRNA was noted in the nucleus (Figure 3.3.5). 
A diffused cytoplasmic uptake of si-FAM by SVGp12 cells (Figure 3.3.6) was noted at 
all si-FAM/peptide molar ratios indicating that cellular localisation of si-FAM was cell 
line dependent, however, the si-FAM uptake was dose-dependent and the si-FAM 
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uptake efficiency in SVGp12 cells was low in comparison to U87-MG cells (Table 
3.3.1).  
 
 
 
Figure 3.3.4: PAGE gel shift analysis using Tat peptide and si-FAM. The Tat peptide was 
used to assess whether si-FAM formed complexes with the peptide. The siRNA was completely 
retarded at 15-fold peptide molar excess. These preliminary results will allow the use of the si-
FAM for siRNA uptake studies. This is typical of three such independent experiments.  
 
 
Table 3.3.1: Tat efficiently delivers siRNA in U87-MG and SVGp12 cells in a dose-
dependent manner. The siRNA/Tat complex uptake in U87-MG and SVGp12 cells was 
performed by counting 150 cells. The data is typical of three independent experiments, ± SD.  
siRNA:Tat molar ratio  1:15 1:30 1:50 Free siRNA  
si-FAM uptake in U87-MG (%) 48.1 ± 3.6 64.9 ± 6.0  73.9 ± 6.4  0  
si-FAM uptake in SVGp12 (%) 32.8 ± 2.3 43.1 ± 3.1 46.0 ± 3.4 0 
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Figure 3.3.5: Uptake of si-FAM in U87-MG glioblastoma. si-FAM (200 nm) was mixed with 
increasing concentrations of Tat peptide giving rise to si-FAM/Tat molar ratios ranging from 
1:15 to 1:50. Following 2 h incubation, the si-FAM uptake was assessed by confocal imaging. 
15, 30 and 50 represents 15-, 30- and 50-fold peptide molar excess to siRNA, respectively. (C) 
represents control without peptide. This is typical of three such independent experiments. 
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Figure 3.3.6: Uptake of si-FAM in SVGp12 cells. si-FAM (200 nm) was mixed with 
increasing concentrations of Tat peptide giving rise to si-FAM/Tat molar ratios ranging from 
1:15 to 1:50. Following 2 h incubation, the si-FAM uptake was assessed by confocal 
microscopy. 15, 30 and 50 represents 15-, 30- and 50-fold peptide molar excess to siRNA, 
respectively. (C) represents control without peptide. This data is representative of three 
independent experiments. 
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3.3.6 sihsp90α–mediated hsp90α knockdown in glioblastoma and non-
tumourigenic cells 
The hsp90α and GAPDH gene expression levels were monitored to examine the gene 
silencing efficacy of sihsp90α/Tat complexes in glioblastoma U87-MG in vitro. The 
hsp90α mRNA levels showed are relative to GAPDH levels. The sihsp90α/Tat 
complexes showed significant hsp90α downregulation using 15, 30 and 50-fold Tat 
peptide molar excess to sihsp90α resulting in 75, 83 and 87% and 2, 12 and 10% gene 
knockdown after 24 and 48 h, respectively (Figure 3.3.7B). At 72 h post treatment, 
hsp90α silencing efficiency of sihsp90α/Tat complexes was 25 and 17% at 1:15 and 
1:30. 
The hsp90α gene expression was also investigated after treating cells with both 
sihsp90α/Tat complexes and 17-AAG in vitro, to assess whether the duration and 
magnitude of hsp90α mRNA knockdown was influenced. After 24 h, a combination of 
sihsp90α/Tat complexes and 17-AAG produced statistically significant hsp90α 
knockdown of 91, 93 and 95% at 15, 30 and 50-fold Tat peptide molar excess to 
sihsp90α, respectively (p ≤ 0.001; Figure 3.3.7B). At 48 and 72 h, the combination 
treatment prompted significant hsp90α mRNA downregulation resulting in 33, 84 and 
93% and 50, 65 and 78% mRNA knockdown after 48 and 72 h at 15, 30 and 50-fold Tat 
peptide molar excess to sihsp90α, respectively. All the qRT-PCR results were also 
validated by agarose gel electrophoresis (Figure 3.3.7A). The mRNA expression level 
of GAPDH was used as an internal standard for quantification in U87-MG cells and 
monitored to accurately determine the degree of downregulation. To examine whether 
Tat peptide itself attenuated RNAi efficacy, increasing concentrations of Tat peptide 
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were used (3, 6 and 10 μM). Intriguingly, cells treated with Tat exhibited a dose-
dependent increase in hsp90α expression after 24, 48 and 72 h in U87-MG.  
The hsp90α mRNA levels in non-tumourigenic cell line SVGp12 were quantitated to 
validate targeting hsp90α as a therapeutic approach. As seen in Figure 3.3.8B, 
negligible levels of hsp90α were detected at all time points in control as well as treated 
cells. The hsp90α expression in SVGp12 cells were expressed as relative to GAPDH 
expression. All the qRT-PCR results were validated using agarose gel electrophoresis 
(Figure 3.3.8A).  
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Figure 3.3.7: Effects of sihsp90α-mediated RNAi on hsp90α knockdown in U87-MG cells. mRNA expression levels of hsp90α and GAPDH in U87-MG 
cells treated with sihsp90α and Hsp90 inhibitor 17-AAG were assessed by agarose gel electrophoresis (A) [hsp90α (left) and GAPDH (right)] and qRT-PCR 
(B) for hsp90α gene expression relative to GAPDH expression after 24, 48 and 72 h. Lane (1) Control; (2) 3 µM; (3) 6 µM; (4) 10 µM; (5) sihsp90α; (6) 1:15; 
(7) 1:30, (8) 1:50; (9) 1:15+17-AAG; (10) 1:30+17-AAG; (11) 1:50+17-AAG. 1:15-1:50+17-AAG represent combinatorial treatment where cells were 
transfected with sihsp90α and subsequently treated with 17-AAG (Data values are mean ± SD, n = 3). *p ≤ 0.05 and **p ≤ 0.001 were considered statistically 
significant. 
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Figure 3.3.8: hsp90α mRNA expression levels in SVGp12 cells. mRNA expression levels of hsp90α and GAPDH in SVGp12 cells transfected with 
sihsp90α/Tat complexes and Hsp90 inhibitor 17-AAG were assessed by agarose gel electrophoresis (A) [hsp90α (left) and GAPDH (right)] and qRT-PCR 
(B), for hsp90α gene expression relative to GAPDH expression after 24, 48 and 72 h. Lane (1) Control; (2) 3 µM; (3) 6 µM; (4) 10 µM; (5) sihsp90α; (6) 
1:15; (7) 1:30, (8) 1:50; (9) 1:15+17-AAG; (10) 1:30+17-AAG; (11) 1:50+17-AAG. 1:15-1:50+17-AAG represent combinatorial treatment where cells were 
transfected with sihsp90α and subsequently treated with 17-AAG (Data values are mean ± SD, n = 3). *p ≤ 0.05 was considered statistically significant. 
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3.3.7 Hsp90α depletion in glioblastoma cells was subsequent to 
treatment with sihsp90α/Tat complexes and 17-AAG 
Treatment with sihsp90α and 17-AAG showed significant effect on the transcriptional 
regulation hsp90α as shown previously. To determine whether the Hsp90α protein 
levels were influenced after the treatment, glioblastoma cells treated with sihsp90α and 
17-AAG were analysed by immunocytochemistry. The cells were stained with 
fluorescently-labelled secondary antibody (FITC) specific to Hsp90α as shown in 
Figure 3.3.9. sihsp90α/Tat complexes significantly reduced Hsp90α protein levels after 
24 and 48 h (Figure 3.3.9A & B) with significant Hsp90α downregulation achieved after 
48 h, whereby Hsp90α expression was reduced by 84% (Table 3.3.2). The RNAi 
efficiency of sihsp90α diminished after 72 h post treatment as evident by the recurrence 
of Hsp90α expression in glioblastoma (Figure 3.3.9C). When sihsp90α transfection was 
accompanied with 17-AAG treatment, the cells exhibited significant reduction of 
Hsp90α levels after 24, 48 and 72 h. The combination treatment significantly reduced 
Hsp90α expression by 98, 99 and 95% after 24, 48 and 72 h, respectively. Glioblastoma 
cells treated with increasing concentrations of Tat alone showed no significant variation 
in Hsp90α expression after 24, 48 or 72 h.  
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Figure 3.3.9: Hsp90α protein expression levels in U87-MG cells after treatment with sihsp90α and 17-AAG. The cells were stained with FITC conjugate 
secondary antibody bound to Hsp90α antigen (green) and propidium iodide (PI) to detect nucleus (red) at ×40 objective magnifications. A: 24 h; B: 48 h; C: 
72 h. Hsp90α protein levels in U87-MG cells post treatment with sihsp90α/Tat complexes and 17-AAG after 24, 48 and 72 h has been listed (D). Hsp90α 
expression analysis using immunofluorescence was performed by counting 150 cells. 1:15-1:50+17-AAG represent combinatorial treatment where cells were 
transfected with sihsp90α and subsequently treated with 17-AAG. This data is representative of three independent experiments. *p ≤ 0.05 was considered 
statistically significant. 
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Table 3.3.2 Treatment with sihsp90α/Tat complexes and 17-AAG reduces Hsp90α protein expression in U87-MG cells. This data is representative of 
three independent experiments. *p ≤ 0.05 and **p ≤ 0.001 were considered statistically significant. 
Incubation 
period (h) 
24  48  72  
Hsp90α 
expression (%) 
Strong (++) Weak (+) Absent (‒) Strong (++) Weak (+) Absent (‒) Strong (++) Weak (+) Absent (‒) 
Control 71.7 ± 1.7 22.1 ± 2.7 6.3 ± 1.1 74.5 ± 2.3 23.2 ± 1.6 4.4 ± 1.3 73.2 ± 1.8 24.1 ± 0.6 2.8 ± 1.3 
3 μM 76.6 ± 0.9* 16.5 ± 2.0* 7.4 ± 0.8* 74.0 ± 2.0 21.3 ± 0.7 5.4 ± 0.6 73.1 ± 1.1 24.7 ± 0.3* 2.8 ± 0.3 
6 μM 76.0 ± 0.5* 18.7 ± 1.0 6.3 ± 0.4 74.1 ± 0.8  23.1 ± 0.7 5.2 ± 1.1* 72.0 ± 0.8 27.1 ± 0.9* 2.8 ± 0.2 
10 μM 71.7 ± 2.5 22.3 ± 0.8 8.0 ± 0.2 74.8 ± 1.7 19.9 ± 0.2 5.3 ± 1.9 72.7 ± 2.9 26.5 ± 2.7 2.9 ± 0.2 
sihsp90α  72.6 ± 1.4 19.3 ± 0.4 8.2 ± 0.9* 72.8 ± 2.7* 23.0 ± 1.2 4.3 ± 1.6 72.7 ± 0.7 25.2 ± 1.5 2.2 ± 0.8 
1:15 40.2 ± 2.5** 34.9 ± 3.6* 25.0 ± 1.2** 27.3 ± 7.3* 43.6 ± 3.2* 29.2 ± 4.2* 30.8 ± 4.6** 58.7 ± 5.6* 10.5 ± 1.0** 
1:30 34.9 ± 4.8* 37.1 ± 0.4* 27.9 ± 4.1* 22.2 ± 1.2** 44.5 ± 1.2** 33.9 ± 0.5** 33.2 ± 4.4** 57.2 ± 1.4** 9.8 ± 2.8* 
1:50 38.2 ± 1.8** 37.0 ± 2.0** 24.9 ± 0.2** 16.0 ± 4.0** 45.9 ± 0.5** 38.2 ± 3.5** 26.0 ± 0.4** 57.2 ± 2.9* 11.8 ± 7.5 
1:15 + 17-AAG 1.3 ± 1.1** 58.0 ± 1.3** 40.8 ± 2.6** 1.4 ± 0.7** 43.1 ± 4.8* 55.5 ± 4.1** 5.4 ± 2.7** 35.1 ± 3.2* 59.6 ± 5.9* 
1:30 + 17-AAG 0.9 ± 0.8** 49.8 ± 2.0** 49.4 ± 2.8** 2.6 ± 2.3** 36.7 ± 0.1* 60.6 ± 2.7** 4.6 ± 3.7** 34.2 ± 3.2* 61.2 ± 6.9* 
1:50 + 17-AAG 2.0 ± 1.8** 39.9 ± 1.4* 58.4 ± 3.5** 1.2 ± 1.0** 36.6 ± 3.8* 62.4 ± 4.9** 4.3 ± 2.2** 37.8 ± 2.2* 58.0 ± 6.5* 
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3.3.8 Effect of Hsp90α inhibition using sihsp90α and 17-AAG on Akt 
kinase activity in glioblastoma U87-MG cells 
The Akt kinase activity, a Hsp90 client protein, was investigated to address whether 
sihsp90α and 17-AAG treatment altered the Akt kinase activity. Transfection of 
sihsp90α with Tat peptide reduced Akt activity to 58.1 and 69.9% after 24 and 48 h but 
the Akt activity was induced after 72 h (Figure 3.3.10). Combination treatment with 
sihsp90α and 17-AAG reduced Akt kinase levels to 49.7% at 50-fold Tat molar excess 
after 24 h (p ≤ 0.05). Similarly, significant reduction in Akt kinase activity was noted 
after 48 and 72 h, as treated cells exhibit loss of Akt activity by 72.3 and 82.9% at 1:50 
sihsp90α:peptide molar ratio (p ≤ 0.001). Even at lower peptide concentrations (i.e. 1:15 
and 1:30), a comparable and statistically significant reduction in Akt activity was 
produced after 48 and 72 h (p ≤ 0.05). Interestingly, although uncomplexed Tat peptides 
were observed to reduce Akt activity after 24 h, Tat induced Akt activity to some extent 
after 48 and 72 h.  
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Figure 3.3.10: Hsp90α inhibition leads to loss of Akt/PKB kinase activity in glioblastoma. The Akt activity was deduced as the fraction of the observed 
Akt activity in treated samples relative to the total Akt activity in the untreated sample after 24, 48 and 72 h. 1:15-1:50+17-AAG represent combinatorial 
treatment where cells were transfected with sihsp90α and subsequently treated with 17-AAG. This data is typical of three independent experiments. Data 
values are mean ± SD, n = 3. *p ≤ 0.05 and **p ≤ 0.001 were considered statistically significant.   
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3.3.9 The effect of sihsp90α/Tat complexes on glioblastoma cell 
viability in combination with 17-AAG 
To examine whether transfected cells exert a biological effect, U87-MG and SVGp12 
cells were treated with increasing concentrations of sihsp90α/Tat complexes ranging 
from 1:15-1:50 (mol sihsp90α:mol peptide) and 17-AAG (0.225 µM) as established 
previously. sihsp90α/Tat complexes, even at the highest concentration was found not to 
be cytotoxic to glioblastoma cells at 24 h and 72 h post treatment. In contrast, after 48 h 
the sihsp90α/Tat complexes showed a dose-dependent reduction in U87-MG cell 
viability with significant cytotoxic effects achieved at 1:30 and 1:50 sihsp90α:peptide 
molar ratio whereby up to 20% tumour cell growth inhibition was recorded (p ≤ 0.05). 
sihsp90α/Tat complexes together with 17-AAG significantly reduced tumour growth by 
41.2, 88.2 and 83.2% after 24, 48 and 72 h, respectively (p ≤ 0.001; Figure 3.3.11). To 
examine whether Tat peptide itself influenced sihsp90α-mediated cytotoxicity in 
glioblastoma, increasing concentrations of Tat peptide were used (3, 6 and 10 μM), 
which corresponded to 1:15, 1:30 and 1:50 when complexed with sihsp90α 
(sihsp90α:peptide). Tat peptide demonstrated no long-term toxic side effects in        
U87-MG cells at all time points examined. sihsp90α/Tat complexes demonstrated no 
significant cytotoxic effects in SVGp12 cells (Figure 3.3.12). A combination of 
sihsp90α/Tat complexes and 17-AAG was found to induce no more than 9.3% cell 
death at any of the time points examined, although this was not significant. In addition, 
Tat peptide did not exhibit long-term toxicity in SVGp12 cells after 24, 48 or 72 h. 
Based on the findings from this study, a clear correlation between the Hsp90α mRNA 
and protein expression profiles, Akt activity and cell viability was observed in 
glioblastoma (Table 3.3.2 and 3.3.3). 
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Figure 3.3.11: Cytotoxicity associated with sihsp90α/Tat and 17-AAG in U87-MG. 1:15-1:50+17-AAG represent combinatorial treatment where cells 
were transfected with sihsp90α and subsequently treated with 17-AAG. sihsp90α represent cells treated with sihsp90α alone without delivery vector. This data 
is typical of three independent experiments, the values are mean ± SD. *p ≤ 0.05 and **p ≤ 0.001 were considered statistically significant. 
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Figure 3.3.12: The effect of sihsp90α/Tat peptide complexes and 17-AAG on non-tumourigenic cell viability. 1:15-1:50+17-AAG represent 
combinatorial treatment where cells were transfected with sihsp90α and subsequently treated with 17-AAG. sihsp90α represent cells treated with sihsp90α 
alone without delivery vector. This data is typical of three independent experiments, the values are mean ± SD. 
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Table 3.3.3: The correlation profile between Hsp90α mRNA and protein expression levels compared to the Akt kinase activity and cell viability in 
glioblastoma. The data values are mean, ± SD, n = 3.  
 sihsp90α:Tat 
molar ratio 
hsp90α mRNA/100 ng Cells Extract (1 x 
10
6
 cells) 
% Akt/PKB Kinase Activity % Cell Viability 
  24 h 48 h 72 h  24 h 48 h 72 h  24 h 48 h 72 h  
Control 8093 ± 770 7915 ± 763 7709 ± 767 100.0 ± 3.0 100.0 ± 3.5  100.0 ± 2.7 100.0 ± 1.7 100.0 ± 3.9 100.0 ± 2.6 
T
a
t 
p
ep
ti
d
e 
a
lo
n
e 
3 µM 6719 ± 51 10357 ± 2393 10197 ± 2752 98.7 ± 6.8 107.6 ± 5.5 104.9 ± 3.6 101.4 ± 1.2 100.2 ± 1.7 102.4 ± 2.4 
6 µM 7874 ± 118 10768 ± 2356 10546 ± 2112 97.3 ± 4.2 104.2 ± 3.9 103.0 ± 1.5 100.4 ± 1.7 100.3 ± 1.5 99.8 ± 3.6 
10 µM 7696 ± 656 11245 ± 2745 10198 ± 1987 88.9 ± 4.3 105.6 ± 1.6 103.6 ± 2.3 100.1 ± 2.4 98.4 ± 0.2 101.2 ± 1.3 
sihsp90α alone 7525 ± 747 7891 ± 689 7855 ± 712 98.1 ± 1.7 98.2 ± 3.2 98.4± 3.7 100.0 ± 2.4 99.2 ± 3.4 97.3 ± 2.4 
si
h
sp
9
0
α
/T
a
t 
co
m
p
le
x
es
 1:15 1781 ± 240 7095 ± 891 6275 ± 1038 58.1 ± 0.9 97.8 ± 7.7 86.6 ± 3.7 99.7 ± 1.4 95.3 ± 2.2 94.4 ± 5.6 
1:30 1216 ± 222 6907 ± 980 7014 ± 1362 58.2 ± 0.4 78.3 ± 8.5 106.0 ± 5.9 98.9 ± 0.3 88.1 ± 5.4 94.7 ± 3.9 
1:50 1156 ± 60 6639 ± 832 8120 ± 1522  61.3 ± 0.9 69.9  ± 6.3 109.5 ± 5.8 100.2 ± 1.7 80.0 ±  6.8 98.0 ± 3.2 
si
h
sp
9
0
α
/T
a
t 
+
 1
7
-
A
A
G
 
1:15 723 ± 191 5177 ± 603 4082 ± 983 53.7 ± 3.1 35.5 ± 8.3 34.9 ± 8.1 59.1 ± 1.8 13.3 ± 4.7 16.8 ± 1.5 
1:30 488 ± 70 1594 ± 686 2939 ± 910 51.2 ± 1.1 29.0 ± 8.6 33.3 ± 8.6 58.8 ± 1.3 11.8 ±4.9 18.2 ± 4.8 
1:50 352 ± 77 577 ± 479 1930 ± 931 49.7 ± 2.2 27.7 ± 7.3 17.1 ± 7.2 59.2 ± 2.1 13.0 ± 6.0 17.7 ± 2.4 
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3.4 Gene silencing and protein inhibition of Hsp90α 
and its implications in vivo 
 
3.4.1 Weight loss assessment in mice surgically implanted with tumour 
cells 
After surgery, the mice (n = 22) were weighed on a frequent basis to monitor tumour 
growth. The first sign of tumour growth in mice is usually indicated by weight loss as 
shown in Figure 3.4.1. However, the initial dip in weight loss observed is due to 
anaesthesia. Recovery in weight was observed within 10 days, after that time the loss in 
weight was permanent indicating tumour growth.  
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Figure 3.4.1: Weight loss assessment in mice implanted with U87-MG-luc2 cells. Each 
curve represents weight loss pattern in each of the 22 mice implanted with tumour cells. A 
typical weight loss profile in mice is characterised by two dips indicated by black arrows, the 
first dip is the effect of anaesthesia and the second dip observed after 10 days post tumour 
implantation indicates tumour growth. The red arrows indicate mice that died before the 
treatment with siRNA and 17-AAG on day 17.  
 
 
3.4.2 siluc/Tat complexes reduce luciferase activity in vitro 
To determine whether Tat peptide effectively binds and delivers siluc into U87-MG-
luc2 cells in vitro, siluc/Tat complexes were formed in serum-free EMEM with 
increasing concentration of Tat peptide at siluc:Tat molar ratios ranging from 1:15 to 
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1:50 and added to U87-MG-luc2 cells seeded 24 h prior to treatment. The luciferase 
activity in treated samples was reduced in a dose-dependent manner with upto 73% 
luciferase knockdown achieved after 24 h (Figure 3.4.2).  
 
 
 
Figure 3.4.2: Luciferase activity in U87-MG-luc2 cells treated with siluc/Tat nanoparticles 
in vitro. The siluc/Tat complexes reduced luciferase expression in treated cells in a dose-
dependent manner. This experiment was performed once in triplicate. The values represented 
are mean ± SD. 
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3.4.3 Luciferase quantitation and H&E staining confirm the presence 
of tumour growth in vivo 
Following tumour implantation, the mice were weighed on a regular basis to study the 
weight loss pattern that indicates the presence of proliferating tumour. In addition, brain 
tissue specimens were collected on day 8 (n = 2) and 12 (n = 2) to further validate the 
presence of a tumour by H&E staining and luciferase quantitation. Stained sections of 
tumour specimen clearly showed the presence of a tumour resulting in distortion of the 
surrounding tissue (Figure 3.4.3A Left) in comparison to the normal brain specimen 
whereby the integrity was intact. Furthermore, luciferase expression in tumour and 
normal tissue was quantitated using Luciferase Assay System to confirm presence of 
tumour. Tumour tissue display high levels of luciferase activity as compared to normal 
tissue where negligible luciferase expression was detected (Figure 3.4.3B).  
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Figure 3.4.3: H&E staining and luciferase quantitation show presence of tumour in mice 
striatum. Tumour and normal tissue were stained with Haematoxylin and Eosin to study the 
tissue composition, structure and integrity (n = 2) (A). Tumour tissue lacks tissue integrity 
mainly attributed to tumour expansion indicated by the arrow. Normal tissue displayed intact 
tissue integrity. Luciferase quantitation validates tumour presence in mice, since tumour tissue 
display high levels of luciferase activity compared to normal tissue (B). The values are mean   
(n = 2). 
 
 
3.4.4 Hsp90α gene expression and Akt kinase activity in mice treated 
with sihsp90α/Tat complexes and 17-AAG 
The hsp90α gene expression in tumour tissue specimens was quantitated by qRT-PCR 
to determine whether the dual targeting of Hsp90α using sihsp90α and 17-AAG holds 
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anti-cancer activity in vivo. The tumour mice models (n = 3) treated with sihsp90α/Tat 
nanoparticles in combination with 17-AAG for 24 h exhibited 73% hsp90α knockdown. 
Mouse bearing tumour (n = 1) treated with siluc/Tat complexes and 17-AAG for 24 h 
was used as negative control (Figure 3.4.4A). The hsp90α expression in tumour tissue 
was normalised to GAPDH expression as well as normal brain tissue within each 
sample to accurately quantitate gene expression. Tat-mediated sihsp90α delivery 
induces chemosensitivity to 17-AAG in vivo and correlates well with findings in vitro. 
The Akt kinase activity was quantitated using Akt/PKB Kinase Activity Assay to 
examine the effects of Hsp90α inhibition on Akt activity in vivo. In xenograft models, 
Hsp90α inhibition exhibited 75% reduction in Akt kinase activity compared to the 
negative control (Figure 3.4.4B). The Akt activity in tumour specimens was normalised 
to normal brain tissue within each sample to accurately quantitate Akt expression. 
Furthermore, the qRT-PCR and Akt kinase activity result demonstrates a strong 
correlation.  
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Figure 3.4.4: sihsp90α/Tat complexes in combination with 17-AAG exhibit hsp90α gene 
and Akt kinase activity knockdown. Xenograft models (n = 3) treated with sihsp90α and 17-
AAG exhibit hsp90α downregulation (A) parallel to reduced Akt activity (B) compared to the 
negative control (n = 1).  
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4.1 Discussion  
 
Gliomas are generally not curable surgically, thus there is a high demand for effective 
adjuvant therapies such as chemotherapy and radiotherapy. Temozolomide, a DNA 
methylating agent commonly used as a chemotherapeutic agent has limitations due to 
drug resistance mainly attributed to the DNA repair enzyme MGMT which irreversibly 
transfers the methyl group of O
6
-methylguanine (formed by TMZ treatment) in DNA to 
a cysteine in its active state (Ohba et al., 2010). The molecular chaperone Hsp90 is of 
major interest as an anticancer drug target (Gaspar et al., 2009; Ohba et al., 2010; 
Sauvageot et al., 2009; Siegelin et al., 2009). In tumours, the induced Hsp90 expression 
is responsible for the dependence of tumour cells to multiple signalling pathways where 
Hsp90 clients play an oncogenic role (Karkoulis et al., 2010). Hsp90 is essential for 
regulating the conformation, stability and function of several oncogenic client proteins 
involved in cell cycle regulation, anti-apoptotic mechanisms and oncogenesis (Gaspar et 
al., 2009). These client proteins contribute extensively to malignant transformation, 
survival and the metastatic potential of cancer cells. Subsequently, the responsibility of 
the Hsp90 in tumorigenesis (Eustace et al., 2004) justifies investigating its expression 
profiles in a set of glioma and control cell lines. There are two main cytoplasmic 
isoforms of the Hsp90 namely, the inducible Hsp90α and the constitutive Hsp90β 
(Sreedhar et al., 2004). Hsp90 is mainly a constitutive dimer (αα or ββ), however, 
monomers and heterodimers also exist. High expression levels of Hsp90α were found in 
three glioma cell lines, confirmed by qRT-PCR, compared to normal cell line which is 
in agreement with previous findings from our laboratory (Shervington et al., 2008), and 
the induced chemosensitivity to Hsp90α inhibition observed in glioblastoma 
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(Cruickshanks et al., 2010) elucidates the importance of Hsp90α in the survival of 
gliomas. Hsp90α was therefore considered as an anti-cancer target for glioma therapy in 
this study.  
Initially the hsp90α expression levels were quantitated in glioma and normal cell lines 
to study the expression pattern of hsp90α. Results indicated the enhanced hsp90α levels 
in glioma cells compared to the normal cell line. Although, normal proteins have limited 
requirement for Hsp90 assistance, tumours are highly dependent on molecular 
chaperone activity to cope with the lethal conditions prevalent in tumours and to 
regulate mutated and functionally deregulated proteins (Luo et al., 2007). This could be 
an attribute to the increased transcriptional regulation of hsp90α in glioma cell lines. 
Due to the short blood half-life, increased side effects and modest survival time of the 
conventional chemotherapy (TMZ), there is an urgent need for novel treatment therapies 
for malignant gliomas with low side effects. 17-AAG was one of the few Hsp90 
inhibitors to enter clinical trials and has since shown positive clinical activity in various 
types of tumours. An IC50 analysis was performed using 17-AAG, whereby a 
comparison between the Hsp90 inhibitor and the conventional therapeutic drug TMZ in 
glioma cell lines (Table 3.1.2) showed >1000-fold reduction in IC50 dose suggesting 
Hsp90 as an anti-cancer target in glioma. The high efficacy of Hsp90 inhibitors can be 
attributed to the higher binding affinity of Hsp90 expressed in tumour cells (100-fold 
higher) to 17-AAG relative to Hsp90 present in normal cells, that results in client 
protein degradation and ultimately cell death (Sauvageot et al., 2009). Moreover, the 
IC50 concentration of Hsp90 inhibitors in U87-MG cells was almost half that observed 
in low grade gliomas (i.e. 1321N1 and GOS-3) which may imply that U87-MG cells 
contain Hsp90 in an activated, multi-chaperone complex which facilitates malignant 
progression (Kamal et al., 2003). Therefore a series of experiments were performed 
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using only the U87-MG glioblastoma cell line in this study. TMZ was found to be 
cytotoxic to non-tumourigenic cells SVGp12 at concentrations utilized, however, 17-
AAG illustrated selectivity towards glioma cells as the toxic effects exhibited on 
SVGp12 cells were considerably lower.  
The present study showed that hsp90α levels in glioma cell lines are significantly higher 
(mean increase of 160-fold) than non-tumourigenic cell line (SVGp12) which agrees 
with a previous study within our laboratory that revealed the presence of Hsp90α 
mRNA and protein level at a highly induced state in glioma cell lines compared to 
normal counterparts (Shervington et al., 2008). In a follow up study, the hsp90α was 
silenced in glioma cell lines using sihsp90α and not only was the hsp90α mRNA 
significantly down-regulated but sihsp90α also induced chemosensitivity to TMZ 
(Cruickshanks et al., 2010). Silencing hsp90α using sihsp90α could thus, be a favorable 
therapeutic approach due to enhanced target specificity and reduced toxicity. The 
benzoquinone ansamycin 17-AAG has previously been shown to inhibit tumour growth 
in human glioma cell lines (Sauvageot et al., 2009). This study investigated anti-tumour 
effects of Hsp90α inhibition using two approaches, using chemical agent 17-AAG 
(protein inhibition) and molecular approach using hsp90α target-specific siRNA (gene 
silencing) with the aim of achieving maximum Hsp90α downregulation.  
Three sets of pre-designed sihsp90α oligos (as described in Figure 2.3.1) were 
previously used in our laboratory to downregulate hsp90α expression in glioblastoma 
(Cruickshanks et al., 2010). Although, sihsp90α oligo 3 that targets exon 9 of the 
hsp90α showed significant hsp90α downregulation, sihsp90α oligos 2 that targets exon 
5 was observed to increase chemosensitivity in glioblastoma after 24 and 48 h, 
suggesting that proximity of the oligo to the initiation site for translation enhances the 
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efficiency of RNAi (Cruickshanks et al., 2010). Consequently, sihsp90α oligo 2 was 
utilized to perform the entire gene silencing experiments in this study. 
In order to assess quantitative gene silencing in GBM using sihsp90α and 17-AAG, 
hsp90α and GAPDH (control) mRNA expressions were measured using qRT-PCR. 
Results showed that a combination of 17-AAG and sihsp90α significantly reduced 
hsp90α copy numbers by 99% in GBM after 48 and 72 h. Sequence specific interactions 
between the siRNA and target mRNA are essential for RNAi functionality, and the 
target site recognition relies on the molecular mechanism of RNA-RNA interactions 
(Elbashir et al., 2001). The target-sequence specificity of sihsp90α was unprecedented 
since the housekeeping gene GAPDH mRNA expression was unaffected. To further 
support our findings, the cytotoxic effects of sihsp90α and 17-AAG on non-
tumourigenic cells SVGp12 was investigated. The SVGp12 cell viability was not 
significantly affected with no more than 5% reduction in viable cells after 48 and 72 h 
which clearly demonstrates selective tumour cell targeting over normal cells. These 
findings correspond to a previous study in our laboratory showing that hsp90α 
expression is highly induced in U87-MG as compared to normal counterpart 
(Shervington et al., 2008). Since hsp90α was transcribed at basal level in SVGp12 and 
other normal brain cell lines as reported previously (Shervington et al., 2008), there was 
no need for further investigation to be carried out on this cell line.  
The concurrent and sequential assays with 17-AAG and sihsp90α were statistically 
analysed to determine which one of the two assays showed significant effects on cell 
viability and gene silencing. Paired-Sample T-test carried out between concurrent and 
sequential assays showed a p-value between 0.227 and 0.177. It was clear that both 
concurrent and sequential assays with 17-AAG and sihsp90α had a similar effect on cell 
viability and mRNA down regulation. However, the results demonstrate that the 
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combination treatment with sihsp90α and 17-AAG had higher efficacy than sihsp90α 
alone. Subsequently, only the concurrent combinatorial assay was utilized to investigate 
Hsp90α protein expression and Akt kinase activity.  
The transcription of human hsp90α gene is regulated by the 5’ upstream promoter 
sequences bearing the heat shock elements (HSEs) known to regulate gene expression 
of hsp90α (Sreedhar et al., 2004). The heat shock factor 1 (HSF1) binds to the HSEs 
and marks the initiation of hsp90α gene transcription. Under normal conditions, HSF1 is 
bound to cytosolic Hsp90 and Hsp70 and hence avoids transcription of heat shock 
genes. However, under stress, or upon inhibition of Hsp90, the Hsp90 chaperone refolds 
partially denatured client proteins which liberates HSF1 consequently resulting in its 
translocation to the nucleus where it initiates transcription of hsp90 gene (Kamal et al., 
2004). This negative feedback mechanism may be the continued source of Hsp90 in 
tumour cells treated with 17-AAG or sihsp90α, which may be responsible for tumour 
survival even after 72 h. In this study, we targeted the inducible isoform hsp90α mRNA 
using sihsp90α and Hsp90 protein using 17-AAG with an aim to achieve maximum 
Hsp90 inhibition. The results from this study indicate that the induced cytotoxicity 
observed in glioblastoma U87-MG and not in non-tumourigenic cell line SVGp12, 
using combination treatment with sihsp90α and17-AAG, may be due to a greater degree 
of Hsp90 inhibition. The results also indicate that SVGp12 cells are not dependent on 
Hsp90 for cell growth and survival. Although, the interaction ratios generated reveal 
that there is no synergistic relationship between sihsp90α treatment and 17-AAG, 
optimising certain variables could provide additional efficacy on growth inhibition of 
glioblastomas. For instance, longer incubations with sihsp90α as well as 17-AAG, and 
using sihsp90α with increasing drug doses could improve the therapeutic value of this 
combination regimen. 
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The fundamental role of Hsp90α in tumour invasion and cell cycle has been previously 
investigated (Eustace et al., 2004). However, altered hsp90α expression post 17-AAG 
treatment has not been studied in glioma. Nevertheless, a study by Clarke et al. 
investigating hsp90α gene expression in colon adenocarcinoma cell lines showed that 
the hsp90α expression in HCT116 (human colon cancer cells) following 17-AAG 
treatment was induced (Clarke et al., 2000). The same treatment on HT29 (human colon 
cancer grade II cell line) had no influence on hsp90α mRNA levels, suggesting that the 
post-transcriptional regulation of hsp90α after 17-AAG treatment was cell line 
dependent (Clarke et al., 2000). In GBM, 17-AAG was observed to downregulate 
hsp90α mRNA expression after 48 and 72 h which correlates with its cytotoxic effects 
in vitro. Numerous studies have been conducted involving the use of 17-AAG, however, 
it is still not clear as to whether the Hsp90 affinity binding of 17-AAG is isoform 
specific or not (Clarke et al., 2000). The present study demonstrates the ability of       
17-AAG to inhibit Hsp90α expression and subsequently reduces Akt kinase activity in 
glioblastoma. 
Hsp90 expression in tumours is 2 to 10-fold higher as compared to its basal expression 
in normal counterparts (Isaacs et al., 2003). In addition to chaperoning mutated and 
deregulated client proteins, Hsp90 is of critical importance in tumour survival and 
progression. Theoretically, silencing hsp90α gene with sihsp90α should lead to tumour 
demise. The overall results from this study reveal non-complementarity between the cell 
viability and qRT-PCR data after sihsp90α treatment. Although, hsp90α mRNA 
expression was reduced by 96%, the cell viability was barely affected at 90%. hsp90α 
gene silencing was effective up to 48 h using sihsp90α, however, sihsp90α vulnerability 
to metabolism within the cell and its inability to duplicate (McAnuff et al., 2007), 
ultimately lead to hsp90α resurgence after 72 h. In contrast, the Hsp90 protein half-life 
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of 36 h may suggest that the efficacy of hsp90α silencing on cell viability was modest 
after 48 and 72 h, owing to the downstream regulation of anti-apoptotic clientele by 
Hsp90 (Basso et al., 2002). The half-life of hsp90α mRNA is 6 h under normal 
conditions but is reduced to 3 h post Hsp90 inhibition using geldanamycin in rat 
gliosarcoma cells (Chang et al., 2006). This suggested that the translational efficiency 
of hsp90α mRNA (i.e. protein synthesis per mRNA) was high in treated cells owing to 
the dependence of malignant cells to Hsp90. Thus, it was reasonable to speculate that 
hsp90α mRNA in glioblastomas were more effectively translated which could be 
responsible for the lack of anti-cancer activity observed post sihsp90α treatment.  
The Hsp90α expression after treatment with 17-AAG and sihsp90α were measured by 
immunocytochemistry. The Hsp90α protein was detected using FITC-conjugated 
secondary antibodies, taking into consideration the intensity, contrast and sharpness of 
the image. The Hsp90α protein expression profiles showed a distinct correlation with 
the hsp90α mRNA expression in U87-MG which strongly suggests that the regulation 
of Hsp90 occurs not only at the post-translational level as proposed by previous 
observations (Karkoulis et al., 2010), but also under transcriptional control.  
The Hsp90 chaperone plays a vital role at maintaining Akt stability (Basso et al., 2002). 
The involvement of Akt kinase in deregulated signalling pathways which facilitates 
tumour progression, survival and invasion, has been well documented (Brader & Eccles, 
2004). Previous studies have demonstrated severe inhibition of Akt-dependent anti-
apoptotic signalling pathways upon the administration of 17-AAG in gastric cancers, 
urinary bladder cancer and osteosarcoma (Gazitt et al., 2009; Karkoulis et al., 2010; 
Lang et al., 2007). To determine whether Hsp90α inhibition/silencing disturbed Akt 
levels in U87-MG, Akt kinase activity was measured using a Akt/PKB Kinase Activity 
Assay. The present study showed downregulation of Akt kinase levels post 17-AAG 
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and sihsp90α treatment which decisively contributes to the cytotoxic potencies of       
17-AAG and sihsp90α after 48 and 72 h. The decrease in cell viability observed in  
U87-MG cells may be attributed to the 17-AAG-dependent inhibition of Akt activity in 
addition to the sihsp90α-mediated hsp90α downregulation which counteracts the tumour 
survival response of hsp90α upregulation (Chang et al., 2006), eventually leading to 
Hsp90 depletion and apoptosis. It has been previously demonstrated that depletion of 
hsp90β by siRNA can induce apoptosis in multiple myeloma (Chatterjee et al., 2007), 
which may suggest cooperating anti-apoptotic properties for Hsp90α and Hsp90β. In 
this study, downregulation of Hsp90α with sihsp90α was insufficient in suppressing Akt 
activity in U87-MG after 72 h, possibly due to the anti-apoptotic role of Hsp90β via 
association with Bcl-2 leading to caspase inactivation and to cell survival (Cohen-
Saidon et al., 2006). In addition, it could be attributed to the inability of siRNA to 
duplicate, reducing silencing efficacy through cell division (McAnuff et al., 2007). This 
may suggest why Akt levels recovered after 72 h following sihsp90α treatment. 
Although, 17-AAG and sihsp90α triggered Akt degradation, interestingly, the most 
significant Akt suppression achieved was relatively higher than the corresponding 
Hsp90α levels. This may suggest that crucial components of the growth and survival 
signalling pathways, such as the Akt kinase, are not regulated by only Hsp90 chaperone. 
Indeed, upregulation of Hsp70 following Hsp90 inhibition using 17-AAG has been 
previously reported in prostate, cervical, and human colon tumours (Clarke et al., 2000; 
McCollum et al., 2006). Furthermore, a recent proteomic study from our laboratory 
showed induced Hsp70 levels post 17-AAG exposure in glioblastoma cells (data 
unpublished). Thus, even though 17-AAG and sihsp90α inhibited Hsp90α levels in 
GBM, compensatory upregulation of Hsp70 may have proven to exhibit regulatory 
effects on Akt (Koren, III et al., 2010). The Akt activity was reduced by 2.3-fold with 
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the dual combination treatment after 72 h despite the Hsp70 compensation. This 
reduction of Akt activity demonstrates induced chemosensitivity in GBM since Hsp90 
binds and protects Akt from dephosphorylation which is responsible for inactivation of 
Bcl-2 family protein Bad and caspase-9, known to be inducers of the intrinsic apoptosis 
pathway (Lanneau et al., 2007). Thus, targeting Hsp70 in addition to Hsp90 could be of 
therapeutic importance for the treatment of glioblastoma. 
For the first time a combination of 17-AAG and siRNA targeting hsp90α has been 
shown to significantly suppress GBM growth after 48 and 72 h in vitro (Mehta et al., 
2011), clearly evident from the reduced Akt activity. This may suggest that mutated 
proteins in GBM may have enhanced Hsp90α binding affinity and are more sensitive to 
Hsp90α inhibition (Cruickshanks et al., 2010). Despite its anti-tumour activity in GBM, 
RNAi efficiency using siRNA is very limited in vivo, mainly due to siRNA degradation 
by nucleases, non-specific immune stimulation and poor cellular uptake (Shim & Kwon, 
2010; Boado, 2005; Schiffelers et al., 2004). However, intracellular delivery of 
biologically active siRNA has been successfully achieved using delivery systems (Han 
et al., 2010; Kumar et al., 2007). Accordingly, these limitations were addressed by 
enhancing cellular siRNA uptake, serum stability and pharmacokinetics using cell-
penetrating peptides. 
Hsp90 has been considered as a vital molecular chaperone for regulating protein 
maturation and function of its voluminous and highly diverse clientele of cancer-related 
proteins (Karkoulis et al., 2010). Through this Hsp90 seems to be crucial for malignant 
transformation, progression and increasing invasive potential of tumour cells (Workman 
et al., 2007). In glioblastoma, Hsp90 levels are highly induced to support a range of 
activated oncoproteins and signalling pathways that glioblastomas are dependent on 
(Collins, 2004). The benzoquinone antibiotic 17-AAG has previously shown anti-
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tumour effects in a number of tumour cell lines and in preclinical models mainly 
attributed to the higher binding affinity of 17-AAG to Hsp90 in tumour cells as 
compared to the native Hsp90 in normal cells and inducing proteasomal degradation of 
its client proteins (Sauvageot et al., 2009). The anti-tumour efficacy of 17-AAG and 
sihsp90α has been shown previously in U87-MG glioblastoma cells in vitro (Mehta et 
al., 2011). Furthermore, Hsp90α, one of the two major isoforms of Hsp90, known to 
have inducible expression and play an important role in cell cycle progression and 
apoptosis exhibits high expression at both mRNA and protein levels in glioma cell lines 
and tissues but not in normal cell lines and tissues (Shervington et al., 2008). This 
corroborated Hsp90α as an anti-glioma target and inhibition of Hsp90α as an approach 
to glioma treatment. A study by Cruickshanks et al. targeted hsp90α by RNAi using 
siRNA in glioblastoma and demonstrated significant hsp90α silencing after 48 h and 
subsequently inducing chemosensitivity to TMZ in glioblastoma in vitro (Cruickshanks 
et al., 2010). The ability of sihsp90α/Tat complexes combined with 17-AAG to induce 
Hsp90α gene and protein knockdown and inhibit tumour growth was evaluated in vitro.  
Efficient delivery of siRNAs to their RNA targets in the cytoplasm is desired for 
regulating gene expression and the activity of certain proteins. However, the major issue 
in gene therapy is the poor bioavailability of the negatively charged siRNA. Commonly 
used transfection systems such as cationic lipids or viruses have several disadvantages; 
the use of cationic lipids is restricted in vitro, and viruses have the tendency to initiate 
immunogenic responses in vivo (Mae & Langel, 2006). Often the complexes formed 
between the siRNA and the carrier are too large for in vivo utilization due to the rapid 
clearance by phagocytes present in the liver and spleen (Astriab-Fisher et al., 2002). On 
the other hand, the effectiveness of many delivery systems is compromised by the 
presence of serum proteins. For efficient translocation of the Tat peptide and a given 
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cargo into the cell, an appropriate number of arginines are required; hence the optimal 
number of Tat peptides required for efficient internalisation of sihsp90α by the cells was 
investigated by gel shift assay (Brooks et al., 2005). The present study evaluated the 
ability of Tat, Cyt c
77-101
 and C105Y to form complexes with sihsp90α, enhance its 
serum stability and transport it through the plasma membrane into the cells. Although, 
Tat efficiently formed complexes with sihsp90α; Cyt c77-101 and C105Y failed to show 
complete retardation of sihsp90α as examined by gel shift assay using PAGE. This was 
confirmed by the upward shift of the band compared to noncomplexed sihsp90α. 
Furthermore, in addition to a standard incubation time of 30 min at 37
°
C, Cyt c
77-101
 and 
C105Y peptides were incubated with sihsp90α for longer incubations periods of 1 and  
2 h, and two-fold the concentration initially used (100-fold peptide molar excess to 
sihsp90α) to assess their ability to form complexes with sihsp90α. Even though the 
incubation time and peptide concentration were increased, the ability of Cyt c
77-101
 and 
C105Y peptides to form complexes with sihsp90α was unaltered since sihsp90α was not 
completely retarded. The use of Cyt c
77-101
 and C105Y peptides for additional analysis 
was therefore considered redundant and was discontinued from further studies.  
A major limitation of siRNA use in vitro and in vivo is the inability of naked siRNA to 
translocate through the cell membrane due to both the size of the siRNA molecule   
(~14 kDa) (Michiue et al., 2009), and the strong anionic charge of the phosphate 
backbone, and low serum stability owing to rapid degradation by the nucleases (Meade 
& Dowdy, 2007; Shim & Kwon, 2010). The Tat CPP has previously been used for 
delivery of oligonucleotides such as siRNA in vitro and in vivo (Chiu et al., 2004; 
Endoh et al., 2008; Moschos et al., 2007a). These CPPs have a high density of 
positively charged amino acids such as arginine and lysine which have been suggested 
to enhance its internalisation potential by interacting with the anionic surface of the 
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plasma membrane (Endoh & Ohtsuki, 2009). As described in this study, sihsp90α/Tat 
complexes were observed to enhance sihsp90α stability significantly in human serum 
(50%) where sihsp90α integrity was maintained up to 36 h. This could be attributed to 
the ability of Tat CPP to form macro-complexes with sihsp90α thus covering the siRNA 
surface with CPPs subsequently reducing susceptibility to serum nucleases. In contrast, 
aqueous sihsp90α was unstable in human serum and exhibited complete degradation 
after 6 h which was in agreement with results reported elsewhere (Schiffelers et al., 
2004).  
Once it was established that sihsp90α/Tat complexes were relatively stable in human 
serum as compared to aqueous sihsp90α, an LDH leakage assay (LLA) was used. LLA 
measures the acute membrane disturbance reportedly caused by peptides at high 
concentrations (El-Andaloussi et al., 2007; Endoh & Ohtsuki, 2009; Hallbrink et al., 
2001). In glioblastoma, Tat either alone or complexed with sihsp90α did not display 
membrane perturbations up to 50-fold peptide molar excess to sihsp90α or 10 µM final 
concentration when used independently. Tat induced membrane disturbance (~15%) at 
100-fold peptide molar excess to sihsp90α or concentration of 20 µM when used 
independently, the peptide concentrations in this study were accordingly restricted to 
1:50 (sihsp90α:Tat ratio) or 10 µM free peptide prevent non-specific interference in the 
observed gene silencing, since CPPs have been suggested to influence the observed 
gene silencing when utilised at high concentrations (Lundberg et al., 2007; Moschos et 
al., 2007a). Interestingly, the non-tumourigenic cells showed negligible LDH leakage at 
concentrations up to 100-fold peptide molar excess to sihsp90α or 20 µM concentration 
(free peptide). The LDH leakage measurements for SVGp12 cells from this study 
complements the acute toxicity profile displayed by Tat peptide in tumour cell lines and 
in immortalised aortic endothelial cells where no significant LDH leakage was reported 
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(Hallbrink et al., 2001; Saar et al., 2005). Although, the acute toxicity profiles of free 
Tat and sihsp90α/Tat complexes did not display any variance in U87-MG or SVGp12 
cells, a comparison of the toxicity profiles between the cell lines is difficult due to the 
lack of a comprehensive study with findings that are consistent because the toxicity of 
peptides is not only dependent on peptide concentrations and the cargo molecule 
utilized but also on the different cell lines and cell passages used (El-Andaloussi et al., 
2007).  
The long term toxicity of Tat was investigated by measuring cell proliferation after 24, 
48 and 72 h in both glioblastoma and non-tumourigenic cells. Tat peptide exhibited no 
long term toxicity at concentrations 3, 6 and 10 μM in U87-MG or SVGp12 cells; 
however, Tat complexed with sihsp90α significantly reduced cell viability in 
glioblastoma. This may suggest that Tat efficiently transports sihsp90α into the cells 
which consequently downregulates hsp90α expression resulting in reduced cell 
viability. On the other hand, it cannot be disputed that cytotoxic effects exhibited could 
in fact be due to Tat itself, but cargo-dependent. Similar findings have been reported 
previously whereby the addition of cargo to the Tat peptide induced its toxicity profile 
in vitro (El-Andaloussi et al., 2007). The data from this study implies that Tat uptake is 
a one-way process resulting in entrapment of the fragment within the cell as free Tat or 
Tat in complex with sihsp90α induces minimal LDH leakage in either U87-MG or 
SVGp12 cells (Baker et al., 2007). In contrast, sihsp90α/Tat significantly reduced cell 
viability in glioblastoma, but not in non-tumourigenic cells. This difference in short- 
and long-term toxicity of Tat peptide highlights the significance of measuring both the 
acute membrane disturbance as well as the long-term toxic effects of Tat because the 
two do not necessarily correlate. The LDH leakage profiles in  U87-MG cells 
demonstrated a slightly higher membrane disturbance exhibited by sihsp90α/Tat 
194 
 
complexes as compared to the free Tat which indicates that strong interaction between 
peptide and siRNA does not essentially reduce the peptide toxicity as previously 
reported (Lundberg et al., 2007). This difference further elaborates the disparity shared 
by these peptides when complexed with siRNA suggesting that the toxicity of peptides 
is siRNA-dependent.  
Moreover, the membrane perturbation effects of Tat were more pronounced in 
glioblastoma cells as compared to non-tumourigenic cells which may suggest that Tat 
could possess selectivity towards malignant cell membranes. Indeed, previous reports 
have demonstrated the inherent selective toxicity of cationic CPPs for the membranes of 
malignant cells, although the exact mechanism of this anti-tumour activity is not fully 
understood (Johnstone et al., 2000; Leuschner & Hansel, 2004). Nonetheless, certain 
features of malignant cell membranes such as varying composition and fluidity, higher 
transmembrane potential, greater negative charge and increased levels of acidic 
components on the cell surface have been ascribed as possible reasons for the selectivity 
of CPPs towards malignant cell membranes (Saar et al., 2005). This could be a possible 
reason as to why Tat did not influence hsp90α gene expression in SVGp12 cells. 
In order to investigate whether the ability of the complex formation of siRNA and Tat 
promotes cellular internalisation, si-FAM/Tat complexes were formed as confirmed by 
gel shift assay, and the cellular uptake of si-FAM/Tat was quantitated using confocal 
microscopy taking into consideration the intensity, contrast and sharpness of the image. 
si-FAM/Tat complexes were internalized by U87-MG cells and SVGp12 cells, 
however, uptake efficiency in SVGp12 cells was low compared to U87-MG cells at 
high peptide concentrations. In addition, the cellular localisation profiles of the 
transfected si-FAM were divergent between the two cell lines. A plausible explanation 
for this behaviour could be that Tat utilizes different internalisation mechanisms in 
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different cell lines depending on the hydrophobicity and electrostatic interaction 
between the arginine residues of the Tat transduction domain and anionic cell 
membrane through transduction and/or macropinocytosis (Patel et al., 2007; Wadia & 
Dowdy, 2005). Thus, it is not surprising that Tat has been simply considered to be an 
opportunistic peptide that interacts with the negative environment of the cell surface, 
initiating cellular internalisation (Brooks et al., 2005).  
The cell plasma membrane is renewed constitutively at an estimated rate of ~2%/min 
(Kilic et al., 2001; Mellman et al., 1986), hence 50-200% of the cell surface can be 
predicted to be internalised per hour suggesting that the higher dose-dependent si-FAM 
uptake efficiency observed in malignant U87-MG cells compared to normal human 
astrocyte cell line SVGp12, could be due to the specific selectivity of cationic peptides, 
in this case Tat, towards malignant cell membranes probably to ubiquitously expressed 
proteoglycans including chondroitin sulfate, dermatan sulfate and heparan sulfate (Mai 
et al., 2002; Richard et al., 2005; Saar et al., 2005). This interaction between si-FAM 
/Tat complexes and the negatively charged cell surface proteoglycans may be the first 
step in cellular internalisation either through transduction or endocytosis, and has 
previously been implicated in translocation of Tat peptide (Sandgren et al., 2002). 
Following membrane interaction, vesicle fusion and budding events occur which lead to 
vesicle formation of the internalised peptide complexes from which they must escape to 
reach the target sites of their cargo. The si-FAM localisation in SVGp12 cells is mainly 
cytoplasmic which may suggest that endosomal escape is efficient, attributed mainly to 
the diffused staining observed since endosomal entrapment of si-FAM causes punctate 
staining patterns as evidenced by confocal microscopy (Fischer et al., 2004), a result 
corroborated when inhibition of endosome acidification displayed only punctate 
staining (Potocky et al., 2003). In U87-MG cells, si-FAM was noted to localise 
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primarily in the nucleus as well as diffused staining in the cytoplasm. This diffused 
staining pattern exhibited by si-FAM may be the effect of pH change in the endosomes 
which may alter Tat conformation subsequently facilitating its escape from the 
endosomes. However, another conceivable explanation could be that the si-FAM/Tat  
complexes are degraded within the endosomes and the diffused staining observed is the 
outcome of the endosomal escape of smaller metabolites with the fluorescent tag (Patel 
et al., 2007).  
The nuclear accumulation of oligonucleotides complexed with CPPs has been suggested 
to occur through different pathways in different cell models. The si-FAM/Tat 
complexes would be expected to exceed size limits for free diffusion of macromolecules 
across the nuclear envelope, thereby requiring active transport mediated by nuclear pore 
complex (NPC) when accompanied by nuclear localisation signal (NLS) (Patel et al., 
2007). Tat peptide, being a derivative of a transcription factor, has the NLS embedded 
in its sequence which may facilitate active transport of si-FAM/Tat complexes into the 
nucleus, but the uptake was not high enough to be visualised in SVGp12 cells. In 
contrast, si-FAM/Tat complexes in rapidly proliferating malignant cells have an extra 
entry point to the nucleus owing to the nuclear envelop break down during mitosis, 
which could be accountable for the higher nuclear localisation of the si-FAM in      
U87-MG cells as compared to normal counterpart. Although evidence suggests that cell 
fixation can lead to artificial uptake and redistribution of Tat (Baker et al., 2007), 
optical and biophysical analysis of live fibroblast uptake of the Tat peptide previously 
reported has essentially confirmed the nuclear penetrating properties of the peptide 
(Ziegler et al., 2005). Additionally, the differences in the si-FAM localisation pattern 
observed between the two cell lines and ability of Tat to efficiently deliver sihsp90α 
with subsequent RNAi activity as well as specific cytotoxicity associated with 
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sihsp90α/Tat suggest that the localisation of si-FAM/Tat complexes in this study is 
unlikely to be a fixation-associated artefact.  
The ability of Tat to effectively deliver sihsp90α and induce anti-cancer activity in vitro 
was assessed using cell viability assay. To confirm whether the observed tumour 
inhibition effects were not due to the intrinsic toxicity of Tat, both U87-MG and 
SVGp12 cells were incubated with increasing concentrations of the peptide and the 
long-term toxicity was examined. Tat peptide exhibited no long-term toxicity after 24, 
48 or 72 h at concentrations up to 10 μM in either of the cell lines used which correlates 
with data reported elsewhere (El-Andaloussi et al., 2007). This suggests that the short- 
or long-term toxicity of Tat peptide may not influence the gene silencing potential of its 
cargo, sihsp90α. However, Tat peptide has been well documented to possess 
uncharacterised bioactivity (Moschos et al., 2007a), in addition to integral roles of 
chaperones in refolding of Tat protein following entry into the cell (Patel et al., 2007). It 
thus seemed reasonable to speculate that Tat may display bioactivity in vitro when used 
at high concentrations. It was for this reason that long-term toxicity analysis was 
performed after 24, 48 as well as 72 h post treatment. Surprisingly, Tat peptide alone 
induced hsp90α levels in U87-MG cells after 48 and 72 h, however, the mechanism 
underlying this response is currently unknown. Previous studies have illustrated 
uncharacterised regulatory activity of Tat on signalling pathways (Fotin-Mleczek et al., 
2005), furthermore, the fact that Tat is derived from the DNA binding domain of HIV-1 
trans-activator protein with high positive charge which at high concentrations has been 
suggested to directly interfere with the gene transcription (Moschos et al., 2007a), could 
be a possible reason for this observation.  
The sihsp90α/Tat complexes did not exhibit cytotoxic effects after 24 or 72 h, but 
significantly reduced U87-MG cell viability after 48 h by 12 and 20% at 1:30 and 1:50 
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sihsp90α:Tat molar ratio, respectively, indicating a dose-dependent response (p ≤ 0.05). 
This may suggest that Tat delivers functional sihsp90α since cells transfected with free 
sihsp90α did not show significant anti-tumour activity. Likewise, the hsp90α and 
GAPDH (control) gene expression levels were monitored by performing qRT-PCR to 
assess quantitative gene silencing, whereby the hsp90α mRNA expression was 
significantly reduced by 78, 85 and 86% after 24 h using 15, 30 and 50-fold Tat peptide 
molar excess to sihsp90α. After 48 and 72 h, the sihsp90α/Tat complexes produced 
mRNA knockdown but was insignificant at all peptide concentrations used. The 
cytotoxicity and qRT-PCR data do not display complementarity which could be 
attributed to the vulnerability of the siRNA to metabolism within the cell due to its 
inability to duplicate (McAnuff et al., 2007); the siRNA integrity in the cells lasts for 
only 3-5 doubling times, therefore gradually reducing its efficacy through cell division 
(Kim, 2003), and the Hsp90 protein half-life of 36 h may suggest why sihsp90α/Tat 
complexes downregulated hsp90α but did not induce anti-cancer activity after 24 and  
72 h owing to the downstream regulation of anti-apoptotic clientele by Hsp90 (Basso et 
al., 2002). Tat-mediated hsp90α knockdown was only significant after 24 h post 
treatment despite significant gene knockdown after 48 and 72 h post sihsp90α treatment 
(Mehta et al., 2011). Revisiting the Tat-mediated siRNA delivery where the localisation 
pattern was predominantly in the nucleus along with diffused cytoplasmic staining in a 
dose-dependent manner, correlates well with the lower RNAi activity observed in this 
study indicating that cytoplasmic localisation of sihsp90α is critical for hsp90α gene 
knockdown (Chiu et al., 2004). It should, however, be pointed out that the actual gene 
silencing efficiency of sihsp90α may be higher than the observed values owing to the 
biological activity of Tat peptide on hsp90α gene expression. The hsp90α mRNA 
downregulation did not correspond with Hsp90α protein expression levels with most 
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Hsp90α degradation observed after 48 h, however, these observations are consistent 
with hsp90α mRNA and protein expression profiles obtained previously (Mehta et al., 
2011). In addition, Tat alone at 10 µM concentration did not show significant effects on 
Hsp90α regulation suggesting that Tat did not affect translational regulation of Hsp90α. 
The ability of Tat-delivered sihsp90α to enhance anti-cancer activity of 17-AAG was 
assessed by measuring the Hsp90α gene and protein expression and cell viability after 
24, 48 and 72 h. hsp90α gene expression was observed to be significantly reduced in a 
dose-dependent manner, though hsp90α levels gradually recovered after 48 and 72 h. 
Despite the reclamation of hsp90α levels, Hsp90α protein levels were significantly 
downregulated at 24, 48 and 72 h dose-dependently, which may imply that the gene 
silencing concomitant to protein inhibition approach applied in this study could be an 
effective method for downregulation of Hsp90, whose activity is absolutely essential for 
oncogenic transformation (Brown et al., 2007; Neckers & Workman, 2012). The 
requirement of Hsp90 chaperone for glioblastoma growth and survival was therefore 
validated, ascribed mainly to the reduced cell viability after 24, 48 and 72 h subsequent 
to Hsp90 inhibition. Hsp90α mRNA and protein expression profiles clearly correlates 
with result from a previous study (Mehta et al., 2011), thus implying that the Tat 
peptide did not significantly influence Hsp90α expression or associated regulatory 
processes in glioblastoma. 
The Akt activity was used to quantitate the extent of Hsp90 inhibition as functional 
Hsp90 is critical for stability and activity of Akt (Liao & Hung, 2010). Hsp90 inhibition 
was tightly associated with loss of Akt activity, most likely responsible for the reduced 
cell viability owing to the role of Akt in anti-apoptotic signalling pathways prevalent in 
glioblastomas (Sauvageot et al., 2009). Tat peptide alone did not display significant 
regulatory effects on Akt activity at concentrations up to 10 μM at all time points 
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examined which corresponds with the cell viability data where no long-term toxicity of 
the peptides was observed. It is noteworthy to mention that the reduced Akt activity 
noted at 10 μM peptide concentration could possibly suggest a modulatory role of Tat 
on Akt kinase since Tat has previously been reported as a regulator of MAP kinase 
(Moschos et al., 2007a), though this response was not significant and did not influence 
U87-MG cell viability. Interestingly, sihsp90α/Tat complexes reduced Akt activity after 
24 and 48 h but Akt levels were observed to recuperate after 72 h in a dose-dependent 
manner which correlates with hsp90α mRNA expression levels, once again suggesting 
that cytoplasmic localisation of sihsp90α is crucial for RNAi. Although one cannot rule 
out the possibility that vital components of the survival signalling pathway, such as the 
Akt kinase, may be regulated by other chaperones, post Hsp90 inhibition. A 
combination of Tat delivered sihsp90α and 17-AAG significantly reduced Akt levels 
especially after 48 and 72 h with subsequent anti-cancer effects in glioblastoma, further 
confirming the association with Hsp90 is vital for Akt activity in glioblastoma. 
Although, Hsp90 inhibition significantly reduced glioblastoma growth in vitro, 
persistent Akt levels may suggest a rescindable effect of this treatment. Most kinases 
have conventionally been considered as Hsp90 clients, however, recent studies have 
suggested the inducible isoform of Hsp70 (Hsp72) as well as the constitutive variant 
Hsc70 to influence Akt levels due to the induced Hsp70 levels subsequent to 17-AAG 
exposure in several tumours including glioblastomas (Koren, III et al., 2010). 
Therefore, targeting Hsp90 may not be sufficient to cause glioblastoma demise.  
The treatment of Tat alone or in complex with sihsp90α did not affect non-tumourigenic 
cell viability even when used together with 17-AAG at all time points examined. The 
lack of hsp90α expression suggests that Hsp90 in SVGp12 cells is in 
latent/uncomplexed state along with low transcriptional regulation. The negligible 
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levels of hsp90α mRNA levels quantitated in SVGp12 cells indicates that glioblastomas 
are more reliant on molecular chaperones for stabilising oncogenic clientele responsible 
for malignant transformation. Moreover, the dual combination treatment with sihsp90α 
and 17-AAG, at the doses utilized, may be critical in the clinical setting whereby a 
frame of dosing can be established such that only glioblastomas are primarily targeted.  
The present study focused on inhibiting Hsp90α at both gene and protein levels that 
simultaneously target several signalling pathways involved in proliferation and survival 
through proteasomal degradation of its oncogenic client proteins. A combination of Tat-
mediated sihsp90α delivery and 17-AAG showed reduced hsp90α expression as well as 
Akt kinase activity in vivo. For these experiments, U87-MG stably transfected with the 
firefly luciferase gene 2 was utilized for two reasons. Firstly, U87-MG-luc2 cells aid in 
the detection of tumours following tumour implantation into mice. Although, weight 
loss is an indication of tumour growth in mice glioblastoma models (Blouw et al., 
2003), quantification of luciferase in tumour tissue yielded a strong luminescence signal 
in comparison to the normal brain tissue confirming presence of a tumour in vivo. 
Secondly, the use of U87-MG-luc2 cells allows targeting of luciferase gene using 
siluc/Tat nanoparticles in vitro, and consequently highlights the versatile nature of the 
Tat-mediated delivery of various siRNA sequences used in this study including 
sihsp90α, siluc and si-FAM (Section 2.15).  
Glioblastomas are at the core of brain tumour therapeutic studies due to several reasons, 
including limited clinical aid and known oncogene mutations (Aoki et al., 2007). In 
addition, the intracranial Ommaya reservoir catheters are regularly placed on 
glioblastoma patients to deliver chemotherapy (Mason, 2008), similar to the stereotaxic 
delivery approach utilized here which could potentially allow the local intracranial 
delivery of the therapeutic siRNA. Thus, by means of synthetic RNAi response, the 
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genetic composition and oncogene addiction of glioblastoma tumours may be exploited 
to our benefit.  
Here, nude mice were utilized as carriers of exogenously introduced human tumour and 
as a model system that closely simulates human disease. The immunodeficiency trait 
accommodates the xenografted tumours and permits growth and expansion in vivo 
which would otherwise not be possible in case of immunocompetent mice. However, 
the use of nude mice models makes it challenging to study the toxic effects that the 
peptide as well as the drug might exert such as the unwanted immune responses 
(Coursindel et al., 2012). On a positive note, the small size of the peptide reduces the 
risk of triggering inflammation responses to certain extent. Whether sihsp90α/Tat 
complexes and 17-AAG stimulate inflammatory responses in in vivo setting requires 
further investigation.  
For gene expression and Akt kinase study, 3 mice were treated with sihsp90α/Tat 
complexes in combination with 17-AAG and 2 mice (control) were treated with 
siluc/Tat complexes and 17-AAG, 17 days post tumour implantation. The 
siRNA:peptide molar ratio of 1:50 was utilized for in vivo siRNA delivery that 
complements the Hsp90α gene knockdown and protein downregulation results in vitro, 
since optimum efficacy was noted at 1:50. Initially, the experimental design included 3 
control groups (1. No treatment; 2. 17-AAG alone (80 mg/kg); 3. siluc/Tat nanoparticles 
+ 17-AAG (negative control)) and 3 treatment groups (sihsp90α/Tat complexes at 1, 2.5 
and 5 mg/kg + 17-AAG) with three animals per group. However, some animals lost 
weight considerably after tumour implantation and showed no sign of recovery as seen 
with other animals with the tumour. These animals (n = 13) were considered redundant 
and were terminated from this study. As to what actually caused the acute weight loss is 
still unknown. Dr Kaido Kurrikoff supervised the in vivo experiments and has worked 
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with animal models for over 10 years but could not justify these as yet uncharacterised 
observations. Due to the unexpected drop of animal numbers to five, the experimental 
design was re-evaluated to comprise of one control group (n = 2) and one treatment 
group (n = 3). Over the period of 24 h when the animals were treated with siRNA and 
17-AAG, unfortunately another animal died from the control group possibly due to the 
expanding tumour. The gene expression and Akt kinase activity results presented in this 
study are preliminary and requires additional repeats in order to validate the results. 
Nonetheless, the data is encouraging.  
Due to the ability to redesign siRNAs complementary to virtually any oncogene mRNA 
target, synthetic RNAi responses can potentially target numerous pathways to induce 
tumour specific lethal responses. Target specific knockdown of oncoproteins by RNAi 
may have added benefit with regards to catalytic inhibition since protein-protein 
interactions are crucial for signal transduction (Michiue et al., 2009). Likewise, the 
ability of RNAi to swiftly adapt to the changing genetic composition of tumours confers 
an extra advantage especially in recurrent tumours where drug resistance has been an 
issue. Here, Tat-mediated sihsp90α delivery demonstrates the chemosensitizing effect in 
vivo concomitant to reduced Akt kinase activity. In addition, the qRT-PCR and Akt 
kinase activity results demonstrate a strong correlation which correlates with the in vitro 
studies. Overall, targeting Hsp90α using molecular and chemical approaches may have 
an anti-tumour potential in the treatment of glioblastomas. 
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5.1 Conclusion 
 
In this study, the level of hsp90α mRNA expression in glioma cell lines was observed to 
be induced and is consistent with previous studies carried out in our laboratory. A 
combination therapy utilizing sihsp90α and 17-AAG significantly downregulated 
Hsp90α mRNA and protein levels in GBM whereby upto 99% and 95.7% knockdown 
was achieved, respectively. The Akt kinase activity, a major survival kinase, was 
significantly reduced following Hsp90α inhibition. In contrast, the combination 
treatment had no significant cytotoxic effect on SVGp12 cell viability and the 
transcriptional regulation of hsp90α was negligible in SVGp12. Given the role of Akt in 
growth signalling pathways, Hsp90α-dependent Akt downregulation was accompanied 
by reduced cell viability in glioblastoma. Thus, targeting Hsp90α using sihsp90α and 
17-AAG may have a therapeutic prospect in the treatment of GBM ascribed to its 
tumour-specific activity.  
The efficient complex formation between sihsp90α and Tat, as confirmed by a gel shift 
assay, effectively delivered functional sihsp90α yielding upto 96% hsp90α gene 
silencing in glioblastoma when combined with 17-AAG. The sihsp90α/Tat complexes 
improved stability of sihsp90α in human serum, although, results suggest 
uncharacterized bioactivity of Tat peptides on hsp90α gene expression in glioblastoma. 
Treatment with sihsp90α/Tat complexes and 17-AAG significantly reduced the Hsp90α 
protein level that was associated with loss of Akt activity and subsequent reduction in 
cell viability in glioblastoma. The same treatment showed no significant impact on non-
tumourigenic cell viability with negligible hsp90α levels in vitro which further validates 
the dependence of glioblastomas on cancer chaperone Hsp90 for tumour progression 
and survival. Acute and long-term toxicity assessment revealed no significant intrinsic 
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toxicity in U87-MG or SVGp12 cells at Tat peptide concentrations used in this study. 
This novel approach of silencing hsp90α using a delivery vehicle concomitant to protein 
inhibition subsequently inducing chemosensitivity in glioblastoma shows great promise 
in in vivo models. 
The effects of Tat-delivered sihsp90α combined with 17-AAG on hsp90α expression 
and the survival kinase Akt was examined in glioblastoma mouse models. The results 
demonstrated that the combined treatment induced a strong RNAi response concomitant 
to reducing Akt kinase activity in vivo. Although, these results are preliminary and 
requires further validation, the anti-cancer effects of targeting Hsp90α using Tat-
mediated sihsp90α combined with 17-AAG is promising. 
The main findings of this study include: 
1. combination therapy using a molecular and chemical approach indicating a 
significant anti-tumour activity resulting in enhanced tumour specificity in vitro. 
2. peptide based delivery vector Tat effectively transfects multiple siRNA 
sequences into mammalian cells which is decisive from a clinical perspective. 
3. the efficient interaction between the peptide and siRNA improving serum 
stability of siRNA. 
4. combination therapy utilizing sihsp90α and 17-AAG induced hsp90α gene 
knockdown with subsequent downregulation of Akt kinase levels in vivo.  
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5.2 Future Work 
 
The molecular chaperone Hsp90 plays a critical role in glioblastoma tumourigenesis and 
has been considered as an ideal therapeutic target due to its versatile properties 
(Elstrand et al., 2012). This study utilized the ansamycin benzoquinone 17-AAG as a 
protein inhibitor due to its positive clinical activity in adult and paediatric tumours. 
However, ansamycins present limitations including suboptimal solubility, cumbersome 
formulations and extensive metabolism (Menezes et al., 2012). Taking this into 
consideration, further work could be carried out using other Hsp90 inhibitors with 
improved pharmacologic properties such as NVP-AUY922, NVP-HSP990, IPI-504, 
IPI-493 and 17-DMAG (Gaspar et al., 2010; Stingl et al., 2012). NVP-AUY922 and 
NVP-HSP990 are synthetic pyrazole/isoxazole resorcinol class of Hsp90 inhibitors 
possessing improved solubility, and IPI-504 and IPI-493 are the reduced forms and 
active metabolites. 17-DMAG has the added benefit of being water soluble, more 
potent, and has an improved oral bioavailability compared to its predecessor 17-AAG 
(Kobayashi et al., 2012).  
Although sihsp90α produced significant hsp90α knockdown in vitro, its vulnerability to 
metabolism within the cell and its inability to duplicate results in a temporary effect 
(McAnuff et al., 2007). However, several reports have focused on the modification of 
the siRNA with a view to enhance its activity and stability in vivo (Bramsen et al., 
2009; Choung et al., 2006; Haringsma et al., 2012; Laursen et al., 2010; Terrazas & 
Kool, 2009). A 2’-OMe and phosphorothioate substitutions at the 3’ end exhibited 
increased siRNA stability in serum without compromising the knockdown efficiency 
(Choung et al., 2006). Likewise, the incorporation of unlocked nucleic acid, an acyclic 
monomer that lack the C2’-C3’-bond of the RNA ribose ring, has been shown to 
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decrease nucleic acid duplex thermostability, increasing biostability and improving 
siRNA efficiency both in vitro and in vivo (Laursen et al., 2010). In addition, a recent 
study showed that 2’F ribose modification coupled with 5’-end phosphorylation 
improves RNAi efficiency in vitro and in vivo (Haringsma et al., 2012). The 
incorporation of chemical modifications in siRNA sequences could represent an 
effective strategy in enhancing siRNA stability without compromising the RNAi 
potency in vitro and in vivo.  
The role of Hsp70 in cell survival pathways and its upregulation in several tumours 
such as prostate, cervical and colon tumours post Hsp90 inhibition (Mehta et al., 2011), 
further supported by recent findings from our laboratory whereby Hsp70 levels were 
induced following 17-AAG treatment in glioblastomas (data unpublished), highlights 
the importance of understanding the anti-apoptotic role of Hsp90-Hsp70 and its 
implications in glioma therapy. Work is presently ongoing in our laboratory focusing at 
downregulating Hsp70 concomitant to Hsp90 using protein inhibitors and RNAi, and 
assessing its tumour inhibition potential which should enhance our understanding of the 
complex role played by these chaperones in tumour progression and survival.  
A recent study by Andaloussi and co-workers, demonstrated the use of a novel CPP 
known as PepFect 6 (PF6), to promote robust RNAi response mainly attributed to its 
ability to facilitate endosomal escape (Andaloussi et al., 2011). PF6-mediated siRNA 
delivery is not significantly hindered by serum proteins and induces a strong RNAi 
response in vivo without toxic side effects. Since PF6/siRNA complexes showed a 
strong gene knockdown effect in brain tissue specimens, future work could involve 
incorporating PF6 peptide along with Tat for systemic delivery of sihsp90α to compare 
the treatment efficacy and toxicity profiles in vivo. 
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The present study showed that the effects of Tat-delivered sihsp90α and 17-AAG on 
hsp90α knockdown and Akt kinase activity in xenograft models were encouraging. 
However, in order to validate these results further experimental repeats are required. 
The experimental design for further work could include 3 control groups (1. No 
treatment; 2. 17-AAG alone (80 mg/kg); 3. siluc/Tat nanoparticles + 17-AAG (negative 
control)) and 3 treatment groups (sihsp90α/Tat complexes at 1, 2.5 and 5 mg/kg 
combined with 17-AAG) with three animals per group. In addition, the toxicity profile 
of Tat could be investigated to determine whether CPPs really possess therapeutic 
implications. 
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7.1 Supplementary Tables 
 
Table 7.1.1: Media formulation, reagents and chemicals used in cell culture. 
Reagents Formulation Supplier 
Dulbecco’s modified 
eagle’s medium 
25 mM Hepes                                        
1.0 g/l glucose                                       
1.0 mM sodium bicarbonate                
0.011 g/l phenol red 
Sigma, UK 
Eagle’s minimum essential 
medium 
2.2 g/l sodium bicarbonate                       
1 g/l glucose                                    
Earle’s salt                                         
0.0053 g/l phenol red 
Sigma, UK 
Foetal bovine serum (FBS) Heat inactivated FBS GIBCO, UK 
Non-essential amino acid 100X non-essential amino acid Sigma, UK 
L-glutamine 200 mM L-glutamine Sigma, UK 
Phosphate buffer saline          
0.1 M 
8 g/l Sodium chloride                                
0.2 g/l Potassium chloride 
Sigma, UK 
Trypsin EDTA 
0.25%, 2.5 g Porcine trypsin 0.2 g EDTA 
in 4Na per liter of Hanks’ balanced salt 
solution with phenol red 
Sigma, UK 
Dimethyl sulfoxide 
(DMSO) 
DMSO 99.5% Sigma, UK 
Trypan blue (0.4%) 0.81% Sodium chloride                   
0.06% Potassium phosphate dibasic 
Sigma UK 
 
Table 7.1.2: A list of reagents and buffers provided with the mRNA isolation kit (Roche 
Applied Science, UK).  
Reagent Components 
   Lysis Buffer 
0.1 M Tris buffer, 0.3 M LiCl, 10 mM EDTA, 1% lithium 
dodecylsulfate, 5mM DTT (dithiothreitol), pH 7.5 
Washing Buffer 10 mM Tris buffer, 0.2 M LiCl and 1 mM EDTA, pH 7.5 
Streptavidin Magnetic 
Particles (SMPs) 
(10 mg/ml) in 50 mM Hepes, 0.1% bovine serum albumin,       
0.1% chloracetamide, 0.01% methylisothiazolone, pH 7.4 
Biotin-labelled 
Oligo(dT)20 probe 
100 pmol biotin-labelled oligo(dT)20 per μl of redistilled water 
Double-distilled Water 
(PCR Grade) 
RNAse free 
Storage Buffer 
10 mM Tris buffer, 0.1% chloracetamide, 0.01% methyliso-
thiazolone, pH 7.5 
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Table 7.1.3: The volume of reagents and buffers used for isolation of mRNA from samples. 
The shaded column depicts the number of cells used and the volumes of the reagents and 
buffers used for mRNA isolation in this study. 
Number of Cells 2 x 10
6
 
Lysing Buffer 0.5 ml 
Volume of SMPs 50 µl     
(0.5 mg) 
Lysing Buffer for 
preparation of SMPs 
70 µl 
Biotin-labelled 
Oligo(dT)20  
0.5 µl      
50 pmol 
Washing Buffer 3 x 200 µl 
Redistilled Water 10 µl 
 
 
Table 7.1.4: The composition and quantity of reagents provided with the LightCycler
®
 
FastStart DNA Master
PLUS
 SYBR Green I kit. The Enzyme master mix was prepared by 
transferring 14 µl of enzyme (1a) into vial of reaction mix (1b). 
Reagents Reagent Compositions Quantity 
LightCycler
®
 FastStart 
Enzyme (1a) 
FastStart Taq DNA Polymerase 1 vial 
H2O, PCR Grade RNase-free H2O 2 ml 
LightCycler
®
 FastStart 
Reaction Mix SYBR 
Green (1b) 
Reaction buffer, dNTP mix (with dUTP 
instead of dTTP), SYBR Green I dye and      
10 mM MgCl2 
3 vials 
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Table 7.1.5: A list of materials and reagents used for agarose gel electrophoresis in this 
study. 
Reagents Suppliers Preparation Working 
concentration 
Ultrapure agarose 
Gibco BRL, 
UK 
0.6-2 g Agarose                             
30-100 ml TBE (1X). Solubilized by 
boiling in a microwave for 3-4 min. 
2% 
weight/volume 
10X TAE 
(Ultrapure 10X 
Tris Acetate 
EDTA 
electrophoresis 
buffer) 
Sigma, UK 
1 M Trizma base                             
0.9 M Acetic acid (1X)                    
0.01 M EDTA                           
Diluted to 1X concentration with 
distilled water 
1X 
Alkaline buffer BDH 
AnalaR, UK 
10 N NaOH                                    
0.5 M EDTA 
1X 
Gel loading dye Sigma, UK 
0.25% w/v Bromophenol blue     
0.25% w/v Xylene cyanole          
40% w/v Sucrose                  
Supplied ready for use 4X 
concentration 
1:4 
(dye:sample) 
100 base pair (bp) 
molecular marker 
Sigma, UK 100 μg supplied ready for use 1 μg/ml 
Ethidium bromide 
10 mg/tablet 
Amresco, UK 
10 mg Ethidium bromide in                
10 ml distilled water. Diluted to     
0.5 μg/ml with distilled water 
1:20 
 
 
Table 7.1.6: The components of the Akt Kinase Activity Assay.  
Components Quantity/Description 
PKB Substrate Microtiter Plate 96-well plate 
Phosphospecific Substrate Antibody 5 ml (1 µg/ml) 
Anti-Rabbit IgG: HRP conjugate 20 µl (1mg/ml) 
Antibody Dilution Buffer 10 ml 
Kinase Assay Dilution Buffer (KADB) 10 ml 
ATP 2 mg, diluted with 2 ml of KADB  
Purified recombinant active PKB/Akt 28 µl 
Wash Buffer 30 ml 
TMB Substrate 10 ml 
Stop Solution 2 10 ml 
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7.2 Supplementary Figures 
 
 
Figure 7.2.1: Gene location of GAPDH represented by the red bar (A) and GAPDH 
sequence obtained from NCBI (B). Primer locations have been highlighted in red and blue 
indicating sense and antisense right primers, respectively. 
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Figure 7.2.2: Gene location of hsp90α represented by the red bar (A) and hsp90α sequence 
obtained from NCBI (B). Primer locations have been highlighted in red and blue indicating 
sense and antisense primers, respectively.  
